##CREATION_DATE=2020-08-15
##ANALYSISTYPE=GERMLINE_SINGLESAMPLE
##PIPELINE=megSAP 0.1-742-ged8ba02
##SAMPLE=<ID=NA12878_03,Gender=n/a,ExternalSampleName=Coriell-DNA,IsTumor=no,IsFFPE=no,DiseaseGroup=Other diseases,DiseaseStatus=affected>
##DESCRIPTION=NA12878_03=Genotype of variant in sample.
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - SNP quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom=Homoyzgous counts for populations (ALL,NFE,AFR) of gnomAD project.
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=ESP_sub=Sub-population allele frequency (EA,AA) in NHLBI Exome Sequencing project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=fathmm-MKL=fathmm-MKL score (for coding/non-coding regions). Deleterious threshold > 0.5.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=NGSD_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=NGSD_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##FILTER=gene_blacklist=The gene(s) are contained on the blacklist of unreliable genes.
##FILTER=off-target=Variant marked as 'off-target'.
#chr	start	end	ref	obs	NA12878_03	filter	quality	gene	variant_type	coding_and_splicing	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom	gnomAD_sub	ESP_sub	phyloP	Sift	PolyPhen	fathmm-MKL	CADD	REVEL	OMIM	ClinVar	HGMD	COSMIC	NGSD_hom	NGSD_het	classification	classification_comment	validation	comment	gene_info
chr1	27682481	27682481	G	A	het	off-target	QUAL=2181;DP=169;AF=0.51;MQM=60	MAP3K6	intron	MAP3K6:ENST00000357582:intron_variant:MODIFIER:exon27/28:c.3711+36C>T::,MAP3K6:ENST00000374040:intron_variant:MODIFIER:exon26/27:c.3687+36C>T::,MAP3K6:ENST00000493901:intron_variant:MODIFIER:exon28/29:c.3711+36C>T::		rs12569127	0.1903	0.2659		0.2162,0.2015,0.1154,0.3242,0.1645	0.3297,0.2274	-0.5000			0.06,0.19	0.09						n/a (AF>5%)	n/a (AF>5%)					MAP3K6 (inh=n/a pLI=0.00)
chr1	27686063	27686063	G	C	hom	off-target	QUAL=6115;DP=198;AF=1.00;MQM=60	MAP3K6	intron	MAP3K6:ENST00000357582:intron_variant:MODIFIER:exon17/28:c.2320-50C>G::,MAP3K6:ENST00000374040:intron_variant:MODIFIER:exon16/27:c.2296-50C>G::,MAP3K6:ENST00000493901:intron_variant:MODIFIER:exon18/29:c.2320-50C>G::		rs7521552		0.9944		0.9658,0.9966,1.0000,0.9953,0.9965	0.9960,0.9648	-0.3520			0.00,0.11	0.01						n/a (AF>5%)	n/a (AF>5%)					MAP3K6 (inh=n/a pLI=0.00)
chr1	27687466	27687466	G	T	het		QUAL=9743;DP=738;AF=0.52;MQM=60	MAP3K6	missense	MAP3K6:ENST00000357582:missense_variant:MODERATE:exon14/29:c.1866C>A:p.Asn622Lys:,MAP3K6:ENST00000374040:missense_variant:MODERATE:exon13/28:c.1842C>A:p.Asn614Lys:,MAP3K6:ENST00000493901:missense_variant:MODERATE:exon15/30:c.1866C>A:p.Asn622Lys:		rs35659744	0.1220	0.2263		0.0485,0.1393,0.0934,0.3034,0.1509	0.2959,0.0572	0.0290	T,T,T	B,B,B	0.03,0.20	1.09	0.04		403071 [benign DISEASE=not specified];		COSM1559294,COSM1559295	n/a (AF>5%)	n/a (AF>5%)					MAP3K6 (inh=n/a pLI=0.00)
chr1	27690359	27690359	T	C	het	off-target	QUAL=1451;DP=111;AF=0.53;MQM=60	MAP3K6	intron	MAP3K6:ENST00000357582:intron_variant:MODIFIER:exon5/28:c.864+49A>G::,MAP3K6:ENST00000374040:intron_variant:MODIFIER:exon4/27:c.840+49A>G::,MAP3K6:ENST00000493901:intron_variant:MODIFIER:exon6/29:c.864+49A>G::	MIRb	rs4307592	0.2196	0.2989		0.3181,0.2184,0.1142,0.3233,0.1667	0.3288,0.3268	0.0910			0.01,0.14	0.07						n/a (AF>5%)	n/a (AF>5%)					MAP3K6 (inh=n/a pLI=0.00)
chr1	27690644	27690644	A	G	het	off-target	QUAL=637;DP=88;AF=0.35;MQM=60	MAP3K6	intron	MAP3K6:ENST00000357582:intron_variant:MODIFIER:exon4/28:c.695+51T>C::,MAP3K6:ENST00000374040:intron_variant:MODIFIER:exon3/27:c.671+51T>C::,MAP3K6:ENST00000493901:intron_variant:MODIFIER:exon5/29:c.695+51T>C::		rs12727507	0.3548	0.4164		0.6819,0.2448,0.1149,0.3567,0.2002	0.3620,0.6494	-0.0660			0.01,0.20	0.01						n/a (AF>5%)	n/a (AF>5%)					MAP3K6 (inh=n/a pLI=0.00)
chr1	45796269	45796269	G	C	hom	off-target	QUAL=264;DP=10;AF=1.00;MQM=60	MUTYH	intron	MUTYH:ENST00000354383:intron_variant:MODIFIER:exon14/15:c.1396-40C>G::,MUTYH:ENST00000355498:intron_variant:MODIFIER:exon14/15:c.1393-40C>G::,MUTYH:ENST00000372098:intron_variant:MODIFIER:exon14/15:c.1468-40C>G::,MUTYH:ENST00000372100:intron_variant:MODIFIER:exon14/15:c.1426-40C>G::,MUTYH:ENST00000372104:intron_variant:MODIFIER:exon15/16:c.1393-40C>G::,MUTYH:ENST00000372110:intron_variant:MODIFIER:exon14/15:c.1438-40C>G::,MUTYH:ENST00000372115:intron_variant:MODIFIER:exon14/15:c.1435-40C>G::,MUTYH:ENST00000448481:intron_variant:MODIFIER:exon14/15:c.1426-40C>G::,MUTYH:ENST00000450313:intron_variant:MODIFIER:exon14/15:c.1477-40C>G::,MUTYH:ENST00000456914:intron_variant:MODIFIER:exon14/15:c.1393-40C>G::,MUTYH:ENST00000488731:intron_variant:MODIFIER:exon5/6:c.478-40C>G::,MUTYH:ENST00000528013:intron_variant:MODIFIER:exon14/15:c.1435-40C>G::,MUTYH:ENST00000528332:intron_variant:MODIFIER:exon5/6:c.520-40C>G::,MUTYH:ENST00000529984:intron_variant:MODIFIER:exon5/6:c.478-40C>G::,MUTYH:ENST00000531105:intron_variant:MODIFIER:exon2/2:c.116-1160C>G::		rs3219493	0.9353	0.9359		0.9586,0.9508,0.8891,0.9114,0.9175	0.9113,0.9555	0.2580			0.00,0.06	0.05		604933 [MUTYH (provisional) Adenomas,multiple colorectal,608456/Gastric cancer,somatic,613659/Colorectal adenomatous polyposis,autosomal recessive,with pilomatricomas,132600];	439920 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					MUTYH (inh=AR pLI=0.00)
chr1	45797505	45797505	C	G	het		QUAL=3120;DP=233;AF=0.52;MQM=60	MUTYH	missense,intron	MUTYH:ENST00000354383:missense_variant:MODERATE:exon12/16:c.933G>C:p.Gln311His:,MUTYH:ENST00000355498:missense_variant:MODERATE:exon12/16:c.930G>C:p.Gln310His:,MUTYH:ENST00000372098:missense_variant:MODERATE:exon12/16:c.1005G>C:p.Gln335His:,MUTYH:ENST00000372100:missense_variant:MODERATE:exon12/16:c.963G>C:p.Gln321His:,MUTYH:ENST00000372104:missense_variant:MODERATE:exon13/17:c.930G>C:p.Gln310His:,MUTYH:ENST00000372110:missense_variant:MODERATE:exon12/16:c.975G>C:p.Gln325His:,MUTYH:ENST00000372115:missense_variant:MODERATE:exon12/16:c.972G>C:p.Gln324His:,MUTYH:ENST00000448481:missense_variant:MODERATE:exon12/16:c.963G>C:p.Gln321His:,MUTYH:ENST00000450313:missense_variant:MODERATE:exon12/16:c.1014G>C:p.Gln338His:,MUTYH:ENST00000456914:missense_variant:MODERATE:exon12/16:c.930G>C:p.Gln310His:,MUTYH:ENST00000488731:intron_variant:MODIFIER:exon3/6:c.188-277G>C::,MUTYH:ENST00000528013:missense_variant:MODERATE:exon12/16:c.972G>C:p.Gln324His:,MUTYH:ENST00000528332:intron_variant:MODIFIER:exon3/6:c.230-277G>C::,MUTYH:ENST00000529984:intron_variant:MODIFIER:exon3/6:c.188-277G>C::,MUTYH:ENST00000531105:intron_variant:MODIFIER:exon2/2:c.116-2396G>C::		rs3219489	0.3135	0.2891		0.2621,0.4876,0.3969,0.2446,0.2371	0.2492,0.2637	0.0510	T,T,T,T,T,T,T,T,T,T, ,T, , , 	B,B,B,B,B,B,B,B,B,B, ,B, , , 	0.15,0.62	0.99	0.04	604933 [MUTYH (provisional) Adenomas,multiple colorectal,608456/Gastric cancer,somatic,613659/Colorectal adenomatous polyposis,autosomal recessive,with pilomatricomas,132600];	41767 [benign DISEASE=Hereditary cancer-predisposing syndrome,Carcinoma of colon,MYH-associated polyposis,not specified,not provided];	CM083726 [CLASS=DFP MUT=ALT PHEN="Reduced activity" GENE=MUTYH];		n/a (AF>5%)	n/a (AF>5%)					MUTYH (inh=AR pLI=0.00)
chr1	45798555	45798555	T	C	hom	off-target	QUAL=5837;DP=190;AF=1.00;MQM=60	MUTYH	intron	MUTYH:ENST00000354383:intron_variant:MODIFIER:exon6/15:c.423+35A>G::,MUTYH:ENST00000355498:intron_variant:MODIFIER:exon6/15:c.420+35A>G::,MUTYH:ENST00000372098:intron_variant:MODIFIER:exon6/15:c.495+35A>G::,MUTYH:ENST00000372100:intron_variant:MODIFIER:exon6/15:c.453+35A>G::,MUTYH:ENST00000372104:intron_variant:MODIFIER:exon7/16:c.420+35A>G::,MUTYH:ENST00000372110:intron_variant:MODIFIER:exon6/15:c.465+35A>G::,MUTYH:ENST00000372115:intron_variant:MODIFIER:exon6/15:c.462+35A>G::,MUTYH:ENST00000448481:intron_variant:MODIFIER:exon6/15:c.453+35A>G::,MUTYH:ENST00000450313:intron_variant:MODIFIER:exon6/15:c.504+35A>G::,MUTYH:ENST00000456914:intron_variant:MODIFIER:exon6/15:c.420+35A>G::,MUTYH:ENST00000488731:intron_variant:MODIFIER:exon2/6:c.116-49A>G::,MUTYH:ENST00000528013:intron_variant:MODIFIER:exon6/15:c.462+35A>G::,MUTYH:ENST00000528332:intron_variant:MODIFIER:exon2/6:c.158-49A>G::,MUTYH:ENST00000529984:intron_variant:MODIFIER:exon2/6:c.116-49A>G::,MUTYH:ENST00000531105:intron_variant:MODIFIER:exon2/2:c.115+1508A>G::		rs3219487	0.9371	0.9393		0.9672,0.9525,0.8883,0.9128,0.9191	0.9120,0.9660	-0.7130			0.03,0.17	-0.10		604933 [MUTYH (provisional) Adenomas,multiple colorectal,608456/Gastric cancer,somatic,613659/Colorectal adenomatous polyposis,autosomal recessive,with pilomatricomas,132600];	257529 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					MUTYH (inh=AR pLI=0.00)
chr1	62713224	62713224	C	G	hom		QUAL=1165;DP=37;AF=1.00;MQM=60	KANK4	missense	KANK4:ENST00000317477:missense_variant:MODERATE:exon3/4:c.217G>C:p.Val73Leu:PF12796,KANK4:ENST00000354381:missense_variant:MODERATE:exon8/9:c.919G>C:p.Val307Leu:PF12796,KANK4:ENST00000371150:missense_variant:MODERATE:exon6/7:c.871G>C:p.Val291Leu:PF12796,KANK4:ENST00000371153:missense_variant:MODERATE:exon9/10:c.2803G>C:p.Val935Leu:PF12796		rs2941679	0.9862	0.9755		0.9936,0.9870,0.9993,0.9637,0.9722	0.9598,0.9923	0.6970	T,T,T,T	B,B,B,B	0.42,0.96	1.53	0.04					n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62713246	62713246	G	A	het		QUAL=1311;DP=117;AF=0.44;MQM=60	KANK4	synonymous	KANK4:ENST00000317477:synonymous_variant:LOW:exon3/4:c.195C>T:p.His65=:PF12796,KANK4:ENST00000354381:synonymous_variant:LOW:exon8/9:c.897C>T:p.His299=:PF12796,KANK4:ENST00000371150:synonymous_variant:LOW:exon6/7:c.849C>T:p.His283=:PF12796,KANK4:ENST00000371153:synonymous_variant:LOW:exon9/10:c.2781C>T:p.His927=:PF12796		rs10889315	0.3189	0.3902		0.3189,0.3306,0.1573,0.4238,0.4071	0.4209,0.3323	-0.5170			0.15,0.93	0.12						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62728784	62728784	A	G	hom		QUAL=38237;DP=1208;AF=1.00;MQM=60	KANK4	5'UTR,missense	KANK4:ENST00000317477:5_prime_UTR_variant:MODIFIER:exon1/4:c.-68T>C::,KANK4:ENST00000354381:missense_variant:MODERATE:exon6/9:c.635T>C:p.Val212Ala:PF12796,KANK4:ENST00000371150:missense_variant:MODERATE:exon4/7:c.587T>C:p.Val196Ala:PF12796,KANK4:ENST00000371153:missense_variant:MODERATE:exon7/10:c.2519T>C:p.Val840Ala:PF12796		rs2666472		0.7543		0.5489,0.8598,0.8450,0.7364,0.7024	0.7338,0.5581	2.8410	 ,T,T,T	 ,B,B,B	0.78,0.95	0.81	0.16					n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62728838	62728838	T	C	hom		QUAL=35339;DP=1140;AF=1.00;MQM=60	KANK4	5'UTR,missense	KANK4:ENST00000317477:5_prime_UTR_variant:MODIFIER:exon1/4:c.-122A>G::,KANK4:ENST00000354381:missense_variant:MODERATE:exon6/9:c.581A>G:p.His194Arg:PF12796,KANK4:ENST00000371150:missense_variant:MODERATE:exon4/7:c.533A>G:p.His178Arg:PF12796,KANK4:ENST00000371153:missense_variant:MODERATE:exon7/10:c.2465A>G:p.His822Arg:PF12796		rs2258470		0.7543		0.5497,0.8599,0.8448,0.7364,0.7025	0.7340,0.5588	3.3080	 ,T,T,T	 ,B,B,B	0.14,0.94	1.32	0.10					n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62728861	62728861	T	C	hom		QUAL=35802;DP=1143;AF=1.00;MQM=60	KANK4	5'UTR,synonymous	KANK4:ENST00000317477:5_prime_UTR_variant:MODIFIER:exon1/4:c.-145A>G::,KANK4:ENST00000354381:synonymous_variant:LOW:exon6/9:c.558A>G:p.Lys186=:,KANK4:ENST00000371150:synonymous_variant:LOW:exon4/7:c.510A>G:p.Lys170=:,KANK4:ENST00000371153:synonymous_variant:LOW:exon7/10:c.2442A>G:p.Lys814=:		rs2260581	0.7163	0.7546		0.5505,0.8600,0.8450,0.7369,0.7025	0.7338,0.5588	0.5670			0.03,0.94	0.64						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62728918	62728918	G	A	hom		QUAL=5593;DP=187;AF=1.00;MQM=60	KANK4	5'UTR,synonymous	KANK4:ENST00000317477:5_prime_UTR_variant:MODIFIER:exon1/4:c.-202C>T::,KANK4:ENST00000354381:synonymous_variant:LOW:exon6/9:c.501C>T:p.Pro167=:,KANK4:ENST00000371150:synonymous_variant:LOW:exon4/7:c.453C>T:p.Pro151=:,KANK4:ENST00000371153:synonymous_variant:LOW:exon7/10:c.2385C>T:p.Pro795=:		rs2262110	0.7161	0.7547		0.5505,0.8598,0.8457,0.7372,0.7024	0.7338,0.5588	-1.7560			0.04,0.94	0.09						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62729015	62729015	G	A	hom	off-target	QUAL=7385;DP=225;AF=1.00;MQM=60	KANK4	5'UTR,intron	KANK4:ENST00000317477:5_prime_UTR_variant:MODIFIER:exon1/4:c.-299C>T::,KANK4:ENST00000354381:intron_variant:MODIFIER:exon5/8:c.436-32C>T::,KANK4:ENST00000371150:intron_variant:MODIFIER:exon3/6:c.388-32C>T::,KANK4:ENST00000371153:intron_variant:MODIFIER:exon6/9:c.2320-32C>T::		rs2262106	0.7095	0.7562		0.5266,0.8589,0.8478,0.7397,0.7032	0.7345,0.5345	0.3490			0.22,0.20	0.66						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62732421	62732421	T	C	het		QUAL=11256;DP=891;AF=0.52;MQM=60	KANK4	missense	KANK4:ENST00000354381:missense_variant:MODERATE:exon5/9:c.418A>G:p.Thr140Ala:,KANK4:ENST00000371150:missense_variant:MODERATE:exon3/7:c.370A>G:p.Thr124Ala:,KANK4:ENST00000371153:missense_variant:MODERATE:exon6/10:c.2302A>G:p.Thr768Ala:		rs11207949	0.3055	0.2960		0.2163,0.4804,0.5865,0.2444,0.1435	0.2449,0.2229	2.3800	T,T,T	B,B,B	0.76,0.33	1.21	0.02					n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62733939	62733939	G	A	het	off-target	QUAL=1676;DP=152;AF=0.46;MQM=60	KANK4	intron	KANK4:ENST00000354381:intron_variant:MODIFIER:exon4/8:c.347+20C>T::,KANK4:ENST00000371150:intron_variant:MODIFIER:exon2/6:c.299+20C>T::,KANK4:ENST00000371153:intron_variant:MODIFIER:exon5/9:c.2231+20C>T::		rs11207950	0.4669	0.4444		0.5710,0.3445,0.2618,0.4139,0.5669	0.4079,0.5570	-0.4570			0.00,0.08	-0.36						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62738904	62738904	T	C	hom		QUAL=2015;DP=76;AF=0.99;MQM=60	KANK4	intron,synonymous	KANK4:ENST00000354381:intron_variant:MODIFIER:exon2/8:c.17-1643A>G::,KANK4:ENST00000371153:synonymous_variant:LOW:exon3/10:c.1872A>G:p.Pro624=:		rs7516290	0.8005	0.7708		0.8575,0.8322,0.8472,0.6895,0.7521	0.6733,0.8543	-0.8540			0.05,0.20	-0.09						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62739198	62739198	G	A	het		QUAL=1755;DP=140;AF=0.49;MQM=60	KANK4	intron,synonymous	KANK4:ENST00000354381:intron_variant:MODIFIER:exon2/8:c.17-1937C>T::,KANK4:ENST00000371153:synonymous_variant:LOW:exon3/10:c.1578C>T:p.Ser526=:		rs17855078	0.2506	0.3046		0.1788,0.2194,0.1247,0.3392,0.4043	0.3309,0.1879	-1.6330			0.07,0.11	-0.64						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62740065	62740065	A	G	het		QUAL=1450;DP=128;AF=0.48;MQM=60	KANK4	intron,synonymous	KANK4:ENST00000354381:intron_variant:MODIFIER:exon2/8:c.17-2804T>C::,KANK4:ENST00000371153:synonymous_variant:LOW:exon3/10:c.711T>C:p.Gly237=:		rs12127930	0.4822	0.4849		0.6175,0.3585,0.2607,0.4389,0.5678	0.4271,0.6078	-1.6810			0.05,0.15	-0.23						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62740446	62740446	T	C	hom		QUAL=7384;DP=239;AF=1.00;MQM=60	KANK4	intron,synonymous	KANK4:ENST00000354381:intron_variant:MODIFIER:exon2/8:c.17-3185A>G::,KANK4:ENST00000371153:synonymous_variant:LOW:exon3/10:c.330A>G:p.Pro110=:		rs2666506	0.8045	0.7700		0.8594,0.8400,0.8650,0.6864,0.7416	0.6742,0.8545	0.0250			0.00,0.20	-0.00						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62740449	62740449	T	C	hom		QUAL=7384;DP=239;AF=1.00;MQM=60	KANK4	intron,synonymous	KANK4:ENST00000354381:intron_variant:MODIFIER:exon2/8:c.17-3188A>G::,KANK4:ENST00000371153:synonymous_variant:LOW:exon3/10:c.327A>G:p.Ser109=:		rs2666507	0.7809	0.7454		0.7771,0.8364,0.8650,0.6862,0.7415	0.6734,0.7730	-1.5990			0.04,0.10	-0.49						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	62740781	62740781	A	-	het	off-target	QUAL=265;DP=121;AF=0.20;MQM=60	KANK4	intron	KANK4:ENST00000354381:intron_variant:MODIFIER:exon2/8:c.17-3520del::,KANK4:ENST00000371153:intron_variant:MODIFIER:exon2/9:c.17-22del::		rs761923018		0.1147		0.0808,0.1637,0.1023,0.1015,0.1765	0.1190,0.1121	0.6420				0.73						n/a (AF>5%)	n/a (AF>5%)					KANK4 (inh=n/a pLI=0.00)
chr1	78578177	78578177	T	C	het		QUAL=4972;DP=413;AF=0.46;MQM=60	GIPC2	intron	GIPC2:ENST00000370759:intron_variant:MODIFIER:exon3/5:c.608-6900T>C::		rs6666954	0.4489	0.3769		0.6107,0.2545,0.6169,0.2756,0.2706	0.2785,0.5873	-1.2050			0.00,0.05	-0.14						n/a (AF>5%)	n/a (AF>5%)					GIPC2 (inh=n/a pLI=0.00)
chr1	120458004	120458004	A	T	het		QUAL=1768;DP=133;AF=0.55;MQM=60	NOTCH2	synonymous	NOTCH2:ENST00000256646:synonymous_variant:LOW:exon34/34:c.7341T>A:p.Gly2447=:		rs6685892	0.1925	0.1687		0.3371,0.0878,0.0292,0.1029,0.1895	0.1038,0.3243	-0.5740			0.09,0.21	1.06		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];	261705 [benign DISEASE=not specified];		COSM5019691	n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120471857	120471857	C	T	het	off-target	QUAL=525;DP=29;AF=0.69;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon22/33:c.3656-22G>A::		rs2493392	0.1925	0.1687		0.3364,0.0876,0.0291,0.1022,0.1898	0.1036,0.3239	0.3380			0.04,0.24	0.03		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120477998	120477998	C	A	het	off-target	QUAL=286;DP=19;AF=0.63;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon22/33:c.3655+97G>T::		rs2453056	0.3013	0.2426		0.5315,0.1818,0.0999,0.1228,0.3015		-0.0200			0.00,0.09	0.01		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120478285	120478285	T	C	het	off-target	QUAL=11662;DP=892;AF=0.51;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon21/33:c.3523-58A>G::		rs5025718	0.6044	0.6698				-1.6160			0.02,0.13	0.08		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120484421	120484421	G	A	het	off-target	QUAL=762;DP=65;AF=0.49;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon17/33:c.2753-44C>T::		rs2493420	0.2714	0.2168		0.4423,0.1785,0.1010,0.1236,0.3023	0.1231,0.4082	0.0360			0.00,0.10	0.30		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120496119	120496119	A	T	het	off-target	QUAL=7154;DP=639;AF=0.45;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon14/33:c.2365+47T>A::		rs7534585	0.1923	0.1672		0.3364,0.0879,0.0292,0.1022,0.1884	0.1031,0.3236	0.2040			0.06,0.22	0.17		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120496127	120496127	A	C	het	off-target	QUAL=7123;DP=638;AF=0.45;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon14/33:c.2365+39T>G::		rs7534586	0.1923	0.1671		0.3364,0.0879,0.0292,0.1022,0.1884	0.1030,0.3236	-0.0920			0.08,0.23	0.17		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120512104	120512104	T	C	hom	off-target	QUAL=18002;DP=571;AF=1.00;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon6/33:c.1108+30A>G::		rs2493409	0.9786	0.9943		0.9216,0.9966,1.0000,0.9995,0.9997	0.9993,0.9233	-2.1020			0.02,0.11	-0.40		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120529750	120529750	A	C	het	off-target	QUAL=11339;DP=925;AF=0.48;MQM=60	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon4/33:c.752-45T>G::		rs2453040	0.1907	0.1663		0.3312,0.0868,0.0295,0.1014,0.1883	0.1026,0.3162	-0.0020			0.09,0.41	0.29		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120539331	120539331	C	T	het		QUAL=25003;DP=1918;AF=0.52;MQM=49	NOTCH2	intron,missense	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon4/33:c.751+289G>A::,NOTCH2:ENST00000602566:missense_variant:MODERATE:exon6/6:c.673G>A:p.Gly225Arg:		rs2124109		0.4380		0.2356,0.4172,0.4619,0.4569,0.4525		-0.7660	 ,T	 ,P	0.02,0.14	0.31		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120611496	120611496	C	A	het		QUAL=276;DP=41;AF=0.49;MQM=47	NOTCH2	intron	NOTCH2:ENST00000256646:intron_variant:MODIFIER:exon1/33:c.73+452G>T::		rs2794164		0.4984		0.5036,0.2933,0.4240,0.2133,0.2382		0.1850			0.00,0.10	0.35		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120611960	120611960	C	T	het		QUAL=4582;DP=1978;AF=0.21;MQM=47	NOTCH2	missense	NOTCH2:ENST00000256646:missense_variant:MODERATE:exon1/34:c.61G>A:p.Ala21Thr:		rs2603926		0.1205		0.1959,0.0625,0.0519,0.1582,0.0937		0.4330	T	B	0.26,0.89	1.55	0.05	600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];			COSM1600651	n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120611964	120611964	G	C	het		QUAL=16640;DP=1978;AF=0.38;MQM=59	NOTCH2	missense	NOTCH2:ENST00000256646:missense_variant:MODERATE:exon1/34:c.57C>G:p.Cys19Trp:		rs11810554		0.4433		0.2568,0.4275,0.4670,0.4594,0.4559		0.7670	T	B	0.33,0.90	2.20	0.10	600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];			COSM132738	n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120612003	120612004	GG	-	het		QUAL=3950;DP=2047;AF=0.20;MQM=48	NOTCH2	frameshift	NOTCH2:ENST00000256646:frameshift_variant:HIGH:exon1/34:c.17_18del:p.Pro6ArgfsTer27:		rs372504208,rs864309621		0.1800		0.2102,0.1169,0.1142,0.2152,0.1600		0.6960				3.04		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];	218795 [benign DISEASE=not specified];		COSM132830	n/a (AF>5%)	n/a (AF>5%)				DX132253_01: wahrscheinlich durch Pseudogen	NOTCH2 (inh=AD pLI=1.00)
chr1	120612006	120612006	G	A	het		QUAL=18646;DP=2048;AF=0.39;MQM=58	NOTCH2	synonymous	NOTCH2:ENST00000256646:synonymous_variant:LOW:exon1/34:c.15C>T:p.Arg5=:		rs4021006	0.3940	0.4512		0.2971,0.4472,0.4627,0.4603,0.4676		1.0740			0.19,0.89	1.46		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];			COSM1320072,COSM1738498	n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr1	120612034	120612034	T	G	het		QUAL=3544;DP=2047;AF=0.20;MQM=47	NOTCH2	5'UTR	NOTCH2:ENST00000256646:5_prime_UTR_variant:MODIFIER:exon1/34:c.-14A>C::	(CGC)n	rs201668322		0.0631		0.0782,0.0294,0.0328,0.0946,0.0343		0.2430			0.16,0.88	1.41		600275 [NOTCH2 (provisional) Alagille syndrome 2,610205/Hajdu-Cheney syndrome,102500];				n/a (AF>5%)	n/a (AF>5%)					NOTCH2 (inh=AD pLI=1.00)
chr2	17941423	17941423	T	G	hom	off-target	QUAL=1007;DP=33;AF=1.00;MQM=60	GEN1,SMC6	intron	GEN1:ENST00000317402:intron_variant:MODIFIER:exon2/13:c.161+52T>G::,GEN1:ENST00000381254:intron_variant:MODIFIER:exon2/13:c.161+52T>G::,SMC6:ENST00000402989:intron_variant:MODIFIER:exon4/29:c.-5-14205A>C::		rs2555072		0.6819		0.4700,0.8168,0.9576,0.6206,0.8617	0.6241,0.5026	-0.6670			0.14,0.18	-0.26						n/a (AF>5%)	n/a (AF>5%)					GEN1 (inh=n/a pLI=0.00), SMC6 (inh=n/a pLI=0.50)
chr2	17942775	17942775	T	A	hom		QUAL=3038;DP=92;AF=1.00;MQM=60	GEN1,SMC6	missense,intron	GEN1:ENST00000317402:missense_variant:MODERATE:exon3/14:c.274T>A:p.Ser92Thr:PF00752,GEN1:ENST00000381254:missense_variant:MODERATE:exon3/14:c.274T>A:p.Ser92Thr:PF00752,SMC6:ENST00000402989:intron_variant:MODIFIER:exon4/29:c.-5-15557A>T::		rs1812152		0.7162		0.7641,0.8391,0.9843,0.6234,0.8736	0.6259,0.7596	0.5660	T,T, 	B,B, 	0.02,0.90	1.00	0.03					n/a (AF>5%)	n/a (AF>5%)					GEN1 (inh=n/a pLI=0.00), SMC6 (inh=n/a pLI=0.50)
chr2	17954027	17954027	G	A	hom		QUAL=972;DP=30;AF=1.00;MQM=60	GEN1,SMC6	missense,intron	GEN1:ENST00000317402:missense_variant:MODERATE:exon8/14:c.929G>A:p.Ser310Asn:,GEN1:ENST00000381254:missense_variant:MODERATE:exon8/14:c.929G>A:p.Ser310Asn:,SMC6:ENST00000402989:intron_variant:MODIFIER:exon4/29:c.-6+15055C>T::		rs300175	0.9770	0.9944		0.9513,0.9973,0.9998,0.9999,0.9843	0.9998,0.9519	-2.1940	T,T, 	B,B, 	0.01,0.10	-0.80	0.02					n/a (AF>5%)	n/a (AF>5%)					GEN1 (inh=n/a pLI=0.00), SMC6 (inh=n/a pLI=0.50)
chr2	17954421	17954421	C	G	hom	off-target	QUAL=3002;DP=93;AF=1.00;MQM=60	GEN1,SMC6	intron	GEN1:ENST00000317402:intron_variant:MODIFIER:exon9/13:c.990+22C>G::,GEN1:ENST00000381254:intron_variant:MODIFIER:exon9/13:c.990+22C>G::,SMC6:ENST00000402989:intron_variant:MODIFIER:exon4/29:c.-6+14661G>C::		rs300177		0.7152		0.7546,0.8384,0.9845,0.6231,0.8733	0.6277,0.7523	-1.9120			0.00,0.09	-0.28						n/a (AF>5%)	n/a (AF>5%)					GEN1 (inh=n/a pLI=0.00), SMC6 (inh=n/a pLI=0.50)
chr2	17962450	17962450	A	G	hom		QUAL=3083;DP=96;AF=1.00;MQM=60	GEN1,SMC6	synonymous,intron	GEN1:ENST00000317402:synonymous_variant:LOW:exon14/14:c.1971A>G:p.Glu657=:,GEN1:ENST00000381254:synonymous_variant:LOW:exon14/14:c.1971A>G:p.Glu657=:,SMC6:ENST00000402989:intron_variant:MODIFIER:exon4/29:c.-6+6632T>C::		rs300168	0.5739	0.5886		0.2141,0.7476,0.9232,0.5148,0.7681	0.5184,0.2460	0.4800			0.72,0.96	1.78						n/a (AF>5%)	n/a (AF>5%)					GEN1 (inh=n/a pLI=0.00), SMC6 (inh=n/a pLI=0.50)
chr2	17962518	17962518	C	T	hom		QUAL=3598;DP=112;AF=1.00;MQM=60	GEN1,SMC6	missense,intron	GEN1:ENST00000317402:missense_variant:MODERATE:exon14/14:c.2039C>T:p.Thr680Ile:,GEN1:ENST00000381254:missense_variant:MODERATE:exon14/14:c.2039C>T:p.Thr680Ile:,SMC6:ENST00000402989:intron_variant:MODIFIER:exon4/29:c.-6+6564G>A::		rs300169	0.7580	0.7038		0.5955,0.8280,0.9844,0.6225,0.8732	0.6245,0.6074	0.1800	T,T, 	B,B, 	0.00,0.16	1.03	0.05					n/a (AF>5%)	n/a (AF>5%)					GEN1 (inh=n/a pLI=0.00), SMC6 (inh=n/a pLI=0.50)
chr2	47601106	47601106	T	C	het		QUAL=747;DP=42;AF=0.71;MQM=60	EPCAM	missense	EPCAM:ENST00000263735:missense_variant:MODERATE:exon3/9:c.344T>C:p.Met115Thr:PF00086,EPCAM:ENST00000405271:missense_variant:MODERATE:exon4/10:c.428T>C:p.Met143Thr:PF00086		rs1126497	0.6661	0.6033		0.8448,0.4716,0.8317,0.4363,0.4807	0.4328,0.8282	0.0410	T,T	B,B	0.08,0.17	1.40	0.18	185535 [EPCAM (confirmed) Diarrhea 5,with tufting enteropathy,congenital,613217/Colorectal cancer,hereditary nonpolyposis,type 8,613244];	183700 [benign/likely benign DISEASE=Hereditary nonpolyposis colon cancer,Hereditary cancer-predisposing syndrome,Lynch syndrome,Lynch syndrome I,not specified];			n/a (AF>5%)	n/a (AF>5%)					EPCAM (inh=AR pLI=0.00)
chr2	47635523	47635523	-	T	het	off-target	QUAL=28;DP=20;AF=0.30;MQM=60	MSH2	intron	MSH2:ENST00000233146:intron_variant:MODIFIER:exon1/15:c.212-4dup::,MSH2:ENST00000406134:intron_variant:MODIFIER:exon1/15:c.212-4dup::,MSH2:ENST00000543555:intron_variant:MODIFIER:exon2/16:c.14-4dup::		rs757515274		0.1994		0.1577,0.2548,0.2148,0.1722,0.2578	0.0400,0.0347					0.04		609309 [MSH2 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 1,120435/Muir-Torre syndrome,158320/Mismatch repair cancer syndrome,276300];	491795 [benign DISEASE=Hereditary cancer-predisposing syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					MSH2 (inh=AR+AD pLI=1.00)
chr2	48010488	48010488	G	A	het		QUAL=143;DP=14;AF=0.50;MQM=60	MSH6	missense	MSH6:ENST00000234420:missense_variant:MODERATE:exon1/10:c.116G>A:p.Gly39Glu:,MSH6:ENST00000540021:missense_variant:MODERATE:exon1/8:c.116G>A:p.Gly39Glu:		rs1042821	0.2009	0.1903		0.2197,0.1038,0.2522,0.1805,0.2120	0.1724,0.1940	1.7020	T,T	B,B	0.05,0.69	1.14	0.16	600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	36581 [benign DISEASE=Hereditary nonpolyposis colon cancer,Hereditary cancer-predisposing syndrome,Lynch syndrome,Hereditary nonpolyposis colorectal cancer type 5,Lynch syndrome I,not specified,not provided];	CM092149 [CLASS=DP MUT=ALT PHEN="Colorectal cancer association with" GENE=MSH6];	COSM3749667	n/a (AF>5%)	n/a (AF>5%)					MSH6 (inh=AR+AD pLI=n/a)
chr2	48018030	48018030	A	G	het	off-target	QUAL=10785;DP=929;AF=0.46;MQM=60	MSH6,FBXO11	intron	MSH6:ENST00000234420:intron_variant:MODIFIER:exon1/9:c.261-36A>G::,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.170-1451T>C::,MSH6:ENST00000538136:intron_variant:MODIFIER:exon1/9:c.-642-36A>G::,MSH6:ENST00000540021:intron_variant:MODIFIER:exon1/7:c.237+7421A>G::		rs1800931	0.0220	0.0389		0.0091,0.0337,0.0191,0.0541,0.0169	0.0536,0.0111	0.8590			0.23,0.27	0.27		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	89301 [benign DISEASE=Lynch syndrome];			11	563					MSH6 (inh=AR+AD pLI=n/a), FBXO11 (inh=AD pLI=1.00)
chr2	48022981	48022981	G	T	het	off-target	QUAL=281;DP=26;AF=0.46;MQM=60	MSH6,FBXO11	intron	MSH6:ENST00000234420:intron_variant:MODIFIER:exon2/9:c.458-52G>T::,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.170-6402C>A::,MSH6:ENST00000538136:intron_variant:MODIFIER:exon2/9:c.-445-52G>T::,MSH6:ENST00000540021:intron_variant:MODIFIER:exon1/7:c.238-2769G>T::	FLAM_C	rs1800934	0.2244	0.2087			0.1912,0.3054	0.3750			0.03,0.14	-0.00		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	89532 [benign DISEASE=Lynch syndrome];			n/a (AF>5%)	n/a (AF>5%)					MSH6 (inh=AR+AD pLI=n/a), FBXO11 (inh=AD pLI=1.00)
chr2	48030692	48030692	T	A	het		QUAL=247;DP=17;AF=0.65;MQM=60	MSH6,FBXO11	synonymous,intron	MSH6:ENST00000234420:synonymous_variant:LOW:exon5/10:c.3306T>A:p.Thr1102=:PF00488,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.169+4642A>T::,MSH6:ENST00000538136:synonymous_variant:LOW:exon5/10:c.2400T>A:p.Thr800=:PF00488,MSH6:ENST00000540021:synonymous_variant:LOW:exon3/8:c.2916T>A:p.Thr972=:PF00488		rs2020910	0.0493	0.0197		0.0079,0.0139,0.2025,0.0018,0.0081	0.0016,0.0100	-2.3650			0.11,0.41	0.53		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	36589 [benign DISEASE=Hereditary nonpolyposis colon cancer,Hereditary cancer-predisposing syndrome,Lynch syndrome,Hereditary nonpolyposis colorectal cancer type 5,not specified];		COSM5021075	3	72	1	[1] Ilnaz Sepahi 29-03-2016 batch import			MSH6 (inh=AR+AD pLI=n/a), FBXO11 (inh=AD pLI=1.00)
chr2	48030838	48030838	A	T	het	off-target	QUAL=2490;DP=238;AF=0.49;MQM=60	MSH6,FBXO11	intron	MSH6:ENST00000234420:intron_variant:MODIFIER:exon5/9:c.3438+14A>T::,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.169+4496T>A::,MSH6:ENST00000538136:intron_variant:MODIFIER:exon5/9:c.2532+14A>T::,MSH6:ENST00000540021:intron_variant:MODIFIER:exon3/7:c.3048+14A>T::		rs2020911	0.4010	0.4111		0.1669,0.5087,0.6244,0.3818,0.4773	0.3816,0.1838	-0.1210			0.04,0.24	-0.04		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	42471 [benign DISEASE=Hereditary cancer-predisposing syndrome,Lynch syndrome,Hereditary nonpolyposis colorectal cancer type 5,not specified];			n/a (AF>5%)	n/a (AF>5%)					MSH6 (inh=AR+AD pLI=n/a), FBXO11 (inh=AD pLI=1.00)
chr2	48032875	48032878	CTAT	-	het	off-target	QUAL=603;DP=44;AF=0.59;MQM=60	MSH6,FBXO11	intron	MSH6:ENST00000234420:intron_variant:MODIFIER:exon7/9:c.3646+35_3646+38del::,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.169+2456_169+2459del::,MSH6:ENST00000538136:intron_variant:MODIFIER:exon7/9:c.2740+35_2740+38del::,MSH6:ENST00000540021:intron_variant:MODIFIER:exon5/7:c.3256+35_3256+38del::		rs2234731	0.7622	0.7064		0.8014,0.5294,0.8699,0.6766,0.7267	0.6648,0.7917	0.4270				-0.15		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	89429 [benign DISEASE=Lynch syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					MSH6 (inh=AR+AD pLI=n/a), FBXO11 (inh=AD pLI=1.00)
chr2	48033551	48033551	C	G	hom	off-target	QUAL=1514;DP=48;AF=1.00;MQM=60	MSH6,FBXO11	intron	MSH6:ENST00000234420:intron_variant:MODIFIER:exon8/9:c.3802-40C>G::,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.169+1783G>C::,MSH6:ENST00000538136:intron_variant:MODIFIER:exon8/9:c.2896-40C>G::,MSH6:ENST00000540021:intron_variant:MODIFIER:exon6/7:c.3412-40C>G::		rs3136367	0.8091	0.7725		0.9189,0.6161,0.8824,0.7299,0.7407	0.7231,0.9124	-0.1120			0.08,0.21	-0.16		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	36594 [benign DISEASE=Lynch syndrome,Hereditary nonpolyposis colorectal cancer type 5,not specified];			n/a (AF>5%)	n/a (AF>5%)					MSH6 (inh=AR+AD pLI=n/a), FBXO11 (inh=AD pLI=1.00)
chr2	48033891	48033891	T	-	het	off-target	QUAL=298;DP=38;AF=0.45;MQM=60	MSH6,FBXO11	intron	MSH6:ENST00000234420:intron_variant:MODIFIER:exon9/9:c.4002-10del::,FBXO11:ENST00000405808:intron_variant:MODIFIER:exon3/3:c.169+1443del::,MSH6:ENST00000538136:intron_variant:MODIFIER:exon9/9:c.3096-10del::,MSH6:ENST00000540021:intron_variant:MODIFIER:exon7/7:c.3612-10del::	(T)n			0.2881				-1.0950				-0.32		600678 [MSH6 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 5,614350/Endometrial cancer,familial,608089/Mismatch repair cancer syndrome,276300];	89508 [likely benign DISEASE=Lynch syndrome,Hereditary nonpolyposis colorectal cancer type 5,not specified];			n/a (AF>5%)	n/a (AF>5%)					MSH6 (inh=AR+AD pLI=n/a), FBXO11 (inh=AD pLI=1.00)
chr2	147596973	147596973	A	G	het		QUAL=10825;DP=818;AF=0.51;MQM=60	AC103881.1	intron&non_coding_transcript	AC103881.1:ENST00000450667:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/5:n.229+1200A>G::		rs4411641	0.5090	0.4881		0.6482,0.6136,0.4410,0.3989,0.4074	0.3998,0.6284	0.2240			0.00,0.04	0.15						n/a (AF>5%)	n/a (AF>5%)					AC103881.1 (inh=n/a pLI=n/a)
chr2	190670539	190670539	-	A	het	off-target	QUAL=45;DP=44;AF=0.20;MQM=60	PMS1	intron,frameshift	PMS1:ENST00000374826:intron_variant:MODIFIER:exon4/4:c.418+70dup::,PMS1:ENST00000409823:intron_variant:MODIFIER:exon4/11:c.418+70dup::,PMS1:ENST00000409985:frameshift_variant:HIGH:exon4/4:c.488dup:p.Leu164ValfsTer4:,PMS1:ENST00000418224:intron_variant:MODIFIER:exon3/11:c.-111+9873dup::,PMS1:ENST00000432292:intron_variant:MODIFIER:exon2/10:c.-110-12193dup::,PMS1:ENST00000441310:intron_variant:MODIFIER:exon4/12:c.418+70dup::,PMS1:ENST00000447232:intron_variant:MODIFIER:exon4/11:c.418+70dup::		rs555414470	0.2153	0.2766		0.3378,0.3240,0.3033,0.2619,0.2157						0.18						n/a (AF>5%)	n/a (AF>5%)					PMS1 (inh=AD pLI=0.00)
chr2	215595164	215595164	G	A	het		QUAL=261;DP=27;AF=0.44;MQM=60	BARD1	missense	BARD1:ENST00000260947:missense_variant:MODERATE:exon10/11:c.1972C>T:p.Arg658Cys:,BARD1:ENST00000432456:missense_variant:MODERATE:exon2/3:c.85C>T:p.Arg29Cys:,BARD1:ENST00000449967:missense_variant:MODERATE:exon9/10:c.1540C>T:p.Arg514Cys:		rs3738888	0.0054	0.0084		0.0020,0.0123,0.0111,0.0087,0.0041	0.0078,0.0023	5.1660	D,D,D	B,B,B	0.98,0.99	3.81	0.10	601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	136500 [benign/likely benign DISEASE=Neoplasm of the breast,Hereditary cancer-predisposing syndrome,Familial cancer of breast,not specified];	CM067650 [CLASS=DP MUT=ALT PHEN="Lung cancer susceptibility to association with" GENE=BARD1];		0	73	2	[2] Ilnaz Sepahi 29-03-2016 batch import	n/a (1xTP, 0xFP)		BARD1 (inh=n/a pLI=0.00)
chr2	215610638	215610638	A	G	het	off-target	QUAL=3825;DP=272;AF=0.51;MQM=60	BARD1	intron	BARD1:ENST00000260947:intron_variant:MODIFIER:exon7/10:c.1678-60T>C::,BARD1:ENST00000449967:intron_variant:MODIFIER:exon6/9:c.1246-60T>C::		rs4986842	0.0030	0.0060				-0.7960			0.06,0.18	0.12		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];				0	62					BARD1 (inh=n/a pLI=0.00)
chr2	215632155	215632155	T	C	het	off-target	QUAL=1539;DP=109;AF=0.57;MQM=60	BARD1	intron	BARD1:ENST00000260947:intron_variant:MODIFIER:exon6/10:c.1568+51A>G::,BARD1:ENST00000449967:intron_variant:MODIFIER:exon5/9:c.1136+51A>G::		rs5031009	0.3662	0.3854		0.3696,0.2928,0.3651,0.3679,0.4028	0.3567,0.3643	-2.0190			0.01,0.14	-0.07		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];				n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215632192	215632192	G	A	het	off-target	QUAL=1787;DP=114;AF=0.57;MQM=60	BARD1	intron	BARD1:ENST00000260947:intron_variant:MODIFIER:exon6/10:c.1568+14C>T::,BARD1:ENST00000449967:intron_variant:MODIFIER:exon5/9:c.1136+14C>T::		rs5031011	0.3522	0.3655		0.3454,0.2870,0.3680,0.3483,0.3945	0.3333,0.3393	-0.8300			0.02,0.20	0.11		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	256214 [benign/likely benign DISEASE=Neoplasm of the breast,Hereditary cancer-predisposing syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215632255	215632255	C	T	het		QUAL=3044;DP=110;AF=0.55;MQM=60	BARD1	missense	BARD1:ENST00000260947:missense_variant:MODERATE:exon6/11:c.1519G>A:p.Val507Met:PF00023,BARD1:ENST00000449967:missense_variant:MODERATE:exon5/10:c.1087G>A:p.Val363Met:PF00023		rs2070094	0.3662	0.3845		0.3734,0.2944,0.3679,0.3711,0.4038	0.2758,0.2901	-5.2630	T,T	B,B	0.02,0.15	-0.39	0.11	601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	140757 [benign/likely benign DISEASE=Neoplasm of the breast,Hereditary cancer-predisposing syndrome,not specified];	CM034384 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=BARD1];		n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215632256	215632256	A	G	hom		QUAL=3044;DP=110;AF=0.55;MQM=60	BARD1	synonymous	BARD1:ENST00000260947:synonymous_variant:LOW:exon6/11:c.1518T>C:p.His506=:PF00023,BARD1:ENST00000449967:synonymous_variant:LOW:exon5/10:c.1086T>C:p.His362=:PF00023		rs2070093	0.7706	0.8177		0.5952,0.8163,0.9529,0.8063,0.8421	0.7806,0.5835	-0.3720			0.01,0.18	0.14		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	183704 [benign/likely benign DISEASE=Neoplasm of the breast,Hereditary cancer-predisposing syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215634055	215634055	C	T	het	off-target	QUAL=2564;DP=270;AF=0.47;MQM=60	BARD1	intron	BARD1:ENST00000260947:intron_variant:MODIFIER:exon4/10:c.1315-19G>A::,BARD1:ENST00000449967:intron_variant:MODIFIER:exon3/9:c.883-19G>A::		rs6704780	0.3652	0.3855		0.3729,0.2943,0.3675,0.3707,0.4014	0.3570,0.3645	-2.4810			0.01,0.31	-0.12		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	256213 [benign DISEASE=Hereditary cancer-predisposing syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215645464	215645464	C	G	het		QUAL=1090;DP=79;AF=0.53;MQM=60	BARD1	missense	BARD1:ENST00000260947:missense_variant:MODERATE:exon4/11:c.1134G>C:p.Arg378Ser:,BARD1:ENST00000449967:missense_variant:MODERATE:exon3/10:c.702G>C:p.Arg234Ser:		rs2229571	0.4593	0.5519		0.3956,0.4112,0.3660,0.6166,0.4856	0.6008,0.3972	-0.6010	T,T	B,B	0.12,0.22	0.56	0.11	601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	142769 [benign/likely benign DISEASE=Neoplasm of the breast,Hereditary cancer-predisposing syndrome,Familial cancer of breast,not specified];	CM076014 [CLASS=DP MUT=ALT PHEN="Breast cancer reduced risk association with" GENE=BARD1];		n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215674090	215674090	T	G	hom	off-target	QUAL=3891;DP=122;AF=1.00;MQM=60	BARD1	intron	BARD1:ENST00000260947:intron_variant:MODIFIER:exon1/10:c.158+46A>C::,BARD1:ENST00000449967:intron_variant:MODIFIER:exon1/9:c.-126+46A>C::		rs35933323	0.7448	0.7484		0.7659,0.8213,0.8132,0.7130,0.6652	0.7315,0.7785	0.1840			0.00,0.07	0.45		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];				n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215674224	215674224	G	A	het		QUAL=8572;DP=821;AF=0.50;MQM=60	BARD1	missense,5'UTR	BARD1:ENST00000260947:missense_variant:MODERATE:exon1/11:c.70C>T:p.Pro24Ser:,BARD1:ENST00000449967:5_prime_UTR_variant:MODIFIER:exon1/10:c.-214C>T::		rs1048108	0.3313	0.3842		0.2181,0.4331,0.3594,0.3776,0.4095	0.3474,0.2153	0.9680	T, 	B, 	0.26,0.91	1.77	0.26	601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	183698 [benign/likely benign DISEASE=Neoplasm of the breast,Hereditary cancer-predisposing syndrome,Familial cancer of breast,not specified];	CM076015 [CLASS=DP MUT=ALT PHEN="Breast cancer reduced risk association with" GENE=BARD1];		n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215674323	215674323	C	G	hom	off-target	QUAL=3254;DP=107;AF=1.00;MQM=60	BARD1	5'UTR	BARD1:ENST00000260947:5_prime_UTR_variant:MODIFIER:exon1/11:c.-30G>C::,BARD1:ENST00000449967:5_prime_UTR_variant:MODIFIER:exon1/10:c.-313G>C::		rs1129804	0.7446	0.7473		0.7652,0.8158,0.8033,0.7081,0.6645	0.7567,0.7998	-0.5760			0.00,0.15	0.21		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	334199 [likely benign DISEASE=Neoplasm of the breast];			n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	215674341	215674341	A	G	hom	off-target	QUAL=3159;DP=106;AF=1.00;MQM=60	BARD1	5'UTR	BARD1:ENST00000260947:5_prime_UTR_variant:MODIFIER:exon1/11:c.-48T>C::,BARD1:ENST00000449967:5_prime_UTR_variant:MODIFIER:exon1/10:c.-331T>C::		rs17489363	0.7450	0.7475		0.7654,0.8159,0.8044,0.7068,0.6635	0.7734,0.8096	-2.4040			0.00,0.10	0.44		601593 [BARD1 (confirmed) Breast cancer,susceptibility to,114480];	334200 [likely benign DISEASE=Neoplasm of the breast];			n/a (AF>5%)	n/a (AF>5%)					BARD1 (inh=n/a pLI=0.00)
chr2	220415596	220415597	GA	-	hom	off-target	QUAL=4914;DP=162;AF=0.99;MQM=60	OBSL1	intron	OBSL1:ENST00000265318:intron_variant:MODIFIER:exon19/19:c.*1078-33_*1078-32del::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon19/19:c.5408-33_5408-32del::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon20/20:c.5684-33_5684-32del::		rs146790993	0.3840	0.4482		0.3842,0.5366,0.4071,0.4443,0.2440	0.4530,0.4066	1.3400				0.86		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220416570	220416570	C	T	hom	off-target	QUAL=341;DP=13;AF=1.00;MQM=60	OBSL1	intron	OBSL1:ENST00000265318:intron_variant:MODIFIER:exon18/19:c.*808-50G>A::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon18/19:c.5138-50G>A::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon19/20:c.5414-50G>A::		rs4672931	0.9287	0.9774		0.7687,0.9821,0.9999,0.9937,0.9992	0.9935,0.8563	-2.3550			0.05,0.17	0.49		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220416803	220416803	A	T	hom	off-target	QUAL=37811;DP=1170;AF=1.00;MQM=60	OBSL1	intron	OBSL1:ENST00000265318:intron_variant:MODIFIER:exon18/19:c.*807+31T>A::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon18/19:c.5137+31T>A::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon19/20:c.5413+31T>A::		rs4672933	0.9782	0.9954		0.9348,0.9955,0.9999,0.9996,0.9998	0.9996,0.9454	-0.5070			0.02,0.21	0.09		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220416942	220416942	G	C	hom		QUAL=1045;DP=34;AF=1.00;MQM=60	OBSL1	splice_region&intron	OBSL1:ENST00000265318:splice_region_variant&intron_variant:LOW:exon17/19:c.*703-4C>G::,OBSL1:ENST00000373876:splice_region_variant&intron_variant:LOW:exon17/19:c.5033-4C>G::,OBSL1:ENST00000404537:splice_region_variant&intron_variant:LOW:exon18/20:c.5309-4C>G::		rs34490902	0.3876	0.4581		0.4036,0.5492,0.4241,0.4683,0.2594	0.4551,0.3923	-0.7820			0.04,0.27	1.36		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	194972 [benign DISEASE=Three M syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220417228	220417228	G	T	hom	off-target	QUAL=2363;DP=79;AF=1.00;MQM=60	OBSL1	intron	OBSL1:ENST00000265318:intron_variant:MODIFIER:exon17/19:c.*702+30C>A::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon17/19:c.5032+30C>A::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon18/20:c.5308+30C>A::		rs60549465	0.3391	0.4210		0.2346,0.5364,0.4153,0.4563,0.2552	0.4426,0.2488	0.6750			0.25,0.20	0.45		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220417266	220417266	C	T	hom		QUAL=4420;DP=146;AF=1.00;MQM=60	OBSL1	3'UTR,missense	OBSL1:ENST00000265318:3_prime_UTR_variant:MODIFIER:exon17/20:c.*694G>A::,OBSL1:ENST00000373876:missense_variant:MODERATE:exon17/20:c.5024G>A:p.Arg1675Gln:PF07679,OBSL1:ENST00000404537:missense_variant:MODERATE:exon18/21:c.5300G>A:p.Arg1767Gln:PF07679		rs59332477	0.3766	0.4426		0.3736,0.5472,0.4202,0.4570,0.2532	0.4456,0.3658	3.5870	 ,T,T	 ,D,D	0.40,0.96	4.04	0.24	610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	288014 [benign DISEASE=Three M syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220419236	220419236	T	C	hom		QUAL=14236;DP=471;AF=1.00;MQM=60	OBSL1	3'UTR,synonymous	OBSL1:ENST00000265318:3_prime_UTR_variant:MODIFIER:exon14/20:c.*230A>G::,OBSL1:ENST00000373876:synonymous_variant:LOW:exon14/20:c.4560A>G:p.Thr1520=:,OBSL1:ENST00000404537:synonymous_variant:LOW:exon15/21:c.4836A>G:p.Thr1612=:		rs10932813	0.9852	0.9967		0.9598,0.9965,1.0000,0.9997,0.9998	0.9996,0.9643	-3.9420			0.04,0.36	1.45		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	334466 [benign DISEASE=Three M syndrome];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220419339	220419339	T	C	hom		QUAL=21638;DP=704;AF=1.00;MQM=60	OBSL1	3'UTR,missense	OBSL1:ENST00000265318:3_prime_UTR_variant:MODIFIER:exon14/20:c.*127A>G::,OBSL1:ENST00000373876:missense_variant:MODERATE:exon14/20:c.4457A>G:p.Gln1486Arg:,OBSL1:ENST00000404537:missense_variant:MODERATE:exon15/21:c.4733A>G:p.Gln1578Arg:		rs10932814	0.9611	0.9872		0.8799,0.9883,1.0000,0.9941,0.9994	0.9925,0.8987	0.1950	 ,T,T	 ,B,B	0.02,0.88	2.10	0.09	610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	334469 [benign DISEASE=Three M syndrome];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220420956	220420956	A	G	hom		QUAL=1398;DP=55;AF=1.00;MQM=60	OBSL1	synonymous,missense	OBSL1:ENST00000265317:synonymous_variant:LOW:exon5/5:c.1092T>C:p.Asp364=:PF07679,OBSL1:ENST00000265318:missense_variant:MODERATE:exon13/20:c.3995T>C:p.Met1332Thr:,OBSL1:ENST00000373876:synonymous_variant:LOW:exon13/20:c.4119T>C:p.Asp1373=:PF07679,OBSL1:ENST00000404537:synonymous_variant:LOW:exon14/21:c.4395T>C:p.Asp1465=:PF07679,OBSL1:ENST00000603926:synonymous_variant:LOW:exon14/14:c.4395T>C:p.Asp1465=:PF07679		rs10932816	0.9637	0.9917		0.8881,0.9929,0.9999,0.9995,0.9996	0.9996,0.9084	-3.7740	 ,D, , , 		0.02,0.17	0.67	0.10	610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	334475 [benign DISEASE=Three M syndrome];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220421417	220421417	C	G	hom		QUAL=23488;DP=738;AF=1.00;MQM=60	OBSL1	missense	OBSL1:ENST00000265317:missense_variant:MODERATE:exon4/5:c.792G>C:p.Glu264Asp:PF07679,OBSL1:ENST00000265318:missense_variant:MODERATE:exon12/20:c.3819G>C:p.Glu1273Asp:PF13895,OBSL1:ENST00000373876:missense_variant:MODERATE:exon12/20:c.3819G>C:p.Glu1273Asp:PF07679,OBSL1:ENST00000404537:missense_variant:MODERATE:exon13/21:c.4095G>C:p.Glu1365Asp:PF07679,OBSL1:ENST00000603926:missense_variant:MODERATE:exon13/14:c.4095G>C:p.Glu1365Asp:PF07679		rs1983210	0.7246	0.7385		0.6127,0.6694,0.7100,0.7405,0.8945	0.7336,0.6377	0.9030	T,T,T,T,T	B,P,P,P,D	0.86,0.93	2.06	0.17	610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	334483 [benign DISEASE=Three M syndrome];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220421456	220421456	C	A	hom	off-target	QUAL=22655;DP=688;AF=1.00;MQM=60	OBSL1	intron	OBSL1:ENST00000265317:intron_variant:MODIFIER:exon3/4:c.764-11G>T::,OBSL1:ENST00000265318:intron_variant:MODIFIER:exon11/19:c.3791-11G>T::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon11/19:c.3791-11G>T::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon12/20:c.4067-11G>T::,OBSL1:ENST00000603926:intron_variant:MODIFIER:exon12/13:c.4067-11G>T::		rs1983211	0.1170	0.1689		0.0307,0.2196,0.1317,0.1826,0.1531	0.1697,0.0374	-0.5030			0.06,0.21	-0.37		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	334484 [benign DISEASE=Three M syndrome];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220422029	220422029	G	A	hom	off-target	QUAL=4770;DP=167;AF=1.00;MQM=60	OBSL1	intron	OBSL1:ENST00000265317:intron_variant:MODIFIER:exon3/4:c.763+516C>T::,OBSL1:ENST00000265318:intron_variant:MODIFIER:exon11/19:c.3790+36C>T::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon11/19:c.3790+516C>T::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon12/20:c.4066+36C>T::,OBSL1:ENST00000603926:intron_variant:MODIFIER:exon12/13:c.4066+36C>T::		rs55873563	0.1188	0.1582		0.0309,0.2144,0.1276,0.1744,0.1484	0.1560,0.0375	-0.4430			0.06,0.58	1.03		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220422400	220422400	C	G	hom	off-target	QUAL=10434;DP=387;AF=1.00;MQM=60	OBSL1	intron	OBSL1:ENST00000265317:intron_variant:MODIFIER:exon3/4:c.763+145G>C::,OBSL1:ENST00000265318:intron_variant:MODIFIER:exon10/19:c.3515-60G>C::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon11/19:c.3790+145G>C::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon11/20:c.3791-60G>C::,OBSL1:ENST00000603926:intron_variant:MODIFIER:exon11/13:c.3791-60G>C::		rs2278200	0.4087	0.4663				-0.7230			0.00,0.08	0.10		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220422686	220422686	C	T	het		QUAL=543;DP=63;AF=0.44;MQM=60	OBSL1	missense	OBSL1:ENST00000265317:missense_variant:MODERATE:exon3/5:c.622G>A:p.Glu208Lys:PF07679,OBSL1:ENST00000265318:missense_variant:MODERATE:exon10/20:c.3373G>A:p.Glu1125Lys:PF07679,OBSL1:ENST00000373876:missense_variant:MODERATE:exon11/20:c.3649G>A:p.Glu1217Lys:PF07679,OBSL1:ENST00000404537:missense_variant:MODERATE:exon11/21:c.3649G>A:p.Glu1217Lys:PF07679,OBSL1:ENST00000603926:missense_variant:MODERATE:exon11/14:c.3649G>A:p.Glu1217Lys:PF07679		rs72957510	0.0070	0.0079		0.0163,0.0019,0.0000,0.0071,0.0023	0.0055,0.0106	0.5010	T,T,T,T,T	B,B,P,P,B	0.10,0.52	1.94	0.03	610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	193901 [conflicting interpretations of pathogenicity DISEASE=Three M syndrome,not specified,not provided];			2	89					OBSL1 (inh=AR pLI=0.00)
chr2	220422774	220422774	A	G	hom		QUAL=24045;DP=760;AF=1.00;MQM=60	OBSL1	synonymous	OBSL1:ENST00000265317:synonymous_variant:LOW:exon3/5:c.534T>C:p.Pro178=:PF07679,OBSL1:ENST00000265318:synonymous_variant:LOW:exon10/20:c.3285T>C:p.Pro1095=:PF07679,OBSL1:ENST00000373876:synonymous_variant:LOW:exon11/20:c.3561T>C:p.Pro1187=:PF07679,OBSL1:ENST00000404537:synonymous_variant:LOW:exon11/21:c.3561T>C:p.Pro1187=:PF07679,OBSL1:ENST00000603926:synonymous_variant:LOW:exon11/14:c.3561T>C:p.Pro1187=:PF07679		rs2278201	0.4191	0.4746		0.5183,0.5506,0.4189,0.4399,0.2553	0.4331,0.5033	-4.6180			0.01,0.16	-0.12		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	334496 [benign DISEASE=Three M syndrome];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220428381	220428381	A	T	het	off-target	QUAL=3406;DP=282;AF=0.45;MQM=60	OBSL1	intron	OBSL1:ENST00000265318:intron_variant:MODIFIER:exon6/19:c.2408-32T>A::,OBSL1:ENST00000289656:intron_variant:MODIFIER:exon6/8:c.1169-32T>A::,OBSL1:ENST00000373873:intron_variant:MODIFIER:exon6/8:c.2408-32T>A::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon6/19:c.2408-32T>A::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon6/20:c.2408-32T>A::,OBSL1:ENST00000603926:intron_variant:MODIFIER:exon6/13:c.2408-32T>A::		rs2303543		0.6445		0.2962,0.5306,0.6835,0.6791,0.7506	0.6778,0.3378	0.7970			0.14,0.36	0.58		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220430203	220430203	C	T	hom		QUAL=23697;DP=741;AF=1.00;MQM=60	OBSL1	missense	OBSL1:ENST00000265318:missense_variant:MODERATE:exon6/20:c.2168G>A:p.Arg723Lys:,OBSL1:ENST00000289656:missense_variant:MODERATE:exon6/9:c.929G>A:p.Arg310Lys:,OBSL1:ENST00000373873:missense_variant:MODERATE:exon6/9:c.2168G>A:p.Arg723Lys:,OBSL1:ENST00000373876:missense_variant:MODERATE:exon6/20:c.2168G>A:p.Arg723Lys:,OBSL1:ENST00000404537:missense_variant:MODERATE:exon6/21:c.2168G>A:p.Arg723Lys:,OBSL1:ENST00000603926:missense_variant:MODERATE:exon6/14:c.2168G>A:p.Arg723Lys:		rs1039898	0.7927	0.8672		0.6286,0.8316,0.9157,0.9033,0.8345	0.9043,0.6721	-0.1210	T,T,T,T,T,T	B,B,B,B,B,B	0.03,0.65	1.03	0.05	610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	334508 [benign DISEASE=Three M syndrome];		COSM3743608,COSM3743609	n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220432709	220432709	A	T	het	off-target	QUAL=9152;DP=726;AF=0.48;MQM=60	OBSL1	intron	OBSL1:ENST00000265318:intron_variant:MODIFIER:exon2/19:c.1283-18T>A::,OBSL1:ENST00000289656:intron_variant:MODIFIER:exon2/8:c.44-18T>A::,OBSL1:ENST00000373873:intron_variant:MODIFIER:exon2/8:c.1283-18T>A::,OBSL1:ENST00000373876:intron_variant:MODIFIER:exon2/19:c.1283-18T>A::,OBSL1:ENST00000404537:intron_variant:MODIFIER:exon2/20:c.1283-18T>A::,OBSL1:ENST00000603926:intron_variant:MODIFIER:exon2/13:c.1283-18T>A::		rs2292360	0.3678	0.4228		0.1781,0.3638,0.4911,0.4520,0.4421	0.4344,0.1948	-0.7300			0.05,0.20	0.09		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];				n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220435034	220435034	A	G	hom		QUAL=20345;DP=649;AF=1.00;MQM=60	OBSL1	synonymous,intron	OBSL1:ENST00000265318:synonymous_variant:LOW:exon1/20:c.921T>C:p.Leu307=:PF07679,OBSL1:ENST00000289656:intron_variant:MODIFIER:exon1/8:c.-228+1082T>C::,OBSL1:ENST00000373873:synonymous_variant:LOW:exon1/9:c.921T>C:p.Leu307=:PF07679,OBSL1:ENST00000373876:synonymous_variant:LOW:exon1/20:c.921T>C:p.Leu307=:PF07679,OBSL1:ENST00000404537:synonymous_variant:LOW:exon1/21:c.921T>C:p.Leu307=:PF07679,OBSL1:ENST00000603926:synonymous_variant:LOW:exon1/14:c.921T>C:p.Leu307=:PF07679		rs10180675	0.7833	0.8651		0.6045,0.8302,0.9151,0.9033,0.8326	0.9044,0.6514	-0.6420			0.06,0.75	2.06		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	193382 [benign DISEASE=Three M syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr2	220435375	220435375	G	A	het		QUAL=376;DP=19;AF=0.84;MQM=60	OBSL1	synonymous,intron	OBSL1:ENST00000265318:synonymous_variant:LOW:exon1/20:c.580C>T:p.Leu194=:PF07679,OBSL1:ENST00000289656:intron_variant:MODIFIER:exon1/8:c.-228+741C>T::,OBSL1:ENST00000373873:synonymous_variant:LOW:exon1/9:c.580C>T:p.Leu194=:PF07679,OBSL1:ENST00000373876:synonymous_variant:LOW:exon1/20:c.580C>T:p.Leu194=:PF07679,OBSL1:ENST00000404537:synonymous_variant:LOW:exon1/21:c.580C>T:p.Leu194=:PF07679,OBSL1:ENST00000603926:synonymous_variant:LOW:exon1/14:c.580C>T:p.Leu194=:PF07679		rs1061399	0.3588	0.4281		0.1553,0.3675,0.4910,0.4556,0.4445	0.3695,0.1427	2.9300			0.71,0.94	2.13		610991 [OBSL1 (confirmed) 3-M syndrome 2,612921];	290129 [benign DISEASE=Three M syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					OBSL1 (inh=AR pLI=0.00)
chr3	10076843	10076844	TT	-	het	off-target	QUAL=1941;DP=168;AF=0.45;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon5/42:c.378-6_378-5del::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon5/42:c.378-6_378-5del::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon5/43:c.378-6_378-5del::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon5/43:c.378-6_378-5del::,FANCD2:ENST00000431693:intron_variant:MODIFIER:exon4/7:c.378-6_378-5del::		rs55973240,rs35198440	0.2129	0.2354		0.4769,0.2346,0.0968,0.2115,0.2537	0.1669,0.4262	1.0130				0.13		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	342255 [benign/likely benign DISEASE=Fanconi anemia,not provided];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10076975	10076975	A	C	het	off-target	QUAL=1279;DP=99;AF=0.48;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon6/42:c.438+58A>C::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon6/42:c.438+58A>C::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon6/43:c.438+58A>C::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon6/43:c.438+58A>C::,FANCD2:ENST00000431693:intron_variant:MODIFIER:exon5/7:c.438+58A>C::		rs17032276	0.1811	0.1962			0.1596,0.3251	2.6730			0.36,0.31	0.37		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];				n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10077955	10077955	A	G	het	off-target	QUAL=553;DP=46;AF=0.63;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon6/42:c.439-16A>G::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon6/42:c.439-16A>G::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon6/43:c.439-16A>G::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon6/43:c.439-16A>G::,FANCD2:ENST00000431693:intron_variant:MODIFIER:exon5/7:c.439-16A>G::		rs17032278	0.1821	0.1945		0.3382,0.1550,0.0669,0.1591,0.1771	0.1645,0.3239	-1.0280			0.01,0.10	0.01		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257083 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10081545	10081545	G	C	het	off-target	QUAL=5185;DP=484;AF=0.47;MQM=60	FANCD2	intron,synonymous	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon9/42:c.695+16G>C::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon9/42:c.695+16G>C::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon9/43:c.695+16G>C::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon9/43:c.695+16G>C::,FANCD2:ENST00000431693:synonymous_variant:LOW:exon8/8:c.711G>C:p.Leu237=:		rs17032283	0.1821	0.1966		0.3356,0.1551,0.0669,0.1587,0.1769	0.1636,0.3212	0.0530			0.05,0.20	-0.07		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257086 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10084224	10084224	C	T	het	off-target	QUAL=14505;DP=1027;AF=0.54;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon10/42:c.784-19C>T::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon10/42:c.784-19C>T::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon10/43:c.784-19C>T::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon10/43:c.784-19C>T::		rs9879080	0.2107	0.2261		0.4350,0.1582,0.0667,0.1594,0.1755	0.1643,0.4251	0.8890			0.00,0.16	0.38		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257087 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10085130	10085130	C	G	het	off-target	QUAL=62;DP=10;AF=0.40;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon12/42:c.990-38C>G::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon12/42:c.990-38C>G::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon12/43:c.990-38C>G::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon12/43:c.990-38C>G::		rs9809061	0.2117	0.2263		0.4348,0.1574,0.0665,0.1584,0.1771	0.1612,0.4040	-0.3390			0.01,0.10	-0.01		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257088 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10085536	10085536	A	G	het		QUAL=2144;DP=294;AF=0.43;MQM=60	FANCD2	synonymous	FANCD2:ENST00000287647:synonymous_variant:LOW:exon14/43:c.1122A>G:p.Val374=:PF14631,FANCD2:ENST00000383806:synonymous_variant:LOW:exon14/43:c.1122A>G:p.Val374=:PF14631,FANCD2:ENST00000383807:synonymous_variant:LOW:exon14/44:c.1122A>G:p.Val374=:PF14631,FANCD2:ENST00000419585:synonymous_variant:LOW:exon14/44:c.1122A>G:p.Val374=:PF14631		rs34046352		0.1939		0.2881,0.0984,0.0385,0.0760,0.0880		-0.0020			0.00,0.07	-0.14		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257065 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10089773	10089773	A	C	het	off-target	QUAL=1155;DP=94;AF=0.52;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon16/42:c.1413+38A>C::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon16/42:c.1413+38A>C::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon16/43:c.1413+38A>C::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon16/43:c.1413+38A>C::		rs7615646	0.1791	0.2214		0.3515,0.2161,0.1216,0.2240,0.2493	0.1636,0.3105	0.3960			0.08,0.24	0.04		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257067 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10094206	10094206	-	T	het	off-target	QUAL=110;DP=25;AF=0.36;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon18/42:c.1656+38dup::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon18/42:c.1656+38dup::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon18/43:c.1656+38dup::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon18/43:c.1656+38dup::	AluSx	rs544799101		0.2108		0.3772,0.2429,0.0409,0.2039,0.1938	0.1386,0.2811					0.51		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];				n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10106532	10106532	C	T	het		QUAL=1275;DP=75;AF=0.64;MQM=60	FANCD2	missense	FANCD2:ENST00000287647:missense_variant:MODERATE:exon23/43:c.2141C>T:p.Pro714Leu:PF14631,FANCD2:ENST00000383806:missense_variant:MODERATE:exon23/43:c.2141C>T:p.Pro714Leu:PF14631,FANCD2:ENST00000383807:missense_variant:MODERATE:exon23/44:c.2141C>T:p.Pro714Leu:PF14631,FANCD2:ENST00000419585:missense_variant:MODERATE:exon23/44:c.2141C>T:p.Pro714Leu:PF14631		rs3864017		0.1870		0.2696,0.1397,0.0527,0.1408,0.1624		-0.1820	T,T,T,T	B,B,B,B	0.05,0.21	-0.36	0.03	613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	134315 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10107520	10107520	G	T	het	off-target	QUAL=12200;DP=1013;AF=0.48;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon24/42:c.2270-28G>T::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon24/42:c.2270-28G>T::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon24/43:c.2270-28G>T::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon24/43:c.2270-28G>T::		rs34608006	0.1753	0.1932		0.3206,0.1540,0.0663,0.1588,0.1782	0.1632,0.3064	0.3780			0.29,0.34	0.31		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257074 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10119917	10119917	T	C	het	off-target	QUAL=741;DP=72;AF=0.46;MQM=60	FANCD2	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon30/42:c.2976+36T>C::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon30/42:c.2976+36T>C::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon30/43:c.2976+36T>C::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon30/43:c.2976+36T>C::		rs6805869	0.2115	0.2259		0.4356,0.1587,0.0669,0.1592,0.1809	0.1640,0.4249	0.0370			0.03,0.18	-0.11		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257077 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00)
chr3	10128965	10128965	-	TT	het	off-target	QUAL=132;DP=41;AF=0.10;MQM=60	FANCD2,FANCD2OS	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon34/42:c.3466+35_3466+36dup::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon34/42:c.3466+35_3466+36dup::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon34/43:c.3466+35_3466+36dup::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon34/43:c.3466+35_3466+36dup::,FANCD2OS:ENST00000524279:intron_variant:MODIFIER:exon2/2:c.*44-5752_*44-5751dup::	(T)n	rs371321981		0.0278		0.0756,0.0247,0.0050,0.0199,0.0299						-0.11		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];				15	6					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10133949	10133949	A	G	het	off-target	QUAL=2575;DP=178;AF=0.55;MQM=60	FANCD2,FANCD2OS	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon38/42:c.3849+13A>G::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon37/42:c.*5+13A>G::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon38/43:c.3849+13A>G::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon38/43:c.3849+13A>G::,FANCD2OS:ENST00000524279:intron_variant:MODIFIER:exon2/2:c.*44-10734T>C::		rs9811771	0.2542	0.2462		0.5032,0.1832,0.0900,0.1599,0.2259	0.1653,0.4902	0.5050			0.00,0.13	0.92		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257079 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10138069	10138069	T	G	het		QUAL=9089;DP=785;AF=0.47;MQM=60	FANCD2,FANCD2OS	synonymous,3'UTR,intron	FANCD2:ENST00000287647:synonymous_variant:LOW:exon42/43:c.4098T>G:p.Leu1366=:PF14631,FANCD2:ENST00000383806:3_prime_UTR_variant:MODIFIER:exon41/43:c.*254T>G::,FANCD2:ENST00000383807:synonymous_variant:LOW:exon42/44:c.4098T>G:p.Leu1366=:PF14631,FANCD2:ENST00000419585:synonymous_variant:LOW:exon42/44:c.4098T>G:p.Leu1366=:PF14631,FANCD2OS:ENST00000524279:intron_variant:MODIFIER:exon2/2:c.*43+7813A>C::		rs2272125	0.2422	0.2404		0.4804,0.1823,0.0900,0.1594,0.2081	0.1647,0.4714	2.5830			0.21,0.96	1.94		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257081 [benign DISEASE=Fanconi anemia,not specified];	CM066071 [CLASS=DP MUT=ALT PHEN="Breast cancer increased risk association with" GENE=FANCD2];		n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10138189	10138189	T	C	het	off-target	QUAL=2797;DP=207;AF=0.53;MQM=60	FANCD2,FANCD2OS	intron	FANCD2:ENST00000287647:intron_variant:MODIFIER:exon42/42:c.4185+33T>C::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon41/42:c.*341+33T>C::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon42/43:c.4185+33T>C::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon42/43:c.4185+33T>C::,FANCD2OS:ENST00000524279:intron_variant:MODIFIER:exon2/2:c.*43+7693A>G::		rs2272124	0.2418	0.2406		0.4805,0.1822,0.0901,0.1594,0.2080	0.1643,0.4714	0.0530			0.00,0.11	0.19		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	257082 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10140671	10140671	G	A	het	off-target	QUAL=10294;DP=680;AF=0.54;MQM=60	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:ENST00000287647:3_prime_UTR_variant:MODIFIER:exon43/43:c.*37G>A::,FANCD2:ENST00000383806:intron_variant:MODIFIER:exon42/42:c.*437+172G>A::,FANCD2:ENST00000383807:intron_variant:MODIFIER:exon43/43:c.4281+172G>A::,FANCD2:ENST00000419585:intron_variant:MODIFIER:exon43/43:c.4281+172G>A::,FANCD2OS:ENST00000524279:intron_variant:MODIFIER:exon2/2:c.*43+5211C>T::		rs7626117	0.3452	0.3366		0.7673,0.2075,0.0901,0.1796,0.2316	0.1874,0.7363	-0.0060			0.00,0.05	0.24		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	342381 [benign DISEASE=Fanconi anemia];			n/a (AF>5%)	n/a (AF>5%)					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	37067097	37067097	A	T	het	off-target	QUAL=1328;DP=239;AF=0.28;MQM=60	MLH1	intron	MLH1:ENST00000231790:intron_variant:MODIFIER:exon11/18:c.1039-31A>T::,MLH1:ENST00000435176:intron_variant:MODIFIER:exon11/18:c.745-31A>T::,MLH1:ENST00000455445:intron_variant:MODIFIER:exon11/18:c.316-31A>T::,MLH1:ENST00000458205:intron_variant:MODIFIER:exon12/19:c.316-31A>T::,MLH1:ENST00000536378:intron_variant:MODIFIER:exon11/18:c.316-31A>T::,MLH1:ENST00000539477:intron_variant:MODIFIER:exon10/17:c.316-31A>T::	(TA)n	rs59684491		0.2230		0.0379,0.0486,0.0357,0.0271,0.0399		-1.5490			0.03,0.17	-0.46		120436 [MLH1 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 2,609310/Mismatch repair cancer syndrome,276300/Muir-Torre syndrome,158320];				n/a (AF>5%)	n/a (AF>5%)					MLH1 (inh=AR+AD pLI=0.97)
chr3	37067099	37067099	A	T	het	off-target	QUAL=1328;DP=239;AF=0.28;MQM=60	MLH1	intron	MLH1:ENST00000231790:intron_variant:MODIFIER:exon11/18:c.1039-29A>T::,MLH1:ENST00000435176:intron_variant:MODIFIER:exon11/18:c.745-29A>T::,MLH1:ENST00000455445:intron_variant:MODIFIER:exon11/18:c.316-29A>T::,MLH1:ENST00000458205:intron_variant:MODIFIER:exon12/19:c.316-29A>T::,MLH1:ENST00000536378:intron_variant:MODIFIER:exon11/18:c.316-29A>T::,MLH1:ENST00000539477:intron_variant:MODIFIER:exon10/17:c.316-29A>T::	(TA)n	rs6771325		0.0362		0.0455,0.0315,0.0769,0.0353,0.0503		-1.5590			0.01,0.11	-0.06		120436 [MLH1 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 2,609310/Mismatch repair cancer syndrome,276300/Muir-Torre syndrome,158320];				316	1384	2	[2] auto-classification 24.10.2017  			MLH1 (inh=AR+AD pLI=0.97)
chr3	142168331	142168331	C	T	hom		QUAL=1594;DP=49;AF=1.00;MQM=60	ATR	synonymous	ATR:ENST00000350721:synonymous_variant:LOW:exon47/47:c.7875G>A:p.Gln2625=:PF02260,ATR:ENST00000383101:synonymous_variant:LOW:exon46/46:c.7683G>A:p.Gln2561=:PF02260		rs1802904	0.9163	0.8880		0.9730,0.7559,0.9330,0.8558,0.9373	0.8614,0.9689	1.2260			0.38,0.96	1.77		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	93669 [benign/likely benign DISEASE=Seckel syndrome,not specified,not provided];			n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142178144	142178144	C	T	het		QUAL=1052;DP=77;AF=0.55;MQM=60	ATR	missense	ATR:ENST00000350721:missense_variant:MODERATE:exon43/47:c.7274G>A:p.Arg2425Gln:PF00454,ATR:ENST00000383101:missense_variant:MODERATE:exon42/46:c.7082G>A:p.Arg2361Gln:PF00454		rs2229032	0.1022	0.1332		0.0788,0.0991,0.0983,0.1599,0.0961	0.1578,0.0881	0.0440	T,T	B,B	0.23,0.63	0.40	0.17	601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	136470 [benign/likely benign DISEASE=Seckel syndrome,not specified,not provided];		COSM149485	n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142188337	142188337	A	C	het		QUAL=9942;DP=682;AF=0.56;MQM=60	ATR,RP11-383G6.3	missense,intron&non_coding_transcript	ATR:ENST00000350721:missense_variant:MODERATE:exon38/47:c.6394T>G:p.Tyr2132Asp:,ATR:ENST00000383101:missense_variant:MODERATE:exon37/46:c.6202T>G:p.Tyr2068Asp:,RP11-383G6.3:ENST00000460977:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.268+2575T>G::		rs28910273	0.0020	0.0032		0.0013,0.0016,0.0000,0.0057,0.0014	0.0069,0.0020	2.3490	T,T, 	B,B, 	0.83,0.98	1.51	0.05	601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	158000 [likely benign DISEASE=not specified,not provided];		COSM5019586	0	50	2	[2] Ilnaz Sepahi 29-03-2016 batch import			ATR (inh=AR+AD pLI=1.00), RP11-383G6.3 (inh=n/a pLI=n/a)
chr3	142215171	142215171	T	C	het	off-target	QUAL=123;DP=8;AF=0.75;MQM=60	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:exon34/46:c.5898+32A>G::,ATR:ENST00000383101:intron_variant:MODIFIER:exon33/45:c.5706+32A>G::	(TA)n	rs11719960		0.0286		0.0000,0.0001,0.0002,0.0002,0.0002	0.0035,0.0009	-1.3110			0.01,0.14	-0.14		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	157998 [likely benign DISEASE=not specified];			0	0					ATR (inh=AR+AD pLI=1.00)
chr3	142215178	142215178	A	C	het	off-target	QUAL=123;DP=8;AF=0.75;MQM=60	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:exon34/46:c.5898+25T>G::,ATR:ENST00000383101:intron_variant:MODIFIER:exon33/45:c.5706+25T>G::	(TA)n	rs7620648		0.6677		0.8439,0.4190,0.4363,0.5582,0.3541	0.5163,0.8048	-0.3320			0.03,0.14	-0.08		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	157997 [likely benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142217537	142217537	A	G	het		QUAL=3564;DP=350;AF=0.51;MQM=60	ATR	synonymous	ATR:ENST00000350721:synonymous_variant:LOW:exon32/47:c.5460T>C:p.Tyr1820=:PF02259,ATR:ENST00000383101:synonymous_variant:LOW:exon31/46:c.5268T>C:p.Tyr1756=:PF02259		rs2227932	0.0669	0.0927		0.0152,0.0394,0.0013,0.1095,0.1605	0.1062,0.0195	1.5160			0.87,0.98	1.70		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	136471 [benign/likely benign DISEASE=Seckel syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142231062	142231062	-	A	het	off-target	QUAL=5;DP=31;AF=0.16;MQM=56	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:exon27/46:c.4852+39dup::,ATR:ENST00000383101:intron_variant:MODIFIER:exon26/45:c.4660+39dup::	(A)n	rs771446118		0.4620		0.1852,0.1553,0.1661,0.1033,0.0865						-0.07		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];				n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142255090	142255090	T	C	het	off-target	QUAL=1306;DP=111;AF=0.46;MQM=60	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:exon19/46:c.3726-47A>G::,ATR:ENST00000383101:intron_variant:MODIFIER:exon18/45:c.3534-47A>G::		rs73240314	0.1172	0.1424		0.1166,0.1044,0.0997,0.1622,0.0993	0.1560,0.1193	-0.1880			0.02,0.14	0.09		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	157979 [likely benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142259707	142259707	A	-	het	off-target	QUAL=9283;DP=907;AF=0.43;MQM=60	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:exon18/46:c.3581+39del::,ATR:ENST00000383101:intron_variant:MODIFIER:exon17/45:c.3389+39del::		rs201551475		0.4586		0.4484,0.4607,0.4670,0.4614,0.4552		6.4460				-0.25		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];				n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142277427	142277427	A	G	het	off-target	QUAL=6988;DP=587;AF=0.48;MQM=60	ATR	intron	ATR:ENST00000350721:intron_variant:MODIFIER:exon8/46:c.1885+39T>C::,ATR:ENST00000383101:intron_variant:MODIFIER:exon7/45:c.1693+39T>C::	(TAGA)n	rs73240318	0.1122	0.1045		0.0180,0.0405,0.0636,0.0967,0.0642	0.1555,0.1103	0.0520			0.07,0.40	0.40		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	157967 [likely benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142277575	142277575	A	T	het		QUAL=3151;DP=274;AF=0.47;MQM=60	ATR	synonymous	ATR:ENST00000350721:synonymous_variant:LOW:exon8/47:c.1776T>A:p.Gly592=:,ATR:ENST00000383101:synonymous_variant:LOW:exon7/46:c.1584T>A:p.Gly528=:		rs2227930	0.5980	0.6300		0.7983,0.4526,0.4670,0.5789,0.4320	0.5950,0.7957	-0.0710			0.13,0.94	0.58		601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	157965 [benign/likely benign DISEASE=Seckel syndrome,not specified,not provided];		COSM149486	n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	142281612	142281612	A	G	het		QUAL=6583;DP=530;AF=0.49;MQM=60	ATR	missense	ATR:ENST00000350721:missense_variant:MODERATE:exon4/47:c.632T>C:p.Met211Thr:,ATR:ENST00000383101:missense_variant:MODERATE:exon4/46:c.632T>C:p.Met211Thr:		rs2227928	0.5974	0.6291		0.7950,0.4548,0.4683,0.5799,0.4358	0.5955,0.7928	1.2740	T,T	B,B	0.11,0.55	1.24	0.09	601215 [ATR (confirmed) Seckel syndrome 1,210600/Cutaneous telangiectasia and cancer syndrome,familial,614564];	93668 [benign/likely benign DISEASE=Seckel syndrome,not specified];		COSM149487	n/a (AF>5%)	n/a (AF>5%)					ATR (inh=AR+AD pLI=1.00)
chr3	156413615	156413615	C	T	hom	off-target	QUAL=1298;DP=275;AF=0.20;MQM=53	TIPARP	intron	TIPARP:ENST00000295924:intron_variant:MODIFIER:exon3/5:c.1087-39C>T::,TIPARP:ENST00000461166:intron_variant:MODIFIER:exon3/5:c.1087-39C>T::,TIPARP:ENST00000486483:intron_variant:MODIFIER:exon3/5:c.1087-39C>T::,TIPARP:ENST00000542783:intron_variant:MODIFIER:exon3/5:c.1087-39C>T::								0.7670			0.04,0.08	-0.17						299	85	2	[2] auto-classification 26.10.2017  			TIPARP (inh=n/a pLI=1.00)
chr3	156421525	156421525	G	T	het	off-target	QUAL=5995;DP=480;AF=0.51;MQM=60	TIPARP	intron	TIPARP:ENST00000295924:intron_variant:MODIFIER:exon5/5:c.1526+34G>T::,TIPARP:ENST00000461166:intron_variant:MODIFIER:exon5/5:c.1526+34G>T::,TIPARP:ENST00000486483:intron_variant:MODIFIER:exon5/5:c.1526+34G>T::,TIPARP:ENST00000542783:intron_variant:MODIFIER:exon5/5:c.1526+34G>T::	AluYm1	rs34277251	0.3832	0.4396		0.0783,0.5674,0.7194,0.4186,0.3791	0.4012,0.0910	-0.1840			0.02,0.46	0.24						n/a (AF>5%)	n/a (AF>5%)					TIPARP (inh=n/a pLI=1.00)
chr3	178917005	178917005	A	G	het	off-target	QUAL=850;DP=54;AF=0.63;MQM=60	PIK3CA	intron	PIK3CA:ENST00000263967:intron_variant:MODIFIER:exon2/20:c.352+40A>G::		rs3729674	0.2734	0.2451		0.4289,0.2052,0.1039,0.1963,0.2419	0.1894,0.4163	0.7790			0.01,0.45	0.55		171834 [PIK3CA (provisional) Ovarian cancer,somatic,167000/Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Gastric cancer,somatic,613659/Hepatocellular carcinoma,somatic,114550/Nonsmall cell lung cancer,somatic,211980/Keratosis,seborrheic,somatic,182000/Nevus,epidermal,somatic,162900/CLOVE syndrome,somatic,612918/Megalencephaly-capillary malformation-polymicrogyria syndrome,somatic,602501/Cowden syndrome 5,615108];				n/a (AF>5%)	n/a (AF>5%)					PIK3CA (inh=AR+AD pLI=1.00)
chr3	178922274	178922274	C	A	hom	off-target	QUAL=13692;DP=480;AF=1.00;MQM=60	PIK3CA	intron	PIK3CA:ENST00000263967:intron_variant:MODIFIER:exon5/20:c.1060-17C>A::		rs2699896	0.5847	0.6189		0.8658,0.4856,0.2629,0.5838,0.5588	0.5854,0.8575	-0.8190			0.01,0.18	0.09		171834 [PIK3CA (provisional) Ovarian cancer,somatic,167000/Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Gastric cancer,somatic,613659/Hepatocellular carcinoma,somatic,114550/Nonsmall cell lung cancer,somatic,211980/Keratosis,seborrheic,somatic,182000/Nevus,epidermal,somatic,162900/CLOVE syndrome,somatic,612918/Megalencephaly-capillary malformation-polymicrogyria syndrome,somatic,602501/Cowden syndrome 5,615108];	259957 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					PIK3CA (inh=AR+AD pLI=1.00)
chr3	178922430	178922430	A	G	hom	off-target	QUAL=1931;DP=64;AF=1.00;MQM=60	PIK3CA	intron	PIK3CA:ENST00000263967:intron_variant:MODIFIER:exon6/20:c.1145+54A>G::		rs3729679	0.5180	0.5565			0.5273,0.7637	-1.0930			0.00,0.11	0.21		171834 [PIK3CA (provisional) Ovarian cancer,somatic,167000/Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Gastric cancer,somatic,613659/Hepatocellular carcinoma,somatic,114550/Nonsmall cell lung cancer,somatic,211980/Keratosis,seborrheic,somatic,182000/Nevus,epidermal,somatic,162900/CLOVE syndrome,somatic,612918/Megalencephaly-capillary malformation-polymicrogyria syndrome,somatic,602501/Cowden syndrome 5,615108];				n/a (AF>5%)	n/a (AF>5%)					PIK3CA (inh=AR+AD pLI=1.00)
chr3	178938747	178938747	A	T	het	off-target	QUAL=4435;DP=376;AF=0.47;MQM=55	PIK3CA	intron	PIK3CA:ENST00000263967:intron_variant:MODIFIER:exon13/20:c.2016-27A>T::		rs6443625	0.2730	0.2446		0.4398,0.2076,0.1121,0.1989,0.2432	0.1807,0.4016	-0.7290			0.01,0.08	-0.66		171834 [PIK3CA (provisional) Ovarian cancer,somatic,167000/Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Gastric cancer,somatic,613659/Hepatocellular carcinoma,somatic,114550/Nonsmall cell lung cancer,somatic,211980/Keratosis,seborrheic,somatic,182000/Nevus,epidermal,somatic,162900/CLOVE syndrome,somatic,612918/Megalencephaly-capillary malformation-polymicrogyria syndrome,somatic,602501/Cowden syndrome 5,615108];				n/a (AF>5%)	n/a (AF>5%)					PIK3CA (inh=AR+AD pLI=1.00)
chr3	178942431	178942431	C	G	hom	off-target	QUAL=183;DP=7;AF=1.00;MQM=60	PIK3CA	intron	PIK3CA:ENST00000263967:intron_variant:MODIFIER:exon15/20:c.2295-57C>G::		rs2699889	0.6294	0.6499				0.1320			0.00,0.09	0.16		171834 [PIK3CA (provisional) Ovarian cancer,somatic,167000/Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Gastric cancer,somatic,613659/Hepatocellular carcinoma,somatic,114550/Nonsmall cell lung cancer,somatic,211980/Keratosis,seborrheic,somatic,182000/Nevus,epidermal,somatic,162900/CLOVE syndrome,somatic,612918/Megalencephaly-capillary malformation-polymicrogyria syndrome,somatic,602501/Cowden syndrome 5,615108];				n/a (AF>5%)	n/a (AF>5%)					PIK3CA (inh=AR+AD pLI=1.00)
chr4	185999587	185999587	T	A	het	off-target	QUAL=686;DP=71;AF=0.46;MQM=60	RP11-386B13.3	intron&non_coding_transcript	RP11-386B13.3:ENST00000509017:intron_variant&non_coding_transcript_variant:MODIFIER:exon5/8:n.1340+6360T>A::		rs6818170	0.6675	0.6815		0.8334,0.5450,0.4173,0.6693,0.6608		0.4470			0.00,0.11	0.63						n/a (AF>5%)	n/a (AF>5%)					RP11-386B13.3 (inh=n/a pLI=n/a)
chr5	57617403	57617403	G	C	het		QUAL=11921;DP=940;AF=0.50;MQM=60				MLT1E1A	rs37535		0.5792				0.8490			0.01,0.11	-0.11						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr5	79950508	79950508	C	T	hom	off-target	QUAL=2919;DP=109;AF=1.00;MQM=60	MSH3,DHFR	5'UTR	MSH3:ENST00000265081:5_prime_UTR_variant:MODIFIER:exon1/24:c.-39C>T::,DHFR:ENST00000439211:5_prime_UTR_variant:MODIFIER:exon1/6:c.-200G>A::		rs1105525	0.1230	0.1573		0.0447,0.0788,0.0683,0.1773,0.2389	0.1616,0.0408	-0.4220			0.02,0.33	0.46		126060 [DHFR (confirmed) Megaloblastic anemia due to dihydrofolate reductase deficiency,613839],600887 [MSH3 (provisional) Endometrial carcinoma,somatic,608089/Familial adenomatous polyposis 4,617100];				n/a (AF>5%)	n/a (AF>5%)					MSH3 (inh=AR pLI=0.00), DHFR (inh=AR pLI=0.24)
chr5	79950512	79950512	A	G	hom	off-target	QUAL=2919;DP=109;AF=1.00;MQM=60	MSH3,DHFR	5'UTR	MSH3:ENST00000265081:5_prime_UTR_variant:MODIFIER:exon1/24:c.-35A>G::,DHFR:ENST00000439211:5_prime_UTR_variant:MODIFIER:exon1/6:c.-204T>C::		rs1105524	0.7043	0.7128		0.9244,0.4855,0.3601,0.6610,0.7612	0.6824,0.9136	-3.6080			0.00,0.29	0.73		126060 [DHFR (confirmed) Megaloblastic anemia due to dihydrofolate reductase deficiency,613839],600887 [MSH3 (provisional) Endometrial carcinoma,somatic,608089/Familial adenomatous polyposis 4,617100];				n/a (AF>5%)	n/a (AF>5%)					MSH3 (inh=AR pLI=0.00), DHFR (inh=AR pLI=0.24)
chr5	79950781	79950781	A	G	het		QUAL=420;DP=38;AF=0.47;MQM=60	MSH3,DHFR	missense&splice_region,5'UTR	MSH3:ENST00000265081:missense_variant&splice_region_variant:MODERATE:exon1/24:c.235A>G:p.Ile79Val:,DHFR:ENST00000439211:5_prime_UTR_variant:MODIFIER:exon1/6:c.-473T>C::		rs1650697	0.7686	0.8573		0.9676,0.9120,0.8238,0.8673,0.8360		-0.4930	T, 	B, 	0.00,0.28	0.48	0.24	126060 [DHFR (confirmed) Megaloblastic anemia due to dihydrofolate reductase deficiency,613839],600887 [MSH3 (provisional) Endometrial carcinoma,somatic,608089/Familial adenomatous polyposis 4,617100];	402591 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					MSH3 (inh=AR pLI=0.00), DHFR (inh=AR pLI=0.24)
chr5	79966178	79966178	G	A	het	off-target	QUAL=5439;DP=416;AF=0.50;MQM=60	MSH3	intron	MSH3:ENST00000265081:intron_variant:MODIFIER:exon4/23:c.792+50G>A::		rs6151630	0.0232	0.0408		0.0109,0.0171,0.0001,0.0549,0.0354	0.0527,0.0116	0.3950			0.03,0.22	0.70		600887 [MSH3 (provisional) Endometrial carcinoma,somatic,608089/Familial adenomatous polyposis 4,617100];				12	624					MSH3 (inh=AR pLI=0.00)
chr5	80149981	80149981	A	G	hom		QUAL=28046;DP=904;AF=1.00;MQM=60	MSH3	missense	MSH3:ENST00000265081:missense_variant:MODERATE:exon21/24:c.2846A>G:p.Gln949Arg:PF00488		rs184967	0.9022	0.8733		0.8936,0.9139,0.9994,0.8408,0.8824	0.8355,0.8938	0.4030	T	B	0.18,0.95	1.76	0.28	600887 [MSH3 (provisional) Endometrial carcinoma,somatic,608089/Familial adenomatous polyposis 4,617100];				n/a (AF>5%)	n/a (AF>5%)					MSH3 (inh=AR pLI=0.00)
chr5	80160597	80160600	AATG	-	het	off-target	QUAL=58;DP=16;AF=0.38;MQM=60	MSH3	intron	MSH3:ENST00000265081:intron_variant:MODIFIER:exon21/23:c.3001-33_3001-30del::		rs3991216	0.4030	0.4859		0.2313,0.3526,0.3823,0.5520,0.5251	0.5373,0.2368	3.2410				0.78		600887 [MSH3 (provisional) Endometrial carcinoma,somatic,608089/Familial adenomatous polyposis 4,617100];				n/a (AF>5%)	n/a (AF>5%)					MSH3 (inh=AR pLI=0.00)
chr5	80168937	80168937	G	A	hom		QUAL=3771;DP=114;AF=1.00;MQM=60	MSH3	missense&splice_region	MSH3:ENST00000265081:missense_variant&splice_region_variant:MODERATE:exon23/24:c.3133G>A:p.Ala1045Thr:PF00488		rs26279	0.7202	0.7300		0.6653,0.7578,0.7463,0.7145,0.7928	0.7094,0.6659	1.0140	T	B	0.55,0.20	0.13	0.11	600887 [MSH3 (provisional) Endometrial carcinoma,somatic,608089/Familial adenomatous polyposis 4,617100];				n/a (AF>5%)	n/a (AF>5%)					MSH3 (inh=AR pLI=0.00)
chr5	112162854	112162854	T	C	het		QUAL=1678;DP=184;AF=0.42;MQM=60	APC	synonymous	APC:ENST00000257430:synonymous_variant:LOW:exon12/16:c.1458T>C:p.Tyr486=:,APC:ENST00000457016:synonymous_variant:LOW:exon12/16:c.1458T>C:p.Tyr486=:,APC:ENST00000508376:synonymous_variant:LOW:exon13/17:c.1458T>C:p.Tyr486=:		rs2229992	0.5100	0.5854		0.1944,0.6995,0.6740,0.5930,0.6384	0.5902,0.2121	1.3010			0.83,0.97	1.94		611731 [APC (confirmed) Adenomatous polyposis coli,175100/Gastric cancer,somatic,613659/Adenoma,periampullary,somatic/Hepatoblastoma,somatic,114550/Desmoid disease,hereditary,135290/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100/Gardner syndrome,175100];	42238 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial adenomatous polyposis 1,Familial colorectal cancer,not specified,APC-Associated Polyposis Disorders];		COSM1432175	n/a (AF>5%)	n/a (AF>5%)					APC (inh=AD pLI=1.00)
chr5	112164561	112164561	G	A	het		QUAL=2531;DP=179;AF=0.51;MQM=60	APC,CTC-554D6.1	synonymous,synonymous&NMD_transcript	APC:ENST00000257430:synonymous_variant:LOW:exon14/16:c.1635G>A:p.Ala545=:PF00514,APC:ENST00000457016:synonymous_variant:LOW:exon14/16:c.1635G>A:p.Ala545=:PF00514,APC:ENST00000508376:synonymous_variant:LOW:exon15/17:c.1635G>A:p.Ala545=:PF00514,CTC-554D6.1:ENST00000520401:synonymous_variant&NMD_transcript_variant:LOW:exon3/8:c.122G>A:p.Ala41=:PF00514		rs351771	0.6661	0.6493		0.5317,0.7344,0.8218,0.6193,0.7132	0.6169,0.5270	1.6080			0.26,0.97	0.88		611731 [APC (confirmed) Adenomatous polyposis coli,175100/Gastric cancer,somatic,613659/Adenoma,periampullary,somatic/Hepatoblastoma,somatic,114550/Desmoid disease,hereditary,135290/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100/Gardner syndrome,175100];	42239 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial adenomatous polyposis 1,Familial colorectal cancer,not specified,APC-Associated Polyposis Disorders];		COSM3760868	n/a (AF>5%)	n/a (AF>5%)					APC (inh=AD pLI=1.00), CTC-554D6.1 (inh=n/a pLI=n/a)
chr5	112175770	112175770	G	A	het		QUAL=5170;DP=423;AF=0.49;MQM=60	APC,CTC-554D6.1	synonymous,intron&NMD_transcript	APC:ENST00000257430:synonymous_variant:LOW:exon16/16:c.4479G>A:p.Thr1493=:PF05923,APC:ENST00000457016:synonymous_variant:LOW:exon16/16:c.4479G>A:p.Thr1493=:PF05923,APC:ENST00000508376:synonymous_variant:LOW:exon17/17:c.4479G>A:p.Thr1493=:PF05923,CTC-554D6.1:ENST00000520401:intron_variant&NMD_transcript_variant:MODIFIER:exon3/7:c.230+11101G>A::		rs41115	0.6655	0.6496		0.5330,0.7351,0.8217,0.6193,0.7125	0.6167,0.5266	0.0930			0.46,0.90	1.51		611731 [APC (confirmed) Adenomatous polyposis coli,175100/Gastric cancer,somatic,613659/Adenoma,periampullary,somatic/Hepatoblastoma,somatic,114550/Desmoid disease,hereditary,135290/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100/Gardner syndrome,175100];	42242 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial adenomatous polyposis 1,Familial colorectal cancer,not specified,APC-Associated Polyposis Disorders];		COSM19714,COSM3760869	n/a (AF>5%)	n/a (AF>5%)					APC (inh=AD pLI=1.00), CTC-554D6.1 (inh=n/a pLI=n/a)
chr5	112176325	112176325	G	A	het		QUAL=233;DP=26;AF=0.50;MQM=60	APC,CTC-554D6.1	synonymous,intron&NMD_transcript	APC:ENST00000257430:synonymous_variant:LOW:exon16/16:c.5034G>A:p.Gly1678=:,APC:ENST00000457016:synonymous_variant:LOW:exon16/16:c.5034G>A:p.Gly1678=:,APC:ENST00000508376:synonymous_variant:LOW:exon17/17:c.5034G>A:p.Gly1678=:,CTC-554D6.1:ENST00000520401:intron_variant&NMD_transcript_variant:MODIFIER:exon3/7:c.230+11656G>A::		rs42427	0.6667	0.6524		0.5352,0.7377,0.8219,0.6240,0.7124	0.6210,0.5297	0.3110			0.21,0.40	0.88		611731 [APC (confirmed) Adenomatous polyposis coli,175100/Gastric cancer,somatic,613659/Adenoma,periampullary,somatic/Hepatoblastoma,somatic,114550/Desmoid disease,hereditary,135290/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100/Gardner syndrome,175100];	42243 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial adenomatous polyposis 1,Familial colorectal cancer,not specified,APC-Associated Polyposis Disorders];		COSM3760870	n/a (AF>5%)	n/a (AF>5%)					APC (inh=AD pLI=1.00), CTC-554D6.1 (inh=n/a pLI=n/a)
chr5	112176559	112176559	T	G	het		QUAL=3246;DP=262;AF=0.49;MQM=60	APC,CTC-554D6.1	synonymous,intron&NMD_transcript	APC:ENST00000257430:synonymous_variant:LOW:exon16/16:c.5268T>G:p.Ser1756=:,APC:ENST00000457016:synonymous_variant:LOW:exon16/16:c.5268T>G:p.Ser1756=:,APC:ENST00000508376:synonymous_variant:LOW:exon17/17:c.5268T>G:p.Ser1756=:,CTC-554D6.1:ENST00000520401:intron_variant&NMD_transcript_variant:MODIFIER:exon3/7:c.230+11890T>G::		rs866006		0.6513		0.5340,0.7355,0.8213,0.6215,0.7132	0.6186,0.5282	0.9850			0.72,0.25	-0.20		611731 [APC (confirmed) Adenomatous polyposis coli,175100/Gastric cancer,somatic,613659/Adenoma,periampullary,somatic/Hepatoblastoma,somatic,114550/Desmoid disease,hereditary,135290/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100/Gardner syndrome,175100];	42245 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial adenomatous polyposis 1,Familial colorectal cancer,not specified,APC-Associated Polyposis Disorders];		COSM4166218	n/a (AF>5%)	n/a (AF>5%)					APC (inh=AD pLI=1.00), CTC-554D6.1 (inh=n/a pLI=n/a)
chr5	112176756	112176756	T	A	het		QUAL=4289;DP=382;AF=0.45;MQM=60	APC,CTC-554D6.1	missense,intron&NMD_transcript	APC:ENST00000257430:missense_variant:MODERATE:exon16/16:c.5465T>A:p.Val1822Asp:,APC:ENST00000457016:missense_variant:MODERATE:exon16/16:c.5465T>A:p.Val1822Asp:,APC:ENST00000508376:missense_variant:MODERATE:exon17/17:c.5465T>A:p.Val1822Asp:,CTC-554D6.1:ENST00000520401:intron_variant&NMD_transcript_variant:MODIFIER:exon3/7:c.230+12087T>A::		rs459552		0.8113		0.9595,0.8279,0.9030,0.7708,0.7816	0.7650,0.9459	3.6530	T,T,T, 	B,B,B, 	0.05,0.95	1.89	0.19	611731 [APC (confirmed) Adenomatous polyposis coli,175100/Gastric cancer,somatic,613659/Adenoma,periampullary,somatic/Hepatoblastoma,somatic,114550/Desmoid disease,hereditary,135290/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100/Gardner syndrome,175100];	21030 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial adenomatous polyposis 1,Familial colorectal cancer,not specified,APC-Associated Polyposis Disorders,not provided];		COSM3760871	n/a (AF>5%)	n/a (AF>5%)					APC (inh=AD pLI=1.00), CTC-554D6.1 (inh=n/a pLI=n/a)
chr5	112177171	112177171	G	A	het		QUAL=9897;DP=815;AF=0.48;MQM=60	APC,CTC-554D6.1	synonymous,intron&NMD_transcript	APC:ENST00000257430:synonymous_variant:LOW:exon16/16:c.5880G>A:p.Pro1960=:PF05923,APC:ENST00000457016:synonymous_variant:LOW:exon16/16:c.5880G>A:p.Pro1960=:PF05923,APC:ENST00000508376:synonymous_variant:LOW:exon17/17:c.5880G>A:p.Pro1960=:PF05923,CTC-554D6.1:ENST00000520401:intron_variant&NMD_transcript_variant:MODIFIER:exon3/7:c.230+12502G>A::		rs465899	0.6665	0.6497		0.5369,0.7350,0.8218,0.6193,0.7119	0.6168,0.5286	-0.1780			0.23,0.91	1.48		611731 [APC (confirmed) Adenomatous polyposis coli,175100/Gastric cancer,somatic,613659/Adenoma,periampullary,somatic/Hepatoblastoma,somatic,114550/Desmoid disease,hereditary,135290/Colorectal cancer,somatic,114500/Brain tumor-polyposis syndrome 2,175100/Gardner syndrome,175100];	42247 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial adenomatous polyposis 1,Familial colorectal cancer,not specified,APC-Associated Polyposis Disorders];		COSM3760872	n/a (AF>5%)	n/a (AF>5%)					APC (inh=AD pLI=1.00), CTC-554D6.1 (inh=n/a pLI=n/a)
chr5	131892979	131892979	G	A	hom	off-target	QUAL=1592;DP=66;AF=0.98;MQM=60	RAD50	5'UTR	RAD50:ENST00000265335:5_prime_UTR_variant:MODIFIER:exon1/25:c.-38G>A::,RAD50:ENST00000378823:5_prime_UTR_variant:MODIFIER:exon1/25:c.-455G>A::		rs4526098	0.9249	0.9797		0.7540,0.9847,0.9999,0.9966,0.9919	0.9977,0.7646	2.2380			0.22,0.54	0.80		604040 [RAD50 (provisional) Nijmegen breakage syndrome-like disorder,613078];				n/a (AF>5%)	n/a (AF>5%)					RAD50 (inh=AR pLI=0.00)
chr5	131915213	131915213	G	A	het	off-target	QUAL=1499;DP=145;AF=0.46;MQM=60	RAD50	intron	RAD50:ENST00000265335:intron_variant:MODIFIER:exon4/24:c.551+19G>A::,RAD50:ENST00000378823:intron_variant:MODIFIER:exon4/24:c.134+19G>A::		rs17166050	0.1677	0.1988		0.1126,0.1445,0.1675,0.2081,0.2280	0.2081,0.1129	-0.1970			0.01,0.13	-0.08		604040 [RAD50 (provisional) Nijmegen breakage syndrome-like disorder,613078];	259870 [benign DISEASE=Nijmegen breakage syndrome-like disorder,not specified,not provided];	CS139954 [CLASS=DFP MUT=ALT PHEN="Acute lymphoblastic leukaemia decreased risk" GENE=RAD50];		n/a (AF>5%)	n/a (AF>5%)					RAD50 (inh=AR pLI=0.00)
chr5	131925483	131925483	G	C	het		QUAL=814;DP=67;AF=0.49;MQM=60	RAD50	missense	RAD50:ENST00000265335:missense_variant:MODERATE:exon9/25:c.1406G>C:p.Gly469Ala:,RAD50:ENST00000378823:missense_variant:MODERATE:exon9/25:c.989G>C:p.Gly330Ala:		rs55653181	0.0002	0.0001		0.0000,0.0000,0.0000,0.0001,0.0000		6.3330	T,T	B,B	0.98,0.99	2.57	0.26	604040 [RAD50 (provisional) Nijmegen breakage syndrome-like disorder,613078];	216618 [uncertain significance DISEASE=Hereditary cancer-predisposing syndrome];			0	4					RAD50 (inh=AR pLI=0.00)
chr5	176334195	176334195	C	T	het	off-target	QUAL=11593;DP=625;AF=0.69;MQM=60	UIMC1	intron	UIMC1:ENST00000377219:intron_variant:MODIFIER:exon12/14:c.1852-17G>A::,UIMC1:ENST00000377227:intron_variant:MODIFIER:exon12/14:c.1849-17G>A::,UIMC1:ENST00000506128:intron_variant:MODIFIER:exon12/14:c.1351-17G>A::,UIMC1:ENST00000511320:intron_variant:MODIFIER:exon12/14:c.1849-17G>A::		rs2292255	0.5905	0.5923		0.8306,0.3515,0.4834,0.5003,0.4705	0.4912,0.8109	-3.9050			0.01,0.05	-0.75						n/a (AF>5%)	n/a (AF>5%)					UIMC1 (inh=n/a pLI=0.02)
chr5	176338288	176338288	C	T	het	off-target	QUAL=3679;DP=323;AF=0.48;MQM=60	UIMC1	intron	UIMC1:ENST00000377219:intron_variant:MODIFIER:exon11/14:c.1679+24G>A::,UIMC1:ENST00000377227:intron_variant:MODIFIER:exon11/14:c.1676+24G>A::,UIMC1:ENST00000506128:intron_variant:MODIFIER:exon11/14:c.1178+24G>A::,UIMC1:ENST00000511320:intron_variant:MODIFIER:exon11/14:c.1676+24G>A::		rs17078630	0.0092	0.0247		0.0057,0.0122,0.0001,0.0362,0.0056	0.0364,0.0079	-2.9760			0.01,0.13	-0.34						14	360					UIMC1 (inh=n/a pLI=0.02)
chr6	35420628	35420628	A	C	het	off-target	QUAL=67;DP=8;AF=0.50;MQM=60	FANCE	intron	FANCE:ENST00000229769:intron_variant:MODIFIER:exon1/9:c.248+58A>C::		rs9470029	0.6172	0.6322				-1.9940			0.00,0.04	0.11		613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];				n/a (AF>5%)	n/a (AF>5%)					FANCE (inh=AR pLI=0.01)
chr6	35423489	35423489	A	G	het	off-target	QUAL=7904;DP=636;AF=0.49;MQM=60	FANCE	intron	FANCE:ENST00000229769:intron_variant:MODIFIER:exon1/9:c.249-35A>G::		rs7757405	0.7766	0.7428		0.8698,0.8206,0.6830,0.6734,0.7461	0.6713,0.8568	1.3540			0.00,0.07	0.74		613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	261434 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCE (inh=AR pLI=0.01)
chr6	35423662	35423662	A	C	het		QUAL=884;DP=100;AF=0.41;MQM=60	FANCE	synonymous	FANCE:ENST00000229769:synonymous_variant:LOW:exon2/10:c.387A>C:p.Pro129=:		rs4713867		0.7433		0.8751,0.8220,0.6831,0.6734,0.7473	0.6717,0.8604	-1.1480			0.00,0.14	-0.07		613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	261435 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCE (inh=AR pLI=0.01)
chr6	35424188	35424188	A	G	het	off-target	QUAL=1441;DP=106;AF=0.53;MQM=60	FANCE	intron	FANCE:ENST00000229769:intron_variant:MODIFIER:exon2/9:c.855+58A>G::		rs3800377		0.7157				-1.5140			0.00,0.05	-0.55		613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];				n/a (AF>5%)	n/a (AF>5%)					FANCE (inh=AR pLI=0.01)
chr6	35425416	35425416	A	G	het	off-target	QUAL=10912;DP=832;AF=0.50;MQM=60	FANCE	intron	FANCE:ENST00000229769:intron_variant:MODIFIER:exon3/9:c.900+39A>G::		rs13214239	0.3596	0.5042		0.1278,0.6335,0.3601,0.5554,0.4299	0.5448,0.1530	-1.0880			0.02,0.15	0.18		613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	261436 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCE (inh=AR pLI=0.01)
chr6	131148863	131148863	A	T	het		QUAL=4396;DP=373;AF=0.52;MQM=60	SMLR1	intron	SMLR1:ENST00000541421:intron_variant:MODIFIER:exon1/1:c.238+72A>T::		rs9388856	0.4794	0.3798				0.0190			0.08,0.21	-0.28						n/a (AF>5%)	n/a (AF>5%)					SMLR1 (inh=n/a pLI=n/a)
chr6	131148891	131148891	-	AT	het	off-target	QUAL=6759;DP=703;AF=0.41;MQM=60	SMLR1	intron	SMLR1:ENST00000541421:intron_variant:MODIFIER:exon1/1:c.238+113_238+114dup::		rs113795427	0.4884	0.3974								-0.07						n/a (AF>5%)	n/a (AF>5%)					SMLR1 (inh=n/a pLI=n/a)
chr7	6026775	6026775	T	C	hom		QUAL=527;DP=22;AF=1.00;MQM=60	PMS2	missense,intron	PMS2:ENST00000265849:missense_variant:MODERATE:exon11/15:c.1621A>G:p.Lys541Glu:,PMS2:ENST00000382321:intron_variant:MODIFIER:exon7/10:c.804-4153A>G::,PMS2:ENST00000406569:missense_variant:MODERATE:exon11/12:c.1621A>G:p.Lys541Glu:,PMS2:ENST00000441476:missense_variant:MODERATE:exon8/12:c.1303A>G:p.Lys435Glu:		rs2228006	0.8832	0.8722		0.9259,0.6676,0.9235,0.8499,0.8954	0.8457,0.9185	1.4430	T, ,T,T	B, ,B,B	0.00,0.13	0.70	0.16	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300/Colorectal cancer,hereditary nonpolyposis,type 4,614337];	135065 [benign DISEASE=Hereditary nonpolyposis colorectal cancer type 4,not specified];			n/a (AF>5%)	n/a (AF>5%)					PMS2 (inh=AR+AD pLI=0.00)
chr7	6036980	6036980	G	C	hom		QUAL=763;DP=26;AF=1.00;MQM=60	PMS2	synonymous	PMS2:ENST00000265849:synonymous_variant:LOW:exon7/15:c.780C>G:p.Ser260=:,PMS2:ENST00000382321:synonymous_variant:LOW:exon7/11:c.780C>G:p.Ser260=:,PMS2:ENST00000406569:synonymous_variant:LOW:exon7/12:c.780C>G:p.Ser260=:,PMS2:ENST00000441476:synonymous_variant:LOW:exon4/12:c.462C>G:p.Ser154=:		rs1805319		0.8205		0.8425,0.6497,0.9231,0.8170,0.8170	0.8148,0.8414	-2.6950			0.03,0.07	-0.28		600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300/Colorectal cancer,hereditary nonpolyposis,type 4,614337];	36693 [benign DISEASE=Hereditary nonpolyposis colon cancer,Hereditary cancer-predisposing syndrome,Lynch syndrome,Hereditary nonpolyposis colorectal cancer type 4,not specified];			n/a (AF>5%)	n/a (AF>5%)					PMS2 (inh=AR+AD pLI=0.00)
chr7	6037057	6037057	-	A	het		QUAL=192;DP=28;AF=0.46;MQM=60	PMS2	splice_region&intron	PMS2:ENST00000265849:splice_region_variant&intron_variant:LOW:exon6/14:c.706-4dup::,PMS2:ENST00000382321:splice_region_variant&intron_variant:LOW:exon6/10:c.706-4dup::,PMS2:ENST00000406569:splice_region_variant&intron_variant:LOW:exon6/11:c.706-4dup::,PMS2:ENST00000441476:splice_region_variant&intron_variant:LOW:exon3/11:c.388-4dup::	(A)n	rs774538869		0.0961		0.0789,0.0862,0.0264,0.0747,0.0462						0.74		600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300/Colorectal cancer,hereditary nonpolyposis,type 4,614337];	198429 [conflicting interpretations of pathogenicity DISEASE=Hereditary nonpolyposis colon cancer,Hereditary cancer-predisposing syndrome,Lynch syndrome,Hereditary nonpolyposis colorectal cancer type 4,not specified];			n/a (AF>5%)	n/a (AF>5%)					PMS2 (inh=AR+AD pLI=0.00)
chr7	128843169	128843169	C	T	hom	off-target	QUAL=315;DP=12;AF=1.00;MQM=60	SMO	intron	SMO:ENST00000249373:intron_variant:MODIFIER:exon1/11:c.332-56C>T::		rs2566871	0.4615	0.4969				-1.5800			0.00,0.08	0.12		601500 [SMO (provisional) Basal cell carcinoma,somatic,605462/Curry-Jones syndrome,somatic mosaic,601707];				n/a (AF>5%)	n/a (AF>5%)					SMO (inh=n/a pLI=0.15)
chr7	128845018	128845018	C	T	hom	off-target	QUAL=6716;DP=206;AF=1.00;MQM=60	SMO	intron	SMO:ENST00000249373:intron_variant:MODIFIER:exon2/11:c.538-26C>T::		rs2703091	0.7524	0.7967		0.6822,0.7138,0.7573,0.8412,0.7656	0.8386,0.6891	-0.1140			0.05,0.20	0.01		601500 [SMO (provisional) Basal cell carcinoma,somatic,605462/Curry-Jones syndrome,somatic mosaic,601707];				n/a (AF>5%)	n/a (AF>5%)					SMO (inh=n/a pLI=0.15)
chr7	128845277	128845277	G	C	hom	off-target	QUAL=1590;DP=55;AF=1.00;MQM=60	SMO	intron	SMO:ENST00000249373:intron_variant:MODIFIER:exon3/11:c.747+24G>C::		rs2075777		0.7964		0.6831,0.7150,0.7583,0.8416,0.7634	0.8385,0.6969	-0.0960			0.10,0.13	-0.47		601500 [SMO (provisional) Basal cell carcinoma,somatic,605462/Curry-Jones syndrome,somatic mosaic,601707];				n/a (AF>5%)	n/a (AF>5%)					SMO (inh=n/a pLI=0.15)
chr7	128846328	128846328	G	C	hom		QUAL=28469;DP=909;AF=1.00;MQM=60	SMO	synonymous	SMO:ENST00000249373:synonymous_variant:LOW:exon6/12:c.1164G>C:p.Gly388=:PF01534		rs2228617	0.7562	0.7982		0.6867,0.7150,0.7695,0.8413,0.7659	0.8391,0.6931	1.1300			0.42,0.97	2.06		601500 [SMO (provisional) Basal cell carcinoma,somatic,605462/Curry-Jones syndrome,somatic mosaic,601707];	403462 [benign DISEASE=not specified];		COSM4004294	n/a (AF>5%)	n/a (AF>5%)					SMO (inh=n/a pLI=0.15)
chr7	128846469	128846469	A	G	hom	off-target	QUAL=27652;DP=857;AF=1.00;MQM=60	SMO	intron	SMO:ENST00000249373:intron_variant:MODIFIER:exon6/11:c.1264+41A>G::		rs2735842	0.7532	0.7970		0.6868,0.7150,0.7578,0.8413,0.7659	0.8391,0.6927	0.2160			0.00,0.07	0.10		601500 [SMO (provisional) Basal cell carcinoma,somatic,605462/Curry-Jones syndrome,somatic mosaic,601707];				n/a (AF>5%)	n/a (AF>5%)					SMO (inh=n/a pLI=0.15)
chr7	142460261	142460261	T	A	hom	off-target	QUAL=2051;DP=69;AF=1.00;MQM=60	PRSS1	intron	PRSS1:ENST00000311737:intron_variant:MODIFIER:exon3/4:c.455-21T>A::,PRSS1:ENST00000486171:intron_variant:MODIFIER:exon4/5:c.497-21T>A::		rs201825825		0.7902		0.6697,0.6663,0.7434,0.6044,0.6175		-0.8960			0.00,0.08	-0.00		276000 [PRSS1 (confirmed) Pancreatitis,hereditary,167800/Trypsinogen deficiency,614044];				n/a (AF>5%)	n/a (AF>5%)					PRSS1 (inh=AR+AD pLI=0.00)
chr7	142460313	142460313	T	C	hom		QUAL=4965;DP=165;AF=1.00;MQM=60	PRSS1	synonymous	PRSS1:ENST00000311737:synonymous_variant:LOW:exon4/5:c.486T>C:p.Asp162=:PF00089,PRSS1:ENST00000486171:synonymous_variant:LOW:exon5/6:c.528T>C:p.Asp176=:PF00089		rs6666	0.3966	0.4118		0.3585,0.4307,0.2095,0.4240,0.2606		-4.3320			0.02,0.08	-0.45		276000 [PRSS1 (confirmed) Pancreatitis,hereditary,167800/Trypsinogen deficiency,614044];	239391 [benign/likely benign DISEASE=Hereditary pancreatitis,not specified];			n/a (AF>5%)	n/a (AF>5%)					PRSS1 (inh=AR+AD pLI=0.00)
chr7	142460865	142460865	T	C	hom		QUAL=10142;DP=357;AF=1.00;MQM=60	PRSS1	synonymous	PRSS1:ENST00000311737:synonymous_variant:LOW:exon5/5:c.738T>C:p.Asn246=:,PRSS1:ENST00000486171:synonymous_variant:LOW:exon6/6:c.780T>C:p.Asn260=:		rs6667	0.3938	0.5213		0.4296,0.5615,0.2303,0.5784,0.3050		0.2230			0.01,0.80	0.20		276000 [PRSS1 (confirmed) Pancreatitis,hereditary,167800/Trypsinogen deficiency,614044];	258803 [likely benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					PRSS1 (inh=AR+AD pLI=0.00)
chr8	90955624	90955624	T	A	het	off-target	QUAL=411;DP=31;AF=0.55;MQM=60	NBN	intron	NBN:ENST00000265433:intron_variant:MODIFIER:exon13/15:c.2071-30A>T::,NBN:ENST00000409330:intron_variant:MODIFIER:exon13/15:c.1825-30A>T::		rs3736639	0.3792	0.3540		0.3205,0.3542,0.4546,0.3254,0.4299	0.3151,0.3116	-0.2360			0.00,0.07	0.03		602667 [NBN (confirmed) Nijmegen breakage syndrome,251260/Aplastic anemia,609135/Leukemia,acute lymphoblastic,613065];	258769 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					NBN (inh=AR pLI=0.00)
chr8	90958422	90958422	T	C	het		QUAL=584;DP=47;AF=0.55;MQM=60	NBN	synonymous	NBN:ENST00000265433:synonymous_variant:LOW:exon13/16:c.2016A>G:p.Pro672=:,NBN:ENST00000409330:synonymous_variant:LOW:exon13/16:c.1770A>G:p.Pro590=:		rs1061302	0.3528	0.3470		0.2289,0.3494,0.4546,0.3251,0.4293	0.3132,0.2276	-0.8170			0.06,0.19	-0.23		602667 [NBN (confirmed) Nijmegen breakage syndrome,251260/Aplastic anemia,609135/Leukemia,acute lymphoblastic,613065];	183696 [benign DISEASE=Hereditary cancer-predisposing syndrome,Microcephaly, normal intelligence and immunodeficiency,not specified];			n/a (AF>5%)	n/a (AF>5%)					NBN (inh=AR pLI=0.00)
chr8	90958530	90958530	T	C	het		QUAL=377;DP=36;AF=0.44;MQM=60	NBN	splice_region&intron	NBN:ENST00000265433:splice_region_variant&intron_variant:LOW:exon12/15:c.1915-7A>G::,NBN:ENST00000409330:splice_region_variant&intron_variant:LOW:exon12/15:c.1669-7A>G::		rs2308962	0.3790	0.3535		0.3179,0.3543,0.4546,0.3254,0.4287	0.3144,0.3107	-1.8420			0.02,0.10	-0.54		602667 [NBN (confirmed) Nijmegen breakage syndrome,251260/Aplastic anemia,609135/Leukemia,acute lymphoblastic,613065];	258768 [benign DISEASE=Hereditary cancer-predisposing syndrome,Microcephaly, normal intelligence and immunodeficiency,not specified];			n/a (AF>5%)	n/a (AF>5%)					NBN (inh=AR pLI=0.00)
chr8	90967711	90967711	A	G	het		QUAL=349;DP=37;AF=0.43;MQM=60	NBN	synonymous	NBN:ENST00000265433:synonymous_variant:LOW:exon10/16:c.1197T>C:p.Asp399=:,NBN:ENST00000409330:synonymous_variant:LOW:exon10/16:c.951T>C:p.Asp317=:		rs709816	0.6086	0.5139		0.7770,0.5788,0.6464,0.3622,0.5123	0.3559,0.7527	0.0420			0.03,0.15	-0.26		602667 [NBN (confirmed) Nijmegen breakage syndrome,251260/Aplastic anemia,609135/Leukemia,acute lymphoblastic,613065];	183701 [benign DISEASE=Hereditary cancer-predisposing syndrome,Microcephaly, normal intelligence and immunodeficiency,not specified];			n/a (AF>5%)	n/a (AF>5%)					NBN (inh=AR pLI=0.00)
chr8	90970935	90970935	G	A	het	off-target	QUAL=463;DP=48;AF=0.42;MQM=60	NBN	intron	NBN:ENST00000265433:intron_variant:MODIFIER:exon9/15:c.1124+18C>T::,NBN:ENST00000409330:intron_variant:MODIFIER:exon9/15:c.878+18C>T::		rs2234744	0.3530	0.3468		0.2289,0.3493,0.4544,0.3250,0.4288	0.3135,0.2279	-0.4390			0.01,0.14	-0.36		602667 [NBN (confirmed) Nijmegen breakage syndrome,251260/Aplastic anemia,609135/Leukemia,acute lymphoblastic,613065];	199080 [benign DISEASE=Hereditary cancer-predisposing syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					NBN (inh=AR pLI=0.00)
chr8	90990479	90990479	C	G	het		QUAL=10738;DP=828;AF=0.50;MQM=60	NBN	missense	NBN:ENST00000265433:missense_variant:MODERATE:exon5/16:c.553G>C:p.Glu185Gln:,NBN:ENST00000409330:missense_variant:MODERATE:exon5/16:c.307G>C:p.Glu103Gln:		rs1805794	0.3570	0.3472		0.2356,0.3498,0.4548,0.3247,0.4290	0.3136,0.2338	2.1330	T,T	B,B	0.09,0.94	1.35	0.10	602667 [NBN (confirmed) Nijmegen breakage syndrome,251260/Aplastic anemia,609135/Leukemia,acute lymphoblastic,613065];	134876 [benign DISEASE=Hereditary cancer-predisposing syndrome,Microcephaly, normal intelligence and immunodeficiency,not specified];	CM034886 [CLASS=DP MUT=ALT PHEN="Lung cancer association with" GENE=NBN];	COSM3685433,COSM4824719	n/a (AF>5%)	n/a (AF>5%)					NBN (inh=AR pLI=0.00)
chr8	90995019	90995019	C	T	het		QUAL=99;DP=19;AF=0.37;MQM=60	NBN	synonymous,5'UTR	NBN:ENST00000265433:synonymous_variant:LOW:exon2/16:c.102G>A:p.Leu34=:PF00498,NBN:ENST00000409330:5_prime_UTR_variant:MODIFIER:exon2/16:c.-145G>A::		rs1063045	0.3792	0.3536		0.3181,0.3542,0.4548,0.3254,0.4292	0.3147,0.3103	-0.2470			0.10,0.85	0.74		602667 [NBN (confirmed) Nijmegen breakage syndrome,251260/Aplastic anemia,609135/Leukemia,acute lymphoblastic,613065];	183697 [benign DISEASE=Hereditary cancer-predisposing syndrome,Microcephaly, normal intelligence and immunodeficiency,not specified];			n/a (AF>5%)	n/a (AF>5%)					NBN (inh=AR pLI=0.00)
chr8	107236280	107236280	G	T	hom		QUAL=20602;DP=650;AF=1.00;MQM=60				LTR33	rs1393978	0.6096	0.5551				-0.5990			0.00,0.05	-0.48						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr9	5921881	5921881	G	A	het		QUAL=15214;DP=1060;AF=0.54;MQM=60	KIAA2026	missense	KIAA2026:ENST00000381461:missense_variant:MODERATE:exon7/7:c.4025C>T:p.Thr1342Ile:,KIAA2026:ENST00000399933:missense_variant:MODERATE:exon8/8:c.4115C>T:p.Thr1372Ile:		rs72697396	0.0002	0.0001		0.0000,0.0000,0.0000,0.0001,0.0001	0.0001,0.0000	1.9050	D,D	B,B	0.39,0.53	1.38	0.03					0	6					KIAA2026 (inh=n/a pLI=n/a)
chr9	17235643	17235643	T	-	het	off-target	QUAL=521;DP=40;AF=0.60;MQM=60	CNTLN	intron	CNTLN:ENST00000262360:intron_variant:MODIFIER:exon3/25:c.535-7del::,CNTLN:ENST00000380641:intron_variant:MODIFIER:exon3/6:c.535-7del::,CNTLN:ENST00000380647:intron_variant:MODIFIER:exon3/25:c.535-7del::,CNTLN:ENST00000425824:intron_variant:MODIFIER:exon3/25:c.535-7del::		rs67017076	0.9133	0.7966		0.9561,0.9063,0.9998,0.7339,0.9304	0.7474,0.9458	1.7450				-0.11						n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17273878	17273878	A	G	het		QUAL=1145;DP=64;AF=0.72;MQM=60	CNTLN	intron	CNTLN:ENST00000262360:intron_variant:MODIFIER:exon6/25:c.987+10A>G::,CNTLN:ENST00000380641:intron_variant:MODIFIER:exon6/6:c.983+14A>G::,CNTLN:ENST00000380647:intron_variant:MODIFIER:exon6/25:c.983+14A>G::,CNTLN:ENST00000425824:intron_variant:MODIFIER:exon6/25:c.987+10A>G::		rs12376938	0.2258	0.2504		0.1701,0.1931,0.0702,0.2635,0.3565	0.2651,0.1674	-1.6410			0.00,0.08	0.18						n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17273926	17273926	C	G	het	off-target	QUAL=173;DP=16;AF=0.50;MQM=60	CNTLN	intron	CNTLN:ENST00000262360:intron_variant:MODIFIER:exon6/25:c.987+58C>G::,CNTLN:ENST00000380641:intron_variant:MODIFIER:exon6/6:c.983+62C>G::,CNTLN:ENST00000380647:intron_variant:MODIFIER:exon6/25:c.983+62C>G::,CNTLN:ENST00000425824:intron_variant:MODIFIER:exon6/25:c.987+58C>G::		rs12379655	0.3343	0.2865				-1.7500			0.00,0.08	0.05						n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17342383	17342383	C	T	hom		QUAL=983;DP=30;AF=1.00;MQM=60	CNTLN	synonymous	CNTLN:ENST00000262360:synonymous_variant:LOW:exon12/26:c.1827C>T:p.Asp609=:,CNTLN:ENST00000380647:synonymous_variant:LOW:exon12/26:c.1827C>T:p.Asp609=:,CNTLN:ENST00000425824:synonymous_variant:LOW:exon12/26:c.1827C>T:p.Asp609=:		rs1442527	0.9495	0.9887		0.8431,0.9917,1.0000,0.9995,0.9998	0.9994,0.8447	2.3280			0.13,0.94	0.40						n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17394536	17394536	C	T	hom		QUAL=1783;DP=56;AF=1.00;MQM=60	CNTLN	missense	CNTLN:ENST00000262360:missense_variant:MODERATE:exon15/26:c.2084C>T:p.Thr695Ile:,CNTLN:ENST00000380647:missense_variant:MODERATE:exon15/26:c.2084C>T:p.Thr695Ile:,CNTLN:ENST00000425824:missense_variant:MODERATE:exon15/26:c.2084C>T:p.Thr695Ile:		rs7035276	0.7806	0.8298		0.6910,0.7726,0.8084,0.8726,0.7388	0.8763,0.6951	0.3250	T,T,T	B,B,B	0.11,0.67	1.13	0.06					n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17394996	17394996	T	C	hom		QUAL=3142;DP=98;AF=1.00;MQM=60	CNTLN	synonymous	CNTLN:ENST00000262360:synonymous_variant:LOW:exon15/26:c.2544T>C:p.His848=:,CNTLN:ENST00000380647:synonymous_variant:LOW:exon15/26:c.2544T>C:p.His848=:,CNTLN:ENST00000425824:synonymous_variant:LOW:exon15/26:c.2544T>C:p.His848=:		rs3739489	0.8411	0.8779		0.7716,0.7908,0.8110,0.9167,0.8700	0.9149,0.7877	0.6140			0.30,0.96	0.44						n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17395108	17395108	C	T	hom	off-target	QUAL=6825;DP=215;AF=1.00;MQM=60	CNTLN	intron	CNTLN:ENST00000262360:intron_variant:MODIFIER:exon15/25:c.2615+41C>T::,CNTLN:ENST00000380647:intron_variant:MODIFIER:exon15/25:c.2615+41C>T::,CNTLN:ENST00000425824:intron_variant:MODIFIER:exon15/25:c.2615+41C>T::		rs3739488	0.7819	0.8304		0.6967,0.7759,0.8096,0.8740,0.7470	0.8765,0.7126	3.8330			0.21,0.97	1.88						n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17409366	17409366	G	A	hom		QUAL=12154;DP=384;AF=1.00;MQM=60	CNTLN	synonymous	CNTLN:ENST00000262360:synonymous_variant:LOW:exon16/26:c.2691G>A:p.Thr897=:,CNTLN:ENST00000380647:synonymous_variant:LOW:exon16/26:c.2691G>A:p.Thr897=:,CNTLN:ENST00000425824:synonymous_variant:LOW:exon16/26:c.2691G>A:p.Thr897=:		rs2780211	0.8389	0.8734		0.7725,0.7916,0.8103,0.9134,0.8495	0.9115,0.7767	0.9030			0.01,0.65	0.43					COSM3982792	n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17457513	17457513	A	-	hom		QUAL=104;DP=4;AF=1.00;MQM=60	CNTLN	intron	CNTLN:ENST00000262360:intron_variant:MODIFIER:exon18/25:c.3115-2del::,CNTLN:ENST00000380647:intron_variant:MODIFIER:exon18/25:c.3115-2del::,CNTLN:ENST00000425824:intron_variant:MODIFIER:exon18/25:c.3115-2del::	(TATATT)n	rs35399020	0.7342	0.8546		0.5928,0.7526,0.6951,0.9109,0.7924	0.9938,0.6590	0.1540				-0.28					COSM5450565,COSM5450566	n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	17494875	17494877	TTT	-	het	off-target	QUAL=317;DP=53;AF=0.28;MQM=60	CNTLN	intron	CNTLN:ENST00000262360:intron_variant:MODIFIER:exon25/25:c.4120-11_4120-9del::,CNTLN:ENST00000380647:intron_variant:MODIFIER:exon25/25:c.4120-7655_4120-7653del::,CNTLN:ENST00000425824:intron_variant:MODIFIER:exon25/25:c.4120-7655_4120-7653del::	AluSx	rs776507555		0.0467		0.0623,0.0743,0.0705,0.0398,0.0275		0.1780				-0.19						157	20	2	[2] auto-classification 15.09.2017  			CNTLN (inh=n/a pLI=0.00)
chr9	17494875	17494875	T	-	het	off-target	QUAL=317;DP=53;AF=0.19;MQM=60	CNTLN	intron	CNTLN:ENST00000262360:intron_variant:MODIFIER:exon25/25:c.4120-9del::,CNTLN:ENST00000380647:intron_variant:MODIFIER:exon25/25:c.4120-7653del::,CNTLN:ENST00000425824:intron_variant:MODIFIER:exon25/25:c.4120-7653del::	AluSx	rs35224903		0.4820		0.2337,0.2078,0.2073,0.0871,0.0989		0.1780				-0.18						n/a (AF>5%)	n/a (AF>5%)					CNTLN (inh=n/a pLI=0.00)
chr9	35074917	35074917	T	C	hom		QUAL=3127;DP=99;AF=1.00;MQM=60	FANCG	splice_region&intron	FANCG:ENST00000378643:splice_region_variant&intron_variant:LOW:exon12/13:c.1636+7A>G::		rs587118	0.2202	0.4029		0.0779,0.5004,0.0033,0.4991,0.2611	0.4993,0.0944	0.2340			0.13,0.60	1.37		602956 [FANCG (confirmed) Fanconi anemia,complementation group G,614082];	259477 [benign DISEASE=Fanconi anemia,not specified,Amyotrophic Lateral Sclerosis, Dominant,Inclusion Body Myopathy, Dominant];			n/a (AF>5%)	n/a (AF>5%)					FANCG (inh=n/a pLI=0.00)
chr9	35077441	35077441	T	C	hom	off-target	QUAL=6891;DP=209;AF=1.00;MQM=60	FANCG	intron	FANCG:ENST00000378643:intron_variant:MODIFIER:exon4/13:c.511-45A>G::		rs554098	0.7015	0.7489		0.7437,0.8448,0.4518,0.7776,0.7075	0.7749,0.7365	-1.4140			0.00,0.06	0.16		602956 [FANCG (confirmed) Fanconi anemia,complementation group G,614082];	259478 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCG (inh=n/a pLI=0.00)
chr9	90062823	90062823	A	G	hom		QUAL=14896;DP=528;AF=1.00;MQM=60					rs12682834	0.6368	0.6502		0.4722,0.6888,0.6838,0.6292,0.7397	0.6168,0.4857	-0.5480			0.00,0.26	-0.31						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr9	98209594	98209594	G	A	het		QUAL=1180;DP=71;AF=0.66;MQM=60	PTCH1	missense	PTCH1:ENST00000331920:missense_variant:MODERATE:exon23/24:c.3944C>T:p.Pro1315Leu:,PTCH1:ENST00000375274:missense_variant:MODERATE:exon23/24:c.3941C>T:p.Pro1314Leu:,PTCH1:ENST00000418258:missense_variant:MODERATE:exon23/24:c.3491C>T:p.Pro1164Leu:,PTCH1:ENST00000421141:missense_variant:MODERATE:exon23/24:c.3491C>T:p.Pro1164Leu:,PTCH1:ENST00000429896:missense_variant:MODERATE:exon23/24:c.3491C>T:p.Pro1164Leu:,PTCH1:ENST00000430669:missense_variant:MODERATE:exon23/23:c.3746C>T:p.Pro1249Leu:,PTCH1:ENST00000437951:missense_variant:MODERATE:exon23/24:c.3746C>T:p.Pro1249Leu:		rs357564	0.3968	0.3889		0.2318,0.4881,0.5637,0.3384,0.4470	0.3298,0.2389	9.4090	D,D,D,D,D,D,D	B,P,B,B,B,P,P	1.00,0.99	3.45	0.44	601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400/Basal cell carcinoma,somatic,605462/Holoprosencephaly 7,610828];	41663 [benign DISEASE=Holoprosencephaly sequence,Gorlin syndrome,Hereditary cancer-predisposing syndrome,not specified,not provided];		COSM1638394	n/a (AF>5%)	n/a (AF>5%)					PTCH1 (inh=AD pLI=1.00)
chr9	98232224	98232224	A	-	het		QUAL=263;DP=59;AF=0.54;MQM=60	PTCH1	intron	PTCH1:ENST00000331920:intron_variant:MODIFIER:exon12/23:c.1729-11del::,PTCH1:ENST00000375274:intron_variant:MODIFIER:exon12/23:c.1726-11del::,PTCH1:ENST00000418258:intron_variant:MODIFIER:exon12/23:c.1276-11del::,PTCH1:ENST00000421141:intron_variant:MODIFIER:exon12/23:c.1276-11del::,PTCH1:ENST00000429896:intron_variant:MODIFIER:exon12/23:c.1276-11del::,PTCH1:ENST00000430669:intron_variant:MODIFIER:exon12/22:c.1531-11del::,PTCH1:ENST00000437951:intron_variant:MODIFIER:exon12/23:c.1531-11del::		rs779000277		0.0011		0.0001,0.0007,0.0000,0.0021,0.0000	0.0018,0.0000	0.6250				-0.32		601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400/Basal cell carcinoma,somatic,605462/Holoprosencephaly 7,610828];				0	19					PTCH1 (inh=AD pLI=1.00)
chr9	98239190	98239190	G	C	hom	off-target	QUAL=1285;DP=42;AF=1.00;MQM=60	PTCH1	intron	PTCH1:ENST00000331920:intron_variant:MODIFIER:exon10/23:c.1504-51C>G::,PTCH1:ENST00000375274:intron_variant:MODIFIER:exon10/23:c.1501-51C>G::,PTCH1:ENST00000418258:intron_variant:MODIFIER:exon10/23:c.1051-51C>G::,PTCH1:ENST00000421141:intron_variant:MODIFIER:exon10/23:c.1051-51C>G::,PTCH1:ENST00000429896:intron_variant:MODIFIER:exon10/23:c.1051-51C>G::,PTCH1:ENST00000430669:intron_variant:MODIFIER:exon10/22:c.1306-51C>G::,PTCH1:ENST00000437951:intron_variant:MODIFIER:exon10/23:c.1306-51C>G::		rs574688	0.1627	0.2283		0.0476,0.2138,0.0596,0.2657,0.2756	0.2624,0.0588	0.6610			0.11,0.23	0.05		601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400/Basal cell carcinoma,somatic,605462/Holoprosencephaly 7,610828];				n/a (AF>5%)	n/a (AF>5%)					PTCH1 (inh=AD pLI=1.00)
chr10	43595968	43595968	A	G	hom		QUAL=16324;DP=535;AF=1.00;MQM=60	RET	synonymous	RET:ENST00000340058:synonymous_variant:LOW:exon2/19:c.135A>G:p.Ala45=:,RET:ENST00000355710:synonymous_variant:LOW:exon2/20:c.135A>G:p.Ala45=:		rs1800858	0.7536	0.7726		0.9538,0.7583,0.5515,0.7404,0.7296	0.7394,0.9453	-2.5110			0.01,0.17	-0.14		164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400/Medullary thyroid carcinoma,155240/Multiple endocrine neoplasia IIB,162300/Central hypoventilation syndrome,congenital,209880/Pheochromocytoma,171300/Hirschsprung disease,susceptibility to,1,142623/Hirschsprung disease,protection against,142623];	167589 [benign DISEASE=not specified];		COSM4144677	n/a (AF>5%)	n/a (AF>5%)					RET (inh=AR+AD pLI=1.00)
chr10	43612226	43612226	C	T	het	off-target	QUAL=2409;DP=326;AF=0.45;MQM=60	RET	intron	RET:ENST00000340058:intron_variant:MODIFIER:exon12/18:c.2284+47C>T::,RET:ENST00000355710:intron_variant:MODIFIER:exon12/19:c.2284+47C>T::		rs760466	0.1206	0.2076		0.0516,0.1822,0.0589,0.2777,0.1326	0.2788,0.0572	-0.9710			0.02,0.13	-0.26		164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400/Medullary thyroid carcinoma,155240/Multiple endocrine neoplasia IIB,162300/Central hypoventilation syndrome,congenital,209880/Pheochromocytoma,171300/Hirschsprung disease,susceptibility to,1,142623/Hirschsprung disease,protection against,142623];	261396 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					RET (inh=AR+AD pLI=1.00)
chr10	43613843	43613843	G	T	hom		QUAL=37745;DP=1158;AF=1.00;MQM=60	RET	synonymous	RET:ENST00000340058:synonymous_variant:LOW:exon13/19:c.2307G>T:p.Leu769=:PF07714,RET:ENST00000355710:synonymous_variant:LOW:exon13/20:c.2307G>T:p.Leu769=:PF07714		rs1800861		0.7799		0.8860,0.7692,0.5073,0.7683,0.6428	0.7653,0.8754	1.2300			0.79,0.94	0.67		164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400/Medullary thyroid carcinoma,155240/Multiple endocrine neoplasia IIB,162300/Central hypoventilation syndrome,congenital,209880/Pheochromocytoma,171300/Hirschsprung disease,susceptibility to,1,142623/Hirschsprung disease,protection against,142623];	167590 [benign DISEASE=not specified];		COSM4418405	n/a (AF>5%)	n/a (AF>5%)					RET (inh=AR+AD pLI=1.00)
chr10	43615505	43615505	G	A	het	off-target	QUAL=9231;DP=736;AF=0.51;MQM=60	RET	intron	RET:ENST00000340058:intron_variant:MODIFIER:exon14/18:c.2608-24G>A::,RET:ENST00000355710:intron_variant:MODIFIER:exon14/19:c.2608-24G>A::		rs2472737	0.1731	0.2082		0.1483,0.1532,0.2333,0.2257,0.1594	0.2214,0.1514	-0.0220			0.01,0.30	0.36		164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400/Medullary thyroid carcinoma,155240/Multiple endocrine neoplasia IIB,162300/Central hypoventilation syndrome,congenital,209880/Pheochromocytoma,171300/Hirschsprung disease,susceptibility to,1,142623/Hirschsprung disease,protection against,142623];	24956 [benign DISEASE=No MEN2 disease,not specified];	CS116395 [CLASS=DP MUT=ALT PHEN="Hirschsprung disease association with" GENE=RET];		n/a (AF>5%)	n/a (AF>5%)					RET (inh=AR+AD pLI=1.00)
chr10	43622217	43622217	T	C	hom	off-target	QUAL=1163;DP=42;AF=1.00;MQM=60	RET	3'UTR,intron	RET:ENST00000340058:3_prime_UTR_variant:MODIFIER:exon19/19:c.*15T>C::,RET:ENST00000355710:intron_variant:MODIFIER:exon19/19:c.3187+47T>C::		rs2075912	0.7550	0.8233		0.9186,0.7959,0.5134,0.8264,0.7405	0.8253,0.9080	1.3820			0.08,0.78	1.33		164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400/Medullary thyroid carcinoma,155240/Multiple endocrine neoplasia IIB,162300/Central hypoventilation syndrome,congenital,209880/Pheochromocytoma,171300/Hirschsprung disease,susceptibility to,1,142623/Hirschsprung disease,protection against,142623];	165056 [benign DISEASE=not specified];	CS032426 [CLASS=DP MUT=ALT PHEN="Hirschsprung disease association with" GENE=RET];		n/a (AF>5%)	n/a (AF>5%)					RET (inh=AR+AD pLI=1.00)
chr10	88635779	88635779	C	A	het		QUAL=850;DP=71;AF=0.56;MQM=52	BMPR1A	missense	BMPR1A:ENST00000372037:missense_variant:MODERATE:exon3/13:c.4C>A:p.Pro2Thr:		rs11528010	0.4998	0.4141		0.6693,0.3901,0.7211,0.2579,0.3005	0.2562,0.6498	3.7690	T	B	0.02,0.92	1.26	0.21	601299 [BMPR1A (confirmed) Polyposis,juvenile intestinal,174900/Polyposis syndrome,hereditary mixed,2,610069/Juvenile polyposis syndrome,infantile form,174900];	41782 [benign DISEASE=Hereditary cancer-predisposing syndrome,Juvenile polyposis syndrome,not specified,Juvenile Polyposis,not provided];			n/a (AF>5%)	n/a (AF>5%)					BMPR1A (inh=AD pLI=0.64)
chr10	88649763	88649763	C	T	het	off-target	QUAL=672;DP=53;AF=0.49;MQM=60	BMPR1A	intron	BMPR1A:ENST00000372037:intron_variant:MODIFIER:exon3/12:c.68-56C>T::		rs7087358	0.5312	0.4605				-0.3980			0.00,0.12	0.14		601299 [BMPR1A (confirmed) Polyposis,juvenile intestinal,174900/Polyposis syndrome,hereditary mixed,2,610069/Juvenile polyposis syndrome,infantile form,174900];				n/a (AF>5%)	n/a (AF>5%)					BMPR1A (inh=AD pLI=0.64)
chr10	88683122	88683122	T	C	het	off-target	QUAL=5568;DP=620;AF=0.45;MQM=60	BMPR1A	intron	BMPR1A:ENST00000372037:intron_variant:MODIFIER:exon11/12:c.1343-11T>C::		rs7074064	0.4966	0.4136		0.6717,0.3663,0.7209,0.2572,0.3034	0.2550,0.6530	-0.4350			0.00,0.21	0.10		601299 [BMPR1A (confirmed) Polyposis,juvenile intestinal,174900/Polyposis syndrome,hereditary mixed,2,610069/Juvenile polyposis syndrome,infantile form,174900];	259286 [benign DISEASE=Hereditary cancer-predisposing syndrome,not specified,Juvenile Polyposis];			n/a (AF>5%)	n/a (AF>5%)					BMPR1A (inh=AD pLI=0.64)
chr10	89720907	89720907	T	G	het	off-target	QUAL=251;DP=29;AF=0.52;MQM=60	PTEN	intron	PTEN:ENST00000371953:intron_variant:MODIFIER:exon8/8:c.1026+32T>G::		rs555895	0.4325	0.3864		0.5005,0.4584,0.4882,0.3349,0.3089	0.3274,0.4790	-0.8620			0.00,0.10	-0.32		601728 [PTEN (confirmed) Cowden syndrome 1,158350/Lhermitte-Duclos syndrome,158350/Bannayan-Riley-Ruvalcaba syndrome,153480/Meningioma,607174/Glioma susceptibility 2,613028/Macrocephaly/autism syndrome,605309/PTEN hamartoma tumor syndrome/VATER association with macrocephaly and ventriculomegaly,276950/Prostate cancer,somatic,176807/Malignant melanoma,somatic,155600/Endometrial carcinoma,somatic,608089/Squamous cell carcinoma,head and neck,somatic,275355];	92810 [benign DISEASE=not specified];		COSM5914	n/a (AF>5%)	n/a (AF>5%)					PTEN (inh=AR+AD pLI=0.99)
chr10	104264107	104264107	C	T	hom		QUAL=9942;DP=414;AF=1.00;MQM=60	SUFU	intron	SUFU:ENST00000369899:intron_variant:MODIFIER:exon1/10:c.182+16C>T::,SUFU:ENST00000369902:intron_variant:MODIFIER:exon1/11:c.182+16C>T::,SUFU:ENST00000423559:intron_variant:MODIFIER:exon1/9:c.182+16C>T::		rs2274351	0.3962	0.4761		0.3118,0.2983,0.3208,0.5476,0.4866	0.5600,0.3225	-0.2610			0.10,0.79	1.85		607035 [SUFU (confirmed) Medulloblastoma,desmoplastic,155255/Meningioma,familial,susceptibility to,607174/Basal cell nevus syndrome,109400/Joubert syndrome 32,617757];	260689 [benign DISEASE=not specified,not provided];			n/a (AF>5%)	n/a (AF>5%)					SUFU (inh=AR+AD pLI=1.00)
chr10	104356822	104356822	A	G	hom	off-target	QUAL=2286;DP=74;AF=1.00;MQM=60	SUFU	intron	SUFU:ENST00000369899:intron_variant:MODIFIER:exon6/10:c.757-75A>G::,SUFU:ENST00000369902:intron_variant:MODIFIER:exon6/11:c.757-75A>G::,SUFU:ENST00000423559:intron_variant:MODIFIER:exon6/9:c.757-75A>G::		rs10786690	0.9902	0.9930				-0.0750			0.01,0.16	0.19		607035 [SUFU (confirmed) Medulloblastoma,desmoplastic,155255/Meningioma,familial,susceptibility to,607174/Basal cell nevus syndrome,109400/Joubert syndrome 32,617757];				n/a (AF>5%)	n/a (AF>5%)					SUFU (inh=AR+AD pLI=1.00)
chr10	104387019	104387019	T	C	het		QUAL=14824;DP=1200;AF=0.49;MQM=60	SUFU	intron	SUFU:ENST00000369902:intron_variant:MODIFIER:exon11/11:c.1365+19T>C::		rs12414407	0.7196	0.6861		0.7561,0.5778,0.7452,0.6469,0.7132	0.6521,0.7379	0.2210			0.01,0.32	0.71		607035 [SUFU (confirmed) Medulloblastoma,desmoplastic,155255/Meningioma,familial,susceptibility to,607174/Basal cell nevus syndrome,109400/Joubert syndrome 32,617757];	260688 [benign DISEASE=not specified,not provided];			n/a (AF>5%)	n/a (AF>5%)					SUFU (inh=AR+AD pLI=1.00)
chr10	104389932	104389932	T	G	hom		QUAL=59615;DP=1897;AF=1.00;MQM=60	SUFU	3'UTR	SUFU:ENST00000369902:3_prime_UTR_variant:MODIFIER:exon12/12:c.*20T>G::		rs4917980	0.9974	0.9995		0.9933,0.9994,1.0000,0.9999,1.0000	1.0000,0.9936	1.3870			0.07,0.81	1.45		607035 [SUFU (confirmed) Medulloblastoma,desmoplastic,155255/Meningioma,familial,susceptibility to,607174/Basal cell nevus syndrome,109400/Joubert syndrome 32,617757];				n/a (AF>5%)	n/a (AF>5%)					SUFU (inh=AR+AD pLI=1.00)
chr11	13102890	13102890	C	A	het	off-target	QUAL=22536;DP=1762;AF=0.50;MQM=60	CTC-497E21.5	intron&non_coding_transcript	CTC-497E21.5:ENST00000531136:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.48-26309G>T::		rs2727397	0.5050	0.5678				0.0460			0.06,0.20	0.21						n/a (AF>5%)	n/a (AF>5%)					CTC-497E21.5 (inh=n/a pLI=n/a)
chr11	13102924	13102924	G	A	het		QUAL=293;DP=26;AF=0.54;MQM=60	CTC-497E21.5	intron&non_coding_transcript	CTC-497E21.5:ENST00000531136:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.48-26343C>T::		rs2583136	0.5052	0.5680				-0.4930			0.00,0.07	0.01						n/a (AF>5%)	n/a (AF>5%)					CTC-497E21.5 (inh=n/a pLI=n/a)
chr11	64572018	64572018	T	C	hom		QUAL=8209;DP=259;AF=1.00;MQM=60	MEN1	missense	MEN1:ENST00000312049:missense_variant:MODERATE:exon10/10:c.1621A>G:p.Thr541Ala:PF05053,MEN1:ENST00000315422:missense_variant:MODERATE:exon10/10:c.1621A>G:p.Thr541Ala:PF05053,MEN1:ENST00000337652:missense_variant:MODERATE:exon10/10:c.1636A>G:p.Thr546Ala:PF05053,MEN1:ENST00000377313:missense_variant:MODERATE:exon9/9:c.1636A>G:p.Thr546Ala:PF05053,MEN1:ENST00000377316:missense_variant:MODERATE:exon8/8:c.1456A>G:p.Thr486Ala:PF05053,MEN1:ENST00000377321:missense_variant:MODERATE:exon10/10:c.1516A>G:p.Thr506Ala:PF05053,MEN1:ENST00000377326:missense_variant:MODERATE:exon9/9:c.1621A>G:p.Thr541Ala:PF05053,MEN1:ENST00000394374:missense_variant:MODERATE:exon10/10:c.1636A>G:p.Thr546Ala:PF05053,MEN1:ENST00000394376:missense_variant:MODERATE:exon11/11:c.1636A>G:p.Thr546Ala:PF05053,MEN1:ENST00000443283:missense_variant:MODERATE:exon10/10:c.1636A>G:p.Thr546Ala:PF05053		rs2959656	0.8345	0.9390		0.7063,0.8813,0.6980,0.9959,0.9948	0.9959,0.7376	0.1310	T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B	0.01,0.39	0.84	0.30	613733 [MEN1 (confirmed) Multiple endocrine neoplasia 1,131100/Carcinoid tumor of lung/Parathyroid adenoma,somatic/Lipoma,somatic/Angiofibroma,somatic/Adrenal adenoma,somatic];	134640 [benign DISEASE=not specified];		COSM255213	n/a (AF>5%)	n/a (AF>5%)					MEN1 (inh=AD pLI=1.00)
chr11	64572557	64572557	A	G	hom		QUAL=6555;DP=204;AF=1.00;MQM=60	MEN1	synonymous,intron	MEN1:ENST00000312049:synonymous_variant:LOW:exon9/10:c.1299T>C:p.His433=:PF05053,MEN1:ENST00000315422:synonymous_variant:LOW:exon9/10:c.1299T>C:p.His433=:PF05053,MEN1:ENST00000337652:synonymous_variant:LOW:exon9/10:c.1314T>C:p.His438=:PF05053,MEN1:ENST00000377313:synonymous_variant:LOW:exon8/9:c.1314T>C:p.His438=:PF05053,MEN1:ENST00000377316:intron_variant:MODIFIER:exon7/7:c.1186-269T>C::,MEN1:ENST00000377321:synonymous_variant:LOW:exon9/10:c.1194T>C:p.His398=:PF05053,MEN1:ENST00000377326:synonymous_variant:LOW:exon8/9:c.1299T>C:p.His433=:PF05053,MEN1:ENST00000394374:synonymous_variant:LOW:exon9/10:c.1314T>C:p.His438=:PF05053,MEN1:ENST00000394376:synonymous_variant:LOW:exon10/11:c.1314T>C:p.His438=:PF05053,MEN1:ENST00000443283:synonymous_variant:LOW:exon9/10:c.1314T>C:p.His438=:PF05053		rs540012	0.9760	0.9944		0.9184,0.9969,0.9999,0.9999,0.9999	0.9997,0.9303	-0.3000			0.07,0.89	1.41		613733 [MEN1 (confirmed) Multiple endocrine neoplasia 1,131100/Carcinoid tumor of lung/Parathyroid adenoma,somatic/Lipoma,somatic/Angiofibroma,somatic/Adrenal adenoma,somatic];	167288 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					MEN1 (inh=AD pLI=1.00)
chr11	64577620	64577620	G	C	het	off-target	QUAL=269;DP=43;AF=0.49;MQM=60	MEN1	intron,5'UTR	MEN1:ENST00000312049:intron_variant:MODIFIER:exon1/9:c.-23-16C>G::,MEN1:ENST00000315422:intron_variant:MODIFIER:exon1/9:c.-23-16C>G::,MEN1:ENST00000337652:intron_variant:MODIFIER:exon1/9:c.-23-16C>G::,MEN1:ENST00000377316:5_prime_UTR_variant:MODIFIER:exon1/8:c.-39C>G::,MEN1:ENST00000377321:intron_variant:MODIFIER:exon1/9:c.-23-16C>G::,MEN1:ENST00000377326:5_prime_UTR_variant:MODIFIER:exon1/9:c.-39C>G::,MEN1:ENST00000394374:intron_variant:MODIFIER:exon1/9:c.-23-16C>G::,MEN1:ENST00000394376:intron_variant:MODIFIER:exon2/10:c.-23-16C>G::,MEN1:ENST00000443283:intron_variant:MODIFIER:exon1/9:c.-23-16C>G::		rs509606	0.1749	0.1813		0.1016,0.3025,0.2901,0.1082,0.1945		0.1970			0.06,0.13	-0.07		613733 [MEN1 (confirmed) Multiple endocrine neoplasia 1,131100/Carcinoid tumor of lung/Parathyroid adenoma,somatic/Lipoma,somatic/Angiofibroma,somatic/Adrenal adenoma,somatic];	439889 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					MEN1 (inh=AD pLI=1.00)
chr11	108100105	108100105	-	TT	het	off-target	QUAL=406;DP=50;AF=0.20;MQM=60	ATM	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon4/62:c.331+68_331+69dup::,ATM:ENST00000452508:intron_variant:MODIFIER:exon5/63:c.331+68_331+69dup::		rs11390378		0.1501		0.0658,0.1820,0.0910,0.1477,0.1860						-0.06		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];				n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108100105	108100105	-	T	het	off-target	QUAL=406;DP=50;AF=0.44;MQM=60	ATM	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon4/62:c.331+69dup::,ATM:ENST00000452508:intron_variant:MODIFIER:exon5/63:c.331+69dup::		rs11390378	0.4848	0.4739		0.4260,0.4749,0.4685,0.4541,0.4781						-0.05		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];				n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108119616	108119616	A	-	het	off-target	QUAL=11;DP=36;AF=0.14;MQM=60	ATM	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon8/62:c.1066-31del::,ATM:ENST00000452508:intron_variant:MODIFIER:exon9/63:c.1066-31del::	AluSp	rs35813860		0.3534		0.3031,0.3542,0.3633,0.3552,0.3728		1.5680				-0.12		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];				n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108129657	108129657	A	G	het	off-target	QUAL=38;DP=16;AF=0.25;MQM=60	ATM	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon15/62:c.2377-56A>G::,ATM:ENST00000452508:intron_variant:MODIFIER:exon16/63:c.2377-56A>G::		rs672655	0.4764	0.4867			0.5619,0.2890	1.4540			0.42,0.91	1.64		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];				n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108141956	108141956	T	-	het	off-target	QUAL=426;DP=192;AF=0.22;MQM=60	ATM	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon19/62:c.2922-8del::,ATM:ENST00000452508:intron_variant:MODIFIER:exon20/63:c.2922-8del::		rs373881770		0.4320		0.4012,0.3161,0.4517,0.4523,0.4590		0.1370				-0.03		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];	490504 [likely benign DISEASE=Hereditary cancer-predisposing syndrome];			n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108150208	108150208	T	-	het		QUAL=889;DP=98;AF=0.39;MQM=60	ATM	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon22/62:c.3285-9del::,ATM:ENST00000452508:intron_variant:MODIFIER:exon23/63:c.3285-9del::	(TTTG)n	rs1799757	0.0675	0.1139		0.0224,0.0613,0.0060,0.1423,0.0765	0.1401,0.0284	0.5990				0.34		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];	181857 [benign/likely benign DISEASE=Ataxia-telangiectasia syndrome,Hereditary cancer-predisposing syndrome,not specified];		COSM5575302,COSM5575303	n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108151707	108151707	-	A	het	off-target	QUAL=1080;DP=77;AF=0.55;MQM=60	ATM	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon23/62:c.3403-13dup::,ATM:ENST00000452508:intron_variant:MODIFIER:exon24/63:c.3403-13dup::		rs3218681		0.5618		0.4511,0.6120,0.3803,0.5620,0.6147	0.5672,0.5346					-0.29		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];	181858 [benign/likely benign DISEASE=Ataxia-telangiectasia syndrome,Hereditary cancer-predisposing syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108175394	108175394	T	C	het		QUAL=161;DP=14;AF=0.57;MQM=60	ATM	splice_region&intron	ATM:ENST00000278616:splice_region_variant&intron_variant:LOW:exon36/62:c.5497-8T>C::,ATM:ENST00000452508:splice_region_variant&intron_variant:LOW:exon37/63:c.5497-8T>C::		rs3092829	0.0132	0.0226		0.0059,0.0185,0.0003,0.0333,0.0062	0.0334,0.0075	1.1230			0.19,0.32	0.40		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];	132706 [benign/likely benign DISEASE=Ataxia-telangiectasia syndrome,Hereditary cancer-predisposing syndrome,not specified];		COSM5019227	11	587	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATM (inh=AR+AD pLI=0.00)
chr11	108175462	108175462	G	A	het		QUAL=388;DP=30;AF=0.53;MQM=60	ATM	missense	ATM:ENST00000278616:missense_variant:MODERATE:exon37/63:c.5557G>A:p.Asp1853Asn:,ATM:ENST00000452508:missense_variant:MODERATE:exon38/64:c.5557G>A:p.Asp1853Asn:		rs1801516	0.0669	0.1146		0.0226,0.0611,0.0060,0.1433,0.0769	0.1402,0.0284	6.3420	T,T	B,B	0.98,0.99	2.82	0.12	607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];	128458 [benign/likely benign DISEASE=Ataxia-telangiectasia syndrome,Hereditary cancer-predisposing syndrome,not specified];	CM077896 [CLASS=DP MUT=ALT PHEN="Breast cancer bilateral association with" GENE=ATM];	COSM41596	n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00)
chr11	108183167	108183167	A	G	hom		QUAL=14178;DP=445;AF=1.00;MQM=60	ATM,C11orf65	missense,intron	ATM:ENST00000278616:missense_variant:MODERATE:exon40/63:c.5948A>G:p.Asn1983Ser:,ATM:ENST00000452508:missense_variant:MODERATE:exon41/64:c.5948A>G:p.Asn1983Ser:,C11orf65:ENST00000525729:intron_variant:MODIFIER:exon6/6:c.641-3369T>C::		rs659243	1.0000	1.0000		1.0000,1.0000,1.0000,1.0000,1.0000		-1.0580	T,T, 	B,B, 	0.01,0.17	0.93	0.02	607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];	133627 [benign DISEASE=not specified];		COSM4590264	n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00), C11orf65 (inh=n/a pLI=0.00)
chr11	108225483	108225483	C	T	het	off-target	QUAL=1990;DP=159;AF=0.48;MQM=60	ATM,C11orf65	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon60/62:c.8787-55C>T::,ATM:ENST00000452508:intron_variant:MODIFIER:exon61/63:c.8787-55C>T::,C11orf65:ENST00000525729:intron_variant:MODIFIER:exon6/6:c.640+31164G>A::		rs664982	0.5351	0.5278			0.5625,0.4162	-1.2540			0.00,0.06	-0.18		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];				n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00), C11orf65 (inh=n/a pLI=0.00)
chr11	108225661	108225661	A	G	het	off-target	QUAL=4410;DP=275;AF=0.58;MQM=60	ATM,C11orf65	intron	ATM:ENST00000278616:intron_variant:MODIFIER:exon61/62:c.8850+60A>G::,ATM:ENST00000452508:intron_variant:MODIFIER:exon62/63:c.8850+60A>G::,C11orf65:ENST00000525729:intron_variant:MODIFIER:exon6/6:c.640+30986T>C::		rs664143	0.6282	0.6048			0.5751,0.6647	-0.7070			0.00,0.06	-0.44		607585 [ATM (confirmed) Ataxia-telangiectasia,208900/Lymphoma,B-cell non-Hodgkin,somatic/Breast cancer,susceptibility to,114480/Lymphoma,mantle cell,somatic/T-cell prolymphocytic leukemia,somatic];				n/a (AF>5%)	n/a (AF>5%)					ATM (inh=AR+AD pLI=0.00), C11orf65 (inh=n/a pLI=0.00)
chr11	125497466	125497466	G	T	het	off-target	QUAL=1071;DP=108;AF=0.49;MQM=60	CHEK1	intron	CHEK1:ENST00000278916:intron_variant:MODIFIER:exon1/10:c.66-36G>T::,CHEK1:ENST00000427383:intron_variant:MODIFIER:exon2/11:c.337+738G>T::,CHEK1:ENST00000428830:intron_variant:MODIFIER:exon2/13:c.66-36G>T::,CHEK1:ENST00000438015:intron_variant:MODIFIER:exon2/12:c.66-36G>T::,CHEK1:ENST00000524737:intron_variant:MODIFIER:exon1/12:c.66-36G>T::,CHEK1:ENST00000534070:intron_variant:MODIFIER:exon2/12:c.66-36G>T::,CHEK1:ENST00000544373:intron_variant:MODIFIER:exon2/11:c.66-36G>T::		rs491528	0.3530	0.3153		0.3777,0.1917,0.4338,0.2944,0.3297	0.2952,0.3690	-0.6630			0.04,0.19	-0.02						n/a (AF>5%)	n/a (AF>5%)					CHEK1 (inh=n/a pLI=0.00)
chr11	125514573	125514573	G	A	het	off-target	QUAL=843;DP=107;AF=0.42;MQM=60	CHEK1	intron	CHEK1:ENST00000278916:intron_variant:MODIFIER:exon9/10:c.1101+410G>A::,CHEK1:ENST00000427383:intron_variant:MODIFIER:exon10/11:c.1281+35G>A::,CHEK1:ENST00000428830:intron_variant:MODIFIER:exon11/13:c.1233+35G>A::,CHEK1:ENST00000438015:intron_variant:MODIFIER:exon11/12:c.1233+35G>A::,CHEK1:ENST00000524737:intron_variant:MODIFIER:exon10/12:c.1233+35G>A::,CHEK1:ENST00000534070:intron_variant:MODIFIER:exon11/12:c.1233+35G>A::,CHEK1:ENST00000544373:intron_variant:MODIFIER:exon11/11:c.1233+35G>A::		rs521102	0.4361	0.5122		0.2748,0.6330,0.3864,0.5184,0.5770	0.5121,0.2887	0.5840			0.19,0.20	0.26						n/a (AF>5%)	n/a (AF>5%)					CHEK1 (inh=n/a pLI=0.00)
chr11	125525195	125525195	A	G	hom		QUAL=1962;DP=59;AF=1.00;MQM=60	CHEK1	missense	CHEK1:ENST00000278916:missense_variant:MODERATE:exon11/11:c.1279A>G:p.Ile427Val:,CHEK1:ENST00000427383:missense_variant:MODERATE:exon12/12:c.1459A>G:p.Ile487Val:,CHEK1:ENST00000428830:missense_variant:MODERATE:exon13/14:c.1411A>G:p.Ile471Val:,CHEK1:ENST00000438015:missense_variant:MODERATE:exon13/13:c.1411A>G:p.Ile471Val:,CHEK1:ENST00000524737:missense_variant:MODERATE:exon12/13:c.1411A>G:p.Ile471Val:,CHEK1:ENST00000534070:missense_variant:MODERATE:exon13/13:c.1411A>G:p.Ile471Val:,CHEK1:ENST00000544373:missense_variant:MODERATE:exon12/12:c.1309A>G:p.Ile437Val:		rs506504		0.9774		0.9952,0.9843,0.9996,0.9627,0.9798	0.9637,0.9936	1.1800	T,T,T,T,T,T,T	B,B,B,B,B,B,B	0.13,0.94	1.18	0.05		496139 [benign DISEASE=not provided];			n/a (AF>5%)	n/a (AF>5%)					CHEK1 (inh=n/a pLI=0.00)
chr12	58144665	58144665	C	T	het	off-target	QUAL=1951;DP=162;AF=0.49;MQM=60	CDK4	intron	CDK4:ENST00000257904:intron_variant:MODIFIER:exon4/7:c.522+41G>A::,CDK4:ENST00000312990:intron_variant:MODIFIER:exon3/6:c.265-211G>A::,CDK4:ENST00000540325:intron_variant:MODIFIER:exon3/6:c.162+41G>A::,CDK4:ENST00000549606:intron_variant:MODIFIER:exon1/3:c.-158+1293G>A::		rs2069502	0.3367	0.3552		0.0741,0.3459,0.6362,0.3213,0.4976	0.3157,0.0910	1.7630			0.29,0.21	0.92		123829 [CDK4 (confirmed) Melanoma,cutaneous malignant,3,609048];				n/a (AF>5%)	n/a (AF>5%)					CDK4 (inh=n/a pLI=0.98)
chr12	58145156	58145156	C	T	het	off-target	QUAL=5467;DP=417;AF=0.58;MQM=60	CDK4	intron	CDK4:ENST00000257904:intron_variant:MODIFIER:exon2/7:c.219-31G>A::,CDK4:ENST00000312990:intron_variant:MODIFIER:exon2/6:c.219-31G>A::,CDK4:ENST00000540325:intron_variant:MODIFIER:exon2/6:c.-7+127G>A::,CDK4:ENST00000549606:intron_variant:MODIFIER:exon1/3:c.-158+802G>A::		rs2270777	0.2480	0.3417		0.1603,0.2332,0.1571,0.4354,0.2377	0.4367,0.1743	-0.8270			0.03,0.18	0.41		123829 [CDK4 (confirmed) Melanoma,cutaneous malignant,3,609048];				n/a (AF>5%)	n/a (AF>5%)					CDK4 (inh=n/a pLI=0.98)
chr13	32890572	32890572	G	A	het	off-target	QUAL=1359;DP=118;AF=0.45;MQM=60	BRCA2	5'UTR	BRCA2:ENST00000380152:5_prime_UTR_variant:MODIFIER:exon2/27:c.-26G>A::,BRCA2:ENST00000544455:5_prime_UTR_variant:MODIFIER:exon2/28:c.-26G>A::		rs1799943	0.2093	0.2455		0.1000,0.1910,0.3749,0.2582,0.2849	0.2633,0.1026	0.4990			0.13,0.34	0.37		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	125965 [benign DISEASE=Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 2,not specified];	CR068211 [CLASS=DFP MUT=ALT PHEN="Breast cancer sporadic protection against" GENE=BRCA2];		n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32903685	32903685	C	T	het	off-target	QUAL=606;DP=44;AF=0.55;MQM=60	BRCA2	intron	BRCA2:ENST00000380152:intron_variant:MODIFIER:exon8/26:c.681+56C>T::,BRCA2:ENST00000544455:intron_variant:MODIFIER:exon8/27:c.681+56C>T::		rs2126042	0.1859	0.2161				-0.2330			0.04,0.16	0.24		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	126192 [benign DISEASE=Hereditary cancer-predisposing syndrome,Breast-ovarian cancer, familial 2,not specified];			n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32905219	32905219	-	T	het	off-target	QUAL=103;DP=107;AF=0.17;MQM=60	BRCA2	intron	BRCA2:ENST00000380152:intron_variant:MODIFIER:exon9/26:c.793+64dup::,BRCA2:ENST00000544455:intron_variant:MODIFIER:exon9/27:c.793+64dup::	AluSx	rs760080447		0.1155		0.1106,0.1416,0.1153,0.1031,0.1417	0.0759,0.0793					-0.32		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];				n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32911888	32911888	A	G	het		QUAL=826;DP=75;AF=0.49;MQM=60	BRCA2	synonymous	BRCA2:ENST00000380152:synonymous_variant:LOW:exon11/27:c.3396A>G:p.Lys1132=:,BRCA2:ENST00000544455:synonymous_variant:LOW:exon11/28:c.3396A>G:p.Lys1132=:		rs1801406	0.2668	0.2984		0.2277,0.2127,0.3820,0.3087,0.2994	0.3074,0.2261	0.2130			0.49,0.90	0.34		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	126010 [benign DISEASE=Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 2,not specified,not provided];		COSM4415776	n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32913055	32913055	A	G	hom		QUAL=32057;DP=994;AF=1.00;MQM=60	BRCA2	synonymous	BRCA2:ENST00000380152:synonymous_variant:LOW:exon11/27:c.4563A>G:p.Leu1521=:PF00634,BRCA2:ENST00000544455:synonymous_variant:LOW:exon11/28:c.4563A>G:p.Leu1521=:PF00634		rs206075		0.9945		0.9252,0.9956,0.9999,0.9996,0.9999	0.9994,0.9296	0.0710			0.00,0.27	0.03		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	132779 [benign DISEASE=Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 2,not specified,not provided];			n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32915005	32915005	G	C	hom		QUAL=857;DP=26;AF=1.00;MQM=60	BRCA2	synonymous	BRCA2:ENST00000380152:synonymous_variant:LOW:exon11/27:c.6513G>C:p.Val2171=:,BRCA2:ENST00000544455:synonymous_variant:LOW:exon11/28:c.6513G>C:p.Val2171=:		rs206076		0.9943		0.9251,0.9955,0.9999,0.9995,0.9999	0.9994,0.9287	-0.8750			0.02,0.13	-0.45		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	132780 [benign DISEASE=Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 2,not specified,not provided];		COSM4147690	n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32929232	32929232	A	G	het		QUAL=437;DP=38;AF=0.50;MQM=60	BRCA2	synonymous	BRCA2:ENST00000380152:synonymous_variant:LOW:exon14/27:c.7242A>G:p.Ser2414=:,BRCA2:ENST00000544455:synonymous_variant:LOW:exon14/28:c.7242A>G:p.Ser2414=:		rs1799955	0.2326	0.2299		0.2156,0.1799,0.3818,0.2163,0.2202	0.2133,0.2077	0.0900			0.06,0.30	0.38		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	126133 [benign DISEASE=Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 2,not specified,not provided];		COSM4415348	n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32929387	32929387	T	C	hom		QUAL=19363;DP=598;AF=1.00;MQM=60	BRCA2	missense	BRCA2:ENST00000380152:missense_variant:MODERATE:exon14/27:c.7397T>C:p.Val2466Ala:,BRCA2:ENST00000544455:missense_variant:MODERATE:exon14/28:c.7397T>C:p.Val2466Ala:		rs169547	0.9758	0.9950		0.9322,0.9958,0.9999,0.9997,0.9999	0.9994,0.9353	2.3520	T,T	B,B	0.00,0.10	0.86	0.09	600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	133738 [benign DISEASE=Ductal breast carcinoma,not specified];			n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32936646	32936646	T	C	hom	off-target	QUAL=2098;DP=63;AF=1.00;MQM=60	BRCA2	intron	BRCA2:ENST00000380152:intron_variant:MODIFIER:exon16/26:c.7806-14T>C::,BRCA2:ENST00000544455:intron_variant:MODIFIER:exon16/27:c.7806-14T>C::		rs9534262	0.5316	0.5470		0.5700,0.5135,0.5571,0.5170,0.4892	0.5037,0.5522	-0.9840			0.02,0.15	0.58		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555/Fanconi anemia,complementation group D1,605724/Prostate cancer,176807/Breast cancer,male,susceptibility to,114480/Wilms tumor,194070/Medulloblastoma,155255/Glioblastoma 3,613029/Pancreatic cancer 2,613347];	126158 [benign DISEASE=Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 2,not specified];	CS147979 [CLASS=FP MUT=ALT PHEN="Alternative splicing" GENE=BRCA2];		n/a (AF>5%)	n/a (AF>5%)					BRCA2 (inh=AR+AD pLI=0.00)
chr13	79766188	79766188	A	G	het		QUAL=10953;DP=825;AF=0.52;MQM=60					rs2988039	0.5066	0.4099		0.7095,0.4285,0.7048,0.2536,0.3500	0.2553,0.6726	-0.9470			0.00,0.07	0.01						n/a (AF>5%)	n/a (AF>5%)					 (inh=n/a pLI=n/a)
chr14	45606387	45606387	A	G	het		QUAL=593;DP=53;AF=0.47;MQM=60	FANCM	missense	FANCM:ENST00000267430:missense_variant:MODERATE:exon2/23:c.624A>G:p.Ile208Met:PF00270,FANCM:ENST00000542564:missense_variant:MODERATE:exon2/22:c.624A>G:p.Ile208Met:PF00270,FANCM:ENST00000556036:missense_variant:MODERATE:exon2/11:c.624A>G:p.Ile208Met:PF00270		rs45547534	0.0054	0.0102		0.0024,0.0064,0.0000,0.0155,0.0103	0.0151,0.0041	0.1240	D,D,D	D,D,P	0.70,0.96	2.88	0.12		241326 [benign DISEASE=Fanconi anemia,not specified];			3	164	2	[2] Ilnaz Sepahi 12-10-2016 batch import			FANCM (inh=AR pLI=0.00)
chr14	68290372	68290372	T	G	het	off-target	QUAL=6800;DP=523;AF=0.50;MQM=60	RAD51B	intron	RAD51B:ENST00000390683:intron_variant:MODIFIER:exon1/9:c.84+28T>G::,RAD51B:ENST00000471583:intron_variant:MODIFIER:exon2/10:c.84+28T>G::,RAD51B:ENST00000487270:intron_variant:MODIFIER:exon2/10:c.84+28T>G::,RAD51B:ENST00000487861:intron_variant:MODIFIER:exon2/10:c.84+28T>G::,RAD51B:ENST00000488612:intron_variant:MODIFIER:exon2/11:c.84+28T>G::		rs17783124	0.2504	0.3193		0.3442,0.1959,0.0748,0.3532,0.2321	0.3587,0.3484	0.1790			0.00,0.12	0.16						n/a (AF>5%)	n/a (AF>5%)					RAD51B (inh=n/a pLI=0.00)
chr14	68301767	68301767	-	A	het	off-target	QUAL=2995;DP=253;AF=0.49;MQM=60	RAD51B	intron	RAD51B:ENST00000390683:intron_variant:MODIFIER:exon2/9:c.199-22dup::,RAD51B:ENST00000471583:intron_variant:MODIFIER:exon3/10:c.199-22dup::,RAD51B:ENST00000487270:intron_variant:MODIFIER:exon3/10:c.199-22dup::,RAD51B:ENST00000487861:intron_variant:MODIFIER:exon3/10:c.199-22dup::,RAD51B:ENST00000488612:intron_variant:MODIFIER:exon3/11:c.199-22dup::		rs531055380	0.3195	0.3701		0.4916,0.2052,0.1435,0.3495,0.2286	0.3608,0.4885					0.02						n/a (AF>5%)	n/a (AF>5%)					RAD51B (inh=n/a pLI=0.00)
chr14	68331675	68331675	A	T	hom	off-target	QUAL=12348;DP=535;AF=0.91;MQM=60	RAD51B	intron	RAD51B:ENST00000390683:intron_variant:MODIFIER:exon3/9:c.316-45A>T::,RAD51B:ENST00000471583:intron_variant:MODIFIER:exon4/10:c.316-45A>T::,RAD51B:ENST00000487270:intron_variant:MODIFIER:exon4/10:c.316-45A>T::,RAD51B:ENST00000487861:intron_variant:MODIFIER:exon4/10:c.316-45A>T::,RAD51B:ENST00000488612:intron_variant:MODIFIER:exon4/11:c.316-45A>T::		rs1474939		0.9758		0.9539,0.9466,0.9250,0.9823,0.9784		-0.7150			0.00,0.07	-0.03						n/a (AF>5%)	n/a (AF>5%)					RAD51B (inh=n/a pLI=0.00)
chr14	68944344	68944344	T	-	het	off-target	QUAL=901;DP=397;AF=0.20;MQM=60	RAD51B	intron	RAD51B:ENST00000390683:intron_variant:MODIFIER:exon9/9:c.1036+9390del::,RAD51B:ENST00000471583:intron_variant:MODIFIER:exon10/10:c.1037-8del::,RAD51B:ENST00000487270:intron_variant:MODIFIER:exon10/10:c.1036+9390del::,RAD51B:ENST00000487861:intron_variant:MODIFIER:exon10/10:c.1036+9390del::,RAD51B:ENST00000488612:intron_variant:MODIFIER:exon10/11:c.1036+9390del::	(T)n	rs768547850		0.3354		0.3344,0.3245,0.3041,0.3393,0.3415		-0.6750				-0.45						n/a (AF>5%)	n/a (AF>5%)					RAD51B (inh=n/a pLI=0.00)
chr14	104165753	104165753	G	A	het		QUAL=12804;DP=967;AF=0.51;MQM=60	KLC1,XRCC3	intron,missense	KLC1:ENST00000334553:intron_variant:MODIFIER:exon15/16:c.1849-1239G>A::,KLC1:ENST00000348520:intron_variant:MODIFIER:exon13/14:c.1651-1239G>A::,XRCC3:ENST00000352127:missense_variant:MODERATE:exon7/9:c.722C>T:p.Thr241Met:PF08423,XRCC3:ENST00000445556:missense_variant:MODERATE:exon7/9:c.722C>T:p.Thr241Met:PF08423,KLC1:ENST00000452929:intron_variant:MODIFIER:exon14/15:c.1782-1239G>A::,XRCC3:ENST00000553264:missense_variant:MODERATE:exon6/8:c.722C>T:p.Thr241Met:PF08423,KLC1:ENST00000554280:intron_variant:MODIFIER:exon14/15:c.1755-1239G>A::,XRCC3:ENST00000554913:missense_variant:MODERATE:exon8/10:c.722C>T:p.Thr241Met:PF08423,XRCC3:ENST00000554974:missense_variant:MODERATE:exon2/4:c.107C>T:p.Thr36Met:PF08423,XRCC3:ENST00000555055:missense_variant:MODERATE:exon8/10:c.722C>T:p.Thr241Met:PF08423,KLC1:ENST00000555836:intron_variant:MODIFIER:exon15/16:c.1822-1239G>A::,KLC1:ENST00000557450:intron_variant:MODIFIER:exon13/14:c.1624-1239G>A::		rs861539	0.2169	0.2910		0.2044,0.1728,0.0543,0.3762,0.2435	0.3782,0.2158	0.6410	 , ,T,T, ,T, ,T,T,T, , 	 , ,B,B, ,B, ,B,B,B, , 	0.41,0.16	0.87	0.03	600675 [XRCC3 (provisional) Melanoma,cutaneous malignant,6,613972/Breast cancer,susceptibility to,114480];	8944 [risk factor DISEASE=Cutaneous malignant melanoma 6];	CM003625 [CLASS=DFP MUT=ALT PHEN="Melanoma association with" GENE=XRCC3];		n/a (AF>5%)	n/a (AF>5%)					KLC1 (inh=n/a pLI=0.74), XRCC3 (inh=n/a pLI=0.00)
chr14	105242966	105242966	T	C	het	off-target	QUAL=1980;DP=134;AF=0.61;MQM=60	AKT1	intron	AKT1:ENST00000349310:intron_variant:MODIFIER:exon5/14:c.287+30A>G::,AKT1:ENST00000402615:intron_variant:MODIFIER:exon4/13:c.287+30A>G::,AKT1:ENST00000407796:intron_variant:MODIFIER:exon4/13:c.287+30A>G::,AKT1:ENST00000544168:intron_variant:MODIFIER:exon2/11:c.101+30A>G::,AKT1:ENST00000554581:intron_variant:MODIFIER:exon3/12:c.287+30A>G::,AKT1:ENST00000554848:intron_variant:MODIFIER:exon4/13:c.287+30A>G::,AKT1:ENST00000555528:intron_variant:MODIFIER:exon4/13:c.287+30A>G::		rs2494735	0.5964	0.4871		0.7128,0.5857,0.6475,0.3563,0.5362	0.3587,0.6925	-3.9800			0.01,0.08	-0.49		164730 [AKT1 (confirmed) Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Ovarian cancer,somatic,167000/Schizophrenia,susceptibility to,181500/Proteus syndrome,somatic,176920/Cowden syndrome 6,615109];				n/a (AF>5%)	n/a (AF>5%)					AKT1 (inh=AD pLI=0.97)
chr14	105258892	105258892	C	T	hom	off-target	QUAL=3612;DP=111;AF=1.00;MQM=60	AKT1	intron	AKT1:ENST00000349310:intron_variant:MODIFIER:exon3/14:c.46+43G>A::,AKT1:ENST00000402615:intron_variant:MODIFIER:exon2/13:c.46+43G>A::,AKT1:ENST00000407796:intron_variant:MODIFIER:exon2/13:c.46+43G>A::,AKT1:ENST00000554581:intron_variant:MODIFIER:exon1/12:c.46+43G>A::,AKT1:ENST00000554848:intron_variant:MODIFIER:exon2/13:c.46+43G>A::,AKT1:ENST00000555528:intron_variant:MODIFIER:exon2/13:c.46+43G>A::		rs2494748	0.3562	0.5148		0.2500,0.4600,0.1961,0.6134,0.4209	0.5381,0.2171	-0.6390			0.02,0.26	0.13		164730 [AKT1 (confirmed) Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Ovarian cancer,somatic,167000/Schizophrenia,susceptibility to,181500/Proteus syndrome,somatic,176920/Cowden syndrome 6,615109];				n/a (AF>5%)	n/a (AF>5%)					AKT1 (inh=AD pLI=0.97)
chr14	105258893	105258893	A	G	hom	off-target	QUAL=3612;DP=111;AF=1.00;MQM=60	AKT1	intron	AKT1:ENST00000349310:intron_variant:MODIFIER:exon3/14:c.46+42T>C::,AKT1:ENST00000402615:intron_variant:MODIFIER:exon2/13:c.46+42T>C::,AKT1:ENST00000407796:intron_variant:MODIFIER:exon2/13:c.46+42T>C::,AKT1:ENST00000554581:intron_variant:MODIFIER:exon1/12:c.46+42T>C::,AKT1:ENST00000554848:intron_variant:MODIFIER:exon2/13:c.46+42T>C::,AKT1:ENST00000555528:intron_variant:MODIFIER:exon2/13:c.46+42T>C::		rs2494749	0.7093	0.8742		0.8889,0.7055,0.3343,0.9248,0.6894	0.9180,0.8917	-1.9390			0.01,0.06	-0.53		164730 [AKT1 (confirmed) Breast cancer,somatic,114480/Colorectal cancer,somatic,114500/Ovarian cancer,somatic,167000/Schizophrenia,susceptibility to,181500/Proteus syndrome,somatic,176920/Cowden syndrome 6,615109];				n/a (AF>5%)	n/a (AF>5%)					AKT1 (inh=AD pLI=0.97)
chr15	40998342	40998342	T	G	het	off-target	QUAL=1309;DP=99;AF=0.56;MQM=60	RAD51	intron	RAD51:ENST00000267868:intron_variant:MODIFIER:exon3/9:c.226-33T>G::,RAD51:ENST00000382643:intron_variant:MODIFIER:exon4/9:c.347-2881T>G::,RAD51:ENST00000423169:intron_variant:MODIFIER:exon3/8:c.226-33T>G::,RAD51:ENST00000532743:intron_variant:MODIFIER:exon4/9:c.347-2881T>G::,RAD51:ENST00000557850:intron_variant:MODIFIER:exon3/7:c.225+4943T>G::		rs45457497	0.3542	0.2708		0.2458,0.5202,0.6757,0.1656,0.2749	0.1627,0.2398	1.7890			0.24,0.39	1.02		179617 [RAD51 (confirmed) Breast cancer,susceptibility to,114480/Mirror movements 2,614508/Fanconi anemia,complementation group R,617244];				n/a (AF>5%)	n/a (AF>5%)					RAD51 (inh=AD pLI=0.99)
chr15	43701947	43701947	A	-	het		QUAL=368;DP=58;AF=0.43;MQM=60	TP53BP1	splice_region&intron	TP53BP1:ENST00000263801:splice_region_variant&intron_variant:LOW:exon24/27:c.5291-8del::,TP53BP1:ENST00000382039:splice_region_variant&intron_variant:LOW:exon23/26:c.5156-8del::,TP53BP1:ENST00000382044:splice_region_variant&intron_variant:LOW:exon24/27:c.5306-8del::,TP53BP1:ENST00000450115:splice_region_variant&intron_variant:LOW:exon24/27:c.5300-8del::		rs56813954	0.2502	0.3494		0.1821,0.3645,0.4192,0.3508,0.3898		0.7510				0.60					COSM1608394,COSM5493271	n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43707808	43707808	A	T	het		QUAL=1611;DP=136;AF=0.46;MQM=60	TP53BP1	synonymous	TP53BP1:ENST00000263801:synonymous_variant:LOW:exon23/28:c.5058T>A:p.Ser1686=:,TP53BP1:ENST00000382039:synonymous_variant:LOW:exon22/27:c.4923T>A:p.Ser1641=:,TP53BP1:ENST00000382044:synonymous_variant:LOW:exon23/28:c.5073T>A:p.Ser1691=:,TP53BP1:ENST00000450115:synonymous_variant:LOW:exon23/28:c.5073T>A:p.Ser1691=:		rs2230451	0.1286	0.1601		0.1698,0.0997,0.0024,0.1891,0.2102	0.1900,0.1690	0.1810			0.62,0.96	0.70						n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43720156	43720156	A	-	het	off-target	QUAL=1195;DP=407;AF=0.17;MQM=60	TP53BP1	intron	TP53BP1:ENST00000263801:intron_variant:MODIFIER:exon18/27:c.3813+58del::,TP53BP1:ENST00000382039:intron_variant:MODIFIER:exon18/26:c.3828+58del::,TP53BP1:ENST00000382044:intron_variant:MODIFIER:exon18/27:c.3828+58del::,TP53BP1:ENST00000450115:intron_variant:MODIFIER:exon18/27:c.3828+58del::	AluJb	rs879219800		0.0163				1.0870				-0.45						28	1931					TP53BP1 (inh=n/a pLI=1.00)
chr15	43720197	43720197	C	T	het	off-target	QUAL=4167;DP=354;AF=0.55;MQM=60	TP53BP1	intron	TP53BP1:ENST00000263801:intron_variant:MODIFIER:exon18/27:c.3813+17G>A::,TP53BP1:ENST00000382039:intron_variant:MODIFIER:exon18/26:c.3828+17G>A::,TP53BP1:ENST00000382044:intron_variant:MODIFIER:exon18/27:c.3828+17G>A::,TP53BP1:ENST00000450115:intron_variant:MODIFIER:exon18/27:c.3828+17G>A::		rs550239	0.3804	0.2747		0.6569,0.2117,0.4097,0.1105,0.2173	0.1128,0.6297	0.2620			0.19,0.24	1.14						n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43724646	43724646	T	G	hom		QUAL=20028;DP=634;AF=1.00;MQM=60	TP53BP1	missense	TP53BP1:ENST00000263801:missense_variant:MODERATE:exon17/28:c.3406A>C:p.Lys1136Gln:,TP53BP1:ENST00000382039:missense_variant:MODERATE:exon17/27:c.3421A>C:p.Lys1141Gln:,TP53BP1:ENST00000382044:missense_variant:MODERATE:exon17/28:c.3421A>C:p.Lys1141Gln:,TP53BP1:ENST00000450115:missense_variant:MODERATE:exon17/28:c.3421A>C:p.Lys1141Gln:		rs2602141	0.5264	0.4422		0.8615,0.3168,0.4146,0.3017,0.4498	0.3036,0.8351	3.2620	T,T,T,T	B,B,B,B	0.01,0.91	1.94	0.08			CM067476 [CLASS=DP MUT=ALT PHEN="Lung cancer susceptibility to association with" GENE=TP53BP1];		n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43730486	43730486	A	G	het	off-target	QUAL=11449;DP=895;AF=0.49;MQM=60	TP53BP1	intron	TP53BP1:ENST00000263801:intron_variant:MODIFIER:exon16/27:c.3176+36T>C::,TP53BP1:ENST00000382039:intron_variant:MODIFIER:exon16/26:c.3191+36T>C::,TP53BP1:ENST00000382044:intron_variant:MODIFIER:exon16/27:c.3191+36T>C::,TP53BP1:ENST00000450115:intron_variant:MODIFIER:exon16/27:c.3191+36T>C::		rs16957730	0.1368	0.1656		0.1966,0.1002,0.0025,0.1891,0.2106	0.1901,0.1976	0.8880			0.09,0.15	0.08						n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43739686	43739686	-	A	het		QUAL=7;DP=21;AF=0.24;MQM=60	TP53BP1	splice_region&intron	TP53BP1:ENST00000263801:splice_region_variant&intron_variant:LOW:exon12/27:c.2702-4dup::,TP53BP1:ENST00000382039:splice_region_variant&intron_variant:LOW:exon12/26:c.2717-4dup::,TP53BP1:ENST00000382044:splice_region_variant&intron_variant:LOW:exon12/27:c.2717-4dup::,TP53BP1:ENST00000450115:splice_region_variant&intron_variant:LOW:exon12/27:c.2717-4dup::		rs753702168		0.0749								1.28						n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43748304	43748304	A	G	hom		QUAL=30186;DP=958;AF=1.00;MQM=60	TP53BP1	synonymous	TP53BP1:ENST00000263801:synonymous_variant:LOW:exon12/28:c.2487T>C:p.Asp829=:,TP53BP1:ENST00000382039:synonymous_variant:LOW:exon12/27:c.2502T>C:p.Asp834=:,TP53BP1:ENST00000382044:synonymous_variant:LOW:exon12/28:c.2502T>C:p.Asp834=:,TP53BP1:ENST00000450115:synonymous_variant:LOW:exon12/28:c.2502T>C:p.Asp834=:		rs690367		0.4464		0.8756,0.3171,0.4145,0.3015,0.4350	0.3032,0.8496	1.1610			0.02,0.13	-0.07					COSM3678192	n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43762196	43762196	C	T	het		QUAL=3267;DP=207;AF=0.57;MQM=60	TP53BP1	missense	TP53BP1:ENST00000263801:missense_variant:MODERATE:exon11/28:c.1234G>A:p.Gly412Ser:,TP53BP1:ENST00000382039:missense_variant:MODERATE:exon11/27:c.1249G>A:p.Gly417Ser:,TP53BP1:ENST00000382044:missense_variant:MODERATE:exon11/28:c.1249G>A:p.Gly417Ser:,TP53BP1:ENST00000450115:missense_variant:MODERATE:exon11/28:c.1249G>A:p.Gly417Ser:		rs689647	0.3824	0.2743		0.6578,0.2149,0.4117,0.1121,0.2249	0.1130,0.6302	1.1390	T,T,T,T	B,B,B,B	0.20,0.80	1.75	0.07			CM107902 [CLASS=DP MUT=ALT PHEN="Basal cell carcinoma reduced risk association with" GENE=TP53BP1];	COSM3678193	n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43767774	43767774	G	C	hom		QUAL=3605;DP=116;AF=1.00;MQM=60	TP53BP1	missense	TP53BP1:ENST00000263801:missense_variant:MODERATE:exon9/28:c.1059C>G:p.Asp353Glu:,TP53BP1:ENST00000382039:missense_variant:MODERATE:exon9/27:c.1074C>G:p.Asp358Glu:,TP53BP1:ENST00000382044:missense_variant:MODERATE:exon9/28:c.1074C>G:p.Asp358Glu:,TP53BP1:ENST00000450115:missense_variant:MODERATE:exon9/28:c.1074C>G:p.Asp358Glu:		rs560191		0.4462		0.8754,0.3163,0.4144,0.3014,0.4352	0.3029,0.8496	0.2260	T,T,T,T	B,B,B,B	0.08,0.92	1.35	0.24			CM067475 [CLASS=DP MUT=ALT PHEN="Lung cancer susceptibility to association with" GENE=TP53BP1];		n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43773036	43773036	A	C	het	off-target	QUAL=10479;DP=864;AF=0.48;MQM=60	TP53BP1	intron	TP53BP1:ENST00000263801:intron_variant:MODIFIER:exon5/27:c.484+57T>G::,TP53BP1:ENST00000382039:intron_variant:MODIFIER:exon5/26:c.499+57T>G::,TP53BP1:ENST00000382044:intron_variant:MODIFIER:exon5/27:c.499+57T>G::,TP53BP1:ENST00000450115:intron_variant:MODIFIER:exon5/27:c.499+57T>G::		rs7173383	0.1368	0.1652				-0.0660			0.04,0.19	-0.03						n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	43784000	43784000	C	T	hom	off-target	QUAL=26780;DP=852;AF=1.00;MQM=60	TP53BP1	intron	TP53BP1:ENST00000263801:intron_variant:MODIFIER:exon3/27:c.272-49G>A::,TP53BP1:ENST00000382039:intron_variant:MODIFIER:exon3/26:c.287-49G>A::,TP53BP1:ENST00000382044:intron_variant:MODIFIER:exon3/27:c.287-49G>A::,TP53BP1:ENST00000450115:intron_variant:MODIFIER:exon3/27:c.287-49G>A::		rs555252	0.9515	0.9872		0.8771,0.9942,0.9992,0.9995,0.9686	0.9994,0.8846	0.0460			0.00,0.53	0.52						n/a (AF>5%)	n/a (AF>5%)					TP53BP1 (inh=n/a pLI=1.00)
chr15	75643615	75643615	-	T	hom	off-target	QUAL=337;DP=115;AF=0.21;MQM=60	NEIL1	intron	NEIL1:ENST00000355059:intron_variant:MODIFIER:exon2/9:c.435-818dup::,NEIL1:ENST00000564784:intron_variant:MODIFIER:exon3/10:c.435-818dup::,NEIL1:ENST00000569035:intron_variant:MODIFIER:exon2/9:c.435-818dup::	AluJr	rs768966115		0.3703								0.34						n/a (AF>5%)	n/a (AF>5%)					NEIL1 (inh=n/a pLI=0.00)
chr16	3639139	3639139	A	G	het		QUAL=1344;DP=102;AF=0.52;MQM=60	SLX4	synonymous	SLX4:ENST00000294008:synonymous_variant:LOW:exon12/15:c.4500T>C:p.Asn1500=:		rs3810812	0.7396	0.6327		0.8815,0.6679,0.7215,0.5136,0.7619	0.5077,0.8594	0.7190			0.00,0.15	-0.10		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	262053 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					SLX4 (inh=AR pLI=0.00)
chr16	3639230	3639230	G	A	het		QUAL=1417;DP=112;AF=0.49;MQM=60	SLX4	missense	SLX4:ENST00000294008:missense_variant:MODERATE:exon12/15:c.4409C>T:p.Pro1470Leu:		rs72778139	0.0002	0.0001		0.0000,0.0001,0.0000,0.0001,0.0000	0.0002,0.0000	0.3390	T	B	0.25,0.84	2.01	0.11	613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];		CM136925 [CLASS=DM MUT=ALT PHEN="Breast and/or ovarian cancer" GENE=SLX4];		0	6					SLX4 (inh=AR pLI=0.00)
chr16	23625463	23625463	A	T	hom	off-target	QUAL=1216;DP=38;AF=1.00;MQM=60	PALB2,CTD-2196E14.3	intron,intron&non_coding_transcript	PALB2:ENST00000261584:intron_variant:MODIFIER:exon10/12:c.3114-51T>A::,CTD-2196E14.3:ENST00000561764:intron_variant&non_coding_transcript_variant:MODIFIER:exon2/3:n.186-3458A>T::		rs249936	0.9968	1.0000		1.0000,1.0000,0.9999,1.0000,0.9861		0.7540			0.00,0.09	0.43		610355 [PALB2 (provisional) Fanconi anemia,complementation group N,610832/Breast cancer,susceptibility to,114480/Pancreatic cancer,susceptibility to,3,613348];	126714 [likely benign DISEASE=Familial cancer of breast];			n/a (AF>5%)	n/a (AF>5%)					PALB2 (inh=AR+AD pLI=0.00), CTD-2196E14.3 (inh=n/a pLI=n/a)
chr16	23640467	23640467	G	A	het	off-target	QUAL=249;DP=23;AF=0.48;MQM=60	PALB2	intron	PALB2:ENST00000261584:intron_variant:MODIFIER:exon6/12:c.2586+58C>T::		rs249954	0.3500	0.3119			0.2376,0.4473	0.3280			0.00,0.08	0.21		610355 [PALB2 (provisional) Fanconi anemia,complementation group N,610832/Breast cancer,susceptibility to,114480/Pancreatic cancer,susceptibility to,3,613348];	126663 [benign DISEASE=Familial cancer of breast];			n/a (AF>5%)	n/a (AF>5%)					PALB2 (inh=AR+AD pLI=0.00)
chr16	68771372	68771372	C	T	hom		QUAL=4027;DP=129;AF=0.99;MQM=60	CDH1	splice_region&intron	CDH1:ENST00000261769:splice_region_variant&intron_variant:LOW:exon1/15:c.48+6C>T::,CDH1:ENST00000422392:splice_region_variant&intron_variant:LOW:exon1/14:c.48+6C>T::		rs3743674	0.7634	0.8150		0.6464,0.7415,0.7644,0.8777,0.7781	0.9074,0.7603	-0.1880			0.00,0.15	0.44		192090 [CDH1 (confirmed) Endometrial carcinoma,somatic,608089/Ovarian carcinoma,somatic,167000/Breast cancer,lobular,114480/Gastric cancer,familial diffuse,with or without cleft lip and/or palate,137215/Prostate cancer,susceptibility to,176807/Blepharocheilodontic syndrome 1,119580];	136692 [benign DISEASE=Hereditary cancer-predisposing syndrome,Hereditary diffuse gastric cancer,not specified];		COSM5461723	n/a (AF>5%)	n/a (AF>5%)					CDH1 (inh=AD pLI=0.20)
chr16	68771418	68771418	-	GCCCCAGCCCCGT	hom	off-target	QUAL=2621;DP=102;AF=1.00;MQM=60	CDH1	intron	CDH1:ENST00000261769:intron_variant:MODIFIER:exon1/15:c.48+62_48+63insCGTGCCCCAGCCC::,CDH1:ENST00000422392:intron_variant:MODIFIER:exon1/14:c.48+62_48+63insCGTGCCCCAGCCC::		rs147838237	0.6887	0.8099		0.6402,0.7370,0.7600,0.8695,0.7751	0.8252,0.7557					0.40		192090 [CDH1 (confirmed) Endometrial carcinoma,somatic,608089/Ovarian carcinoma,somatic,167000/Breast cancer,lobular,114480/Gastric cancer,familial diffuse,with or without cleft lip and/or palate,137215/Prostate cancer,susceptibility to,176807/Blepharocheilodontic syndrome 1,119580];				n/a (AF>5%)	n/a (AF>5%)					CDH1 (inh=AD pLI=0.20)
chr16	68857441	68857441	T	C	het		QUAL=14801;DP=1164;AF=0.52;MQM=60	CDH1	synonymous	CDH1:ENST00000261769:synonymous_variant:LOW:exon13/16:c.2076T>C:p.Ala692=:,CDH1:ENST00000422392:synonymous_variant:LOW:exon12/15:c.1893T>C:p.Ala631=:		rs1801552	0.7187	0.6961		0.8921,0.6663,0.6486,0.6246,0.6539	0.6322,0.8803	-0.0840			0.00,0.10	0.48		192090 [CDH1 (confirmed) Endometrial carcinoma,somatic,608089/Ovarian carcinoma,somatic,167000/Breast cancer,lobular,114480/Gastric cancer,familial diffuse,with or without cleft lip and/or palate,137215/Prostate cancer,susceptibility to,176807/Blepharocheilodontic syndrome 1,119580];	142770 [benign DISEASE=Hereditary cancer-predisposing syndrome,Hereditary diffuse gastric cancer,not specified];	CM1414917 [CLASS=DP MUT=ALT PHEN="Gastric cancer early-onset diffuse association with" GENE=CDH1];	COSM3755010	n/a (AF>5%)	n/a (AF>5%)					CDH1 (inh=AD pLI=0.20)
chr16	81816733	81816733	C	T	het		QUAL=4992;DP=430;AF=0.51;MQM=60	PLCG2	intron	PLCG2:ENST00000359376:intron_variant:MODIFIER:exon1/32:c.-47-2815C>T::		rs8045964	0.4241	0.4297		0.3914,0.3652,0.2773,0.4233,0.6318	0.4231,0.3910	-0.4270			0.00,0.10	-0.07		600220 [PLCG2 (provisional) Familial cold autoinflammatory syndrome 3,614468/Autoinflammation,antibody deficiency,and immune dysregulation syndrome,614878];				n/a (AF>5%)	n/a (AF>5%)					PLCG2 (inh=AD pLI=1.00)
chr16	81816787	81816787	T	A	hom	off-target	QUAL=24041;DP=746;AF=1.00;MQM=60	PLCG2	intron	PLCG2:ENST00000359376:intron_variant:MODIFIER:exon1/32:c.-47-2761T>A::		rs4476171		0.9994				-1.8260			0.01,0.14	-0.13		600220 [PLCG2 (provisional) Familial cold autoinflammatory syndrome 3,614468/Autoinflammation,antibody deficiency,and immune dysregulation syndrome,614878];				n/a (AF>5%)	n/a (AF>5%)					PLCG2 (inh=AD pLI=1.00)
chr16	89805261	89805261	A	G	hom	off-target	QUAL=18058;DP=580;AF=1.00;MQM=60	ZNF276,FANCA	3'UTR,intron	ZNF276:ENST00000289816:3_prime_UTR_variant:MODIFIER:exon11/11:c.*607A>G::,FANCA:ENST00000389301:intron_variant:MODIFIER:exon42/42:c.4260+29T>C::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon42/42:c.4264+29T>C::		rs1800359		0.7261		0.9382,0.7865,0.9865,0.5917,0.8020	0.5876,0.9172	-3.5420			0.12,0.14	-0.13		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255266 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					ZNF276 (inh=n/a pLI=0.00), FANCA (inh=AR pLI=0.00)
chr16	89805977	89805977	G	A	het	off-target	QUAL=2205;DP=181;AF=0.48;MQM=60	ZNF276,FANCA	3'UTR,intron	ZNF276:ENST00000289816:3_prime_UTR_variant:MODIFIER:exon11/11:c.*1323G>A::,FANCA:ENST00000389301:intron_variant:MODIFIER:exon39/42:c.3935-16C>T::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon39/42:c.3935-16C>T::		rs1061646	0.5381	0.4248		0.5489,0.6126,0.7266,0.2935,0.4711	0.2691,0.5005	0.8660			0.27,0.27	0.26		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255264 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					ZNF276 (inh=n/a pLI=0.00), FANCA (inh=AR pLI=0.00)
chr16	89806347	89806347	A	T	het	off-target	QUAL=873;DP=48;AF=0.71;MQM=60	ZNF276,FANCA	3'UTR,intron	ZNF276:ENST00000289816:3_prime_UTR_variant:MODIFIER:exon11/11:c.*1693A>T::,FANCA:ENST00000389301:intron_variant:MODIFIER:exon39/42:c.3934+55T>A::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon39/42:c.3934+55T>A::		rs7195906	0.7065	0.5477		0.7791,0.6664,0.9827,0.3806,0.5900		-0.5840			0.02,0.13	0.06		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	135541 [not provided DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					ZNF276 (inh=n/a pLI=0.00), FANCA (inh=AR pLI=0.00)
chr16	89815217	89815217	C	T	het	off-target	QUAL=1919;DP=159;AF=0.51;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon32/42:c.3240-42G>A::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon32/42:c.3240-42G>A::		rs1800345	0.5449	0.4272		0.5590,0.6301,0.7560,0.2996,0.4789	0.2993,0.5392	-0.7250			0.03,0.14	-0.17		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255254 [benign DISEASE=not specified];	CS137887 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=FANCA];		n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89818491	89818491	T	C	het	off-target	QUAL=9378;DP=751;AF=0.49;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon31/42:c.3066+55A>G::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon31/42:c.3066+55A>G::		rs3743860	0.5865	0.4733			0.3843,0.5477	-0.1670			0.01,0.10	0.07		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];				n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89831510	89831510	C	A	het	off-target	QUAL=11990;DP=972;AF=0.48;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon27/42:c.2602-36G>T::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon27/42:c.2602-36G>T::		rs2159116	0.0933	0.1465		0.0343,0.1014,0.0034,0.1839,0.1865	0.1720,0.0380	-3.3830			0.08,0.16	-0.53		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255248 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89836323	89836323	C	T	het		QUAL=835;DP=96;AF=0.41;MQM=60	FANCA	missense	FANCA:ENST00000389301:missense_variant:MODERATE:exon26/43:c.2426G>A:p.Gly809Asp:,FANCA:ENST00000568369:missense_variant:MODERATE:exon26/43:c.2426G>A:p.Gly809Asp:		rs7195066	0.6667	0.4758		0.6789,0.6519,0.9851,0.3098,0.5892	0.3142,0.6586	0.3050	T,T	B,B	0.02,0.14	0.12	0.20	607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	134254 [benign DISEASE=Fanconi anemia,not specified];	CM137288 [CLASS=R MUT=ALT PHEN="Fanconi anaemia A" GENE=FANCA];		n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89838078	89838078	A	G	het		QUAL=12861;DP=1060;AF=0.48;MQM=60	FANCA	splice_region&intron	FANCA:ENST00000389301:splice_region_variant&intron_variant:LOW:exon23/42:c.2151+8T>C::,FANCA:ENST00000568369:splice_region_variant&intron_variant:LOW:exon23/42:c.2151+8T>C::		rs1800340	0.5599	0.4371		0.5222,0.6342,0.7456,0.3038,0.5709	0.3077,0.5045	-0.8300			0.02,0.11	-0.36		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255245 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89845194	89845194	A	G	het	off-target	QUAL=6225;DP=616;AF=0.53;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon20/42:c.1826+15T>C::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon20/42:c.1826+15T>C::		rs1800337	0.6825	0.5225		0.6934,0.6612,0.9840,0.3813,0.5919	0.3887,0.6827	-1.4990			0.00,0.10	-0.05		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255241 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89849480	89849480	C	T	hom		QUAL=6739;DP=202;AF=1.00;MQM=60	FANCA	missense	FANCA:ENST00000389301:missense_variant:MODERATE:exon16/43:c.1501G>A:p.Gly501Ser:,FANCA:ENST00000568369:missense_variant:MODERATE:exon16/43:c.1501G>A:p.Gly501Ser:		rs2239359	0.6240	0.5222		0.6941,0.6224,0.8547,0.3918,0.4941	0.3810,0.6804	-0.0380	T,T	B,B	0.02,0.16	-0.57	0.26	607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	134244 [benign DISEASE=Fanconi anemia,not specified];	CM137880 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=FANCA];		n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89857964	89857964	T	C	het	off-target	QUAL=14528;DP=1042;AF=0.53;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon13/42:c.1226-20A>G::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon13/42:c.1226-20A>G::		rs1800330	0.5719	0.4402		0.5615,0.6367,0.7561,0.3044,0.5674	0.3095,0.5494	-4.9640			0.00,0.07	-0.23		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255232 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89858505	89858505	T	C	het	off-target	QUAL=4325;DP=304;AF=0.51;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon12/42:c.1084-29A>G::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon12/42:c.1084-29A>G::		rs6500452	0.5317	0.4178		0.5171,0.6300,0.7522,0.2942,0.4777	0.3001,0.5066	-1.3030			0.02,0.12	-0.18		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255229 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89858525	89858525	C	G	het	off-target	QUAL=4352;DP=307;AF=0.51;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon12/42:c.1084-49G>C::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon12/42:c.1084-49G>C::		rs1800287		0.5441		0.7654,0.6640,0.9838,0.3822,0.5887	0.3912,0.7480	-0.2040			0.01,0.14	-0.08		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255230 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89859008	89859008	G	A	het	off-target	QUAL=930;DP=105;AF=0.40;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon11/42:c.1007-53C>T::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon11/42:c.1007-53C>T::		rs3856	0.5302	0.4014			0.2913,0.5036	0.5740			0.33,0.28	0.15		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];				n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89859016	89859016	T	-	het	off-target	QUAL=875;DP=105;AF=0.40;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon11/42:c.1007-61del::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon11/42:c.1007-61del::		rs35617323	0.6430	0.4866			0.3919,0.5693	0.7490				-0.13		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];				n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89866043	89866043	T	C	het		QUAL=9337;DP=734;AF=0.49;MQM=60	FANCA	missense	FANCA:ENST00000389301:missense_variant:MODERATE:exon9/43:c.796A>G:p.Thr266Ala:,FANCA:ENST00000389302:missense_variant:MODERATE:exon9/11:c.796A>G:p.Thr266Ala:,FANCA:ENST00000534992:missense_variant:MODERATE:exon9/11:c.796A>G:p.Thr266Ala:,FANCA:ENST00000543736:missense_variant:MODERATE:exon8/10:c.700A>G:p.Thr234Ala:,FANCA:ENST00000563673:missense_variant:MODERATE:exon9/10:c.796A>G:p.Thr266Ala:,FANCA:ENST00000568369:missense_variant:MODERATE:exon9/43:c.796A>G:p.Thr266Ala:		rs7190823	0.6905	0.5344		0.7275,0.6670,0.9841,0.3851,0.5902	0.3937,0.7257	0.4020	T,T,T,T,T,T	B,B,B,B,B,B	0.00,0.25	0.17	0.08	607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	134294 [benign DISEASE=Fanconi anemia,not specified];	CM137879 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=FANCA];		n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr16	89869761	89869761	T	C	hom	off-target	QUAL=3854;DP=115;AF=1.00;MQM=60	FANCA	intron	FANCA:ENST00000389301:intron_variant:MODIFIER:exon7/42:c.710-12A>G::,FANCA:ENST00000389302:intron_variant:MODIFIER:exon7/10:c.710-12A>G::,FANCA:ENST00000534992:intron_variant:MODIFIER:exon7/10:c.710-12A>G::,FANCA:ENST00000543736:intron_variant:MODIFIER:exon6/9:c.614-12A>G::,FANCA:ENST00000563673:intron_variant:MODIFIER:exon7/9:c.710-12A>G::,FANCA:ENST00000568369:intron_variant:MODIFIER:exon7/42:c.710-12A>G::		rs1800286		0.7226		0.9247,0.7830,0.9885,0.5912,0.7963	0.5880,0.9065	-1.9650			0.01,0.11	0.69		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	255269 [benign DISEASE=Fanconi anemia,not specified];			n/a (AF>5%)	n/a (AF>5%)					FANCA (inh=AR pLI=0.00)
chr17	7572980	7572980	T	G	het		QUAL=68;DP=223;AF=0.36;MQM=60	TP53	missense,intron,3'UTR	TP53:ENST00000269305:missense_variant:MODERATE:exon11/11:c.1129A>C:p.Thr377Pro:,TP53:ENST00000359597:intron_variant:MODIFIER:exon8/8:c.994-3418A>C::,TP53:ENST00000413465:intron_variant:MODIFIER:exon6/6:c.782+4519A>C::,TP53:ENST00000420246:3_prime_UTR_variant:MODIFIER:exon12/12:c.*236A>C::,TP53:ENST00000445888:missense_variant:MODERATE:exon11/11:c.1129A>C:p.Thr377Pro:,TP53:ENST00000455263:3_prime_UTR_variant:MODIFIER:exon12/12:c.*148A>C::		rs774269719		0.0003		0.0005,0.0000,0.0001,0.0004,0.0002		0.4640	T, , , ,T, 	B, , , ,B, 	0.64,0.95	1.88	0.35	191170 [TP53 (confirmed) Colorectal cancer,114500/Li-Fraumeni syndrome,151623/Hepatocellular carcinoma,114550/Osteosarcoma,259500/Choroid plexus papilloma,260500/Nasopharyngeal carcinoma,607107/Pancreatic cancer,260350/Adrenal cortical carcinoma,202300/Breast cancer,114480/Basal cell carcinoma 7,614740/Glioma susceptibility 1,137800];			COSM1658764	0	30					TP53 (inh=AR+AD pLI=0.97)
chr17	7572996	7572996	G	T	het		QUAL=41;DP=216;AF=0.32;MQM=60	TP53	synonymous,intron,3'UTR	TP53:ENST00000269305:synonymous_variant:LOW:exon11/11:c.1113C>A:p.Ser371=:,TP53:ENST00000359597:intron_variant:MODIFIER:exon8/8:c.994-3434C>A::,TP53:ENST00000413465:intron_variant:MODIFIER:exon6/6:c.782+4503C>A::,TP53:ENST00000420246:3_prime_UTR_variant:MODIFIER:exon12/12:c.*220C>A::,TP53:ENST00000445888:synonymous_variant:LOW:exon11/11:c.1113C>A:p.Ser371=:,TP53:ENST00000455263:3_prime_UTR_variant:MODIFIER:exon12/12:c.*132C>A::		rs765530090		0.0000		0.0000,0.0000,0.0000,0.0000,0.0000		-0.1270			0.52,0.94	0.56		191170 [TP53 (confirmed) Colorectal cancer,114500/Li-Fraumeni syndrome,151623/Hepatocellular carcinoma,114550/Osteosarcoma,259500/Choroid plexus papilloma,260500/Nasopharyngeal carcinoma,607107/Pancreatic cancer,260350/Adrenal cortical carcinoma,202300/Breast cancer,114480/Basal cell carcinoma 7,614740/Glioma susceptibility 1,137800];				0	1					TP53 (inh=AR+AD pLI=0.97)
chr17	7579472	7579472	G	C	het		QUAL=7662;DP=573;AF=0.54;MQM=60	TP53	missense	TP53:ENST00000269305:missense_variant:MODERATE:exon4/11:c.215C>G:p.Pro72Arg:,TP53:ENST00000359597:missense_variant:MODERATE:exon3/9:c.215C>G:p.Pro72Arg:,TP53:ENST00000413465:missense_variant:MODERATE:exon3/7:c.215C>G:p.Pro72Arg:,TP53:ENST00000420246:missense_variant:MODERATE:exon4/12:c.215C>G:p.Pro72Arg:,TP53:ENST00000445888:missense_variant:MODERATE:exon4/11:c.215C>G:p.Pro72Arg:,TP53:ENST00000455263:missense_variant:MODERATE:exon4/12:c.215C>G:p.Pro72Arg:		rs1042522		0.6686		0.3788,0.7140,0.5709,0.7378,0.5004	0.7452,0.4051	1.0160	T,T,T,T,T,T	B,B,B,B,B,B	0.36,0.50	0.54	0.37	191170 [TP53 (confirmed) Colorectal cancer,114500/Li-Fraumeni syndrome,151623/Hepatocellular carcinoma,114550/Osteosarcoma,259500/Choroid plexus papilloma,260500/Nasopharyngeal carcinoma,607107/Pancreatic cancer,260350/Adrenal cortical carcinoma,202300/Breast cancer,114480/Basal cell carcinoma 7,614740/Glioma susceptibility 1,137800];	12351 [drug response DISEASE=CODON 72 POLYMORPHISM, (rs1042522),Li-Fraumeni syndrome 1,Hereditary cancer-predisposing syndrome,Li-Fraumeni syndrome,not specified,antineoplastic agents response - Efficacy, Toxicity/ADR,cisplatin response - Efficacy, Toxicity/ADR,cyclophosphamide response - Efficacy, Toxicity/ADR,fluorouracil response - Efficacy, Toxicity/ADR,paclitaxel response - Efficacy, Toxicity/ADR,not provided];		COSM250061,COSM45985,COSM5731057	n/a (AF>5%)	n/a (AF>5%)					TP53 (inh=AR+AD pLI=0.97)
chr17	7579644	7579659	CCCCAGCCCTCCAGGT	-	het	off-target	QUAL=124;DP=26;AF=0.58;MQM=60	TP53	intron	TP53:ENST00000269305:intron_variant:MODIFIER:exon3/10:c.96+41_97-54del::,TP53:ENST00000359597:intron_variant:MODIFIER:exon2/8:c.96+41_97-54del::,TP53:ENST00000413465:intron_variant:MODIFIER:exon2/6:c.96+41_97-54del::,TP53:ENST00000420246:intron_variant:MODIFIER:exon3/11:c.96+41_97-54del::,TP53:ENST00000445888:intron_variant:MODIFIER:exon3/10:c.96+41_97-54del::,TP53:ENST00000455263:intron_variant:MODIFIER:exon3/11:c.96+41_97-54del::				0.8232			0.7951,0.6615	1.4060				0.13		191170 [TP53 (confirmed) Colorectal cancer,114500/Li-Fraumeni syndrome,151623/Hepatocellular carcinoma,114550/Osteosarcoma,259500/Choroid plexus papilloma,260500/Nasopharyngeal carcinoma,607107/Pancreatic cancer,260350/Adrenal cortical carcinoma,202300/Breast cancer,114480/Basal cell carcinoma 7,614740/Glioma susceptibility 1,137800];	440349 [benign DISEASE=Hereditary cancer-predisposing syndrome,not specified];			n/a (AF>5%)	n/a (AF>5%)					TP53 (inh=AR+AD pLI=0.97)
chr17	29553485	29553485	G	A	hom		QUAL=2535;DP=86;AF=1.00;MQM=60	NF1	synonymous	NF1:ENST00000356175:synonymous_variant:LOW:exon18/57:c.2034G>A:p.Pro678=:,NF1:ENST00000358273:synonymous_variant:LOW:exon18/58:c.2034G>A:p.Pro678=:		rs2285892	0.4968	0.4369		0.6838,0.4952,0.5198,0.3019,0.3701	0.2891,0.6648	-1.2980			0.04,0.37	0.15		613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200/Leukemia,juvenile myelomonocytic,607785/Neurofibromatosis,familial spinal,162210/Neurofibromatosis-Noonan syndrome,601321/Watson syndrome,193520];	183826 [benign/likely benign DISEASE=Hereditary cancer-predisposing syndrome,Neurofibromatosis, type 1,Cafe-au-lait macules with pulmonary stenosis,Neurofibromatosis, familial spinal,Neurofibromatosis-Noonan syndrome,not specified,not provided];		COSM5009865	n/a (AF>5%)	n/a (AF>5%)					NF1 (inh=AD pLI=1.00)
chr17	29559061	29559061	-	T	het	off-target	QUAL=450;DP=157;AF=0.24;MQM=60	NF1	intron	NF1:ENST00000356175:intron_variant:MODIFIER:exon24/56:c.3198-4dup::,NF1:ENST00000358273:intron_variant:MODIFIER:exon24/57:c.3198-4dup::	(T)n	rs371047262		0.1966		0.1414,0.2126,0.2616,0.0852,0.0990	0.0459,0.0367					0.24		613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200/Leukemia,juvenile myelomonocytic,607785/Neurofibromatosis,familial spinal,162210/Neurofibromatosis-Noonan syndrome,601321/Watson syndrome,193520];				n/a (AF>5%)	n/a (AF>5%)					NF1 (inh=AD pLI=1.00)
chr17	29559932	29559932	C	A	hom	off-target	QUAL=1030;DP=35;AF=1.00;MQM=60	NF1	intron	NF1:ENST00000356175:intron_variant:MODIFIER:exon26/56:c.3496+33C>A::,NF1:ENST00000358273:intron_variant:MODIFIER:exon26/57:c.3496+33C>A::		rs2066736	0.4581	0.4125		0.6162,0.4875,0.4382,0.3006,0.3654	0.2878,0.5906	0.1440			0.12,0.18	-0.01		613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200/Leukemia,juvenile myelomonocytic,607785/Neurofibromatosis,familial spinal,162210/Neurofibromatosis-Noonan syndrome,601321/Watson syndrome,193520];	257285 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					NF1 (inh=AD pLI=1.00)
chr17	29563077	29563077	T	G	hom	off-target	QUAL=11310;DP=418;AF=0.95;MQM=60	NF1	intron	NF1:ENST00000356175:intron_variant:MODIFIER:exon29/56:c.3974+38T>G::,NF1:ENST00000358273:intron_variant:MODIFIER:exon29/57:c.3974+38T>G::	(T)n	rs9894862		0.0112		0.0150,0.0172,0.0069,0.0094,0.0078		0.5520			0.34,0.33	0.05		613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200/Leukemia,juvenile myelomonocytic,607785/Neurofibromatosis,familial spinal,162210/Neurofibromatosis-Noonan syndrome,601321/Watson syndrome,193520];	257286 [benign DISEASE=not specified];			190	990	2	[2] auto-classification 20.11.2017  			NF1 (inh=AD pLI=1.00)
chr17	29563085	29563085	-	TG	hom	off-target	QUAL=9581;DP=390;AF=0.94;MQM=60	NF1	intron	NF1:ENST00000356175:intron_variant:MODIFIER:exon29/56:c.3974+47_3974+48insGT::,NF1:ENST00000358273:intron_variant:MODIFIER:exon29/57:c.3974+47_3974+48insGT::	(T)n			0.0029								-0.23		613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200/Leukemia,juvenile myelomonocytic,607785/Neurofibromatosis,familial spinal,162210/Neurofibromatosis-Noonan syndrome,601321/Watson syndrome,193520];				190	735	2	[2] auto-classification 20.11.2017  			NF1 (inh=AD pLI=1.00)
chr17	29663625	29663625	-	A	hom	off-target	QUAL=840;DP=41;AF=0.78;MQM=60	NF1	intron	NF1:ENST00000356175:intron_variant:MODIFIER:exon40/56:c.6085-17dup::,NF1:ENST00000358273:intron_variant:MODIFIER:exon41/57:c.6148-17dup::		rs553817239		0.3401		0.3488,0.3390,0.3022,0.2243,0.1986						-0.25		613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200/Leukemia,juvenile myelomonocytic,607785/Neurofibromatosis,familial spinal,162210/Neurofibromatosis-Noonan syndrome,601321/Watson syndrome,193520];	495785 [benign DISEASE=not provided];			n/a (AF>5%)	n/a (AF>5%)					NF1 (inh=AD pLI=1.00)
chr17	29670190	29670190	C	G	hom	off-target	QUAL=5223;DP=163;AF=1.00;MQM=60	NF1	intron	NF1:ENST00000356175:intron_variant:MODIFIER:exon47/56:c.7126+37C>G::,NF1:ENST00000358273:intron_variant:MODIFIER:exon48/57:c.7189+37C>G::,NF1:ENST00000417592:intron_variant:MODIFIER:exon3/10:c.328+37C>G::,NF1:ENST00000444181:intron_variant:MODIFIER:exon5/16:c.568+37C>G::		rs7405740	0.8738	0.9082		0.7989,0.8870,0.8802,0.9151,0.9488	0.9191,0.8127	-1.4310			0.00,0.07	0.04		613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200/Leukemia,juvenile myelomonocytic,607785/Neurofibromatosis,familial spinal,162210/Neurofibromatosis-Noonan syndrome,601321/Watson syndrome,193520];	257300 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					NF1 (inh=AD pLI=1.00)
chr17	33433487	33433487	C	T	hom		QUAL=2531;DP=85;AF=1.00;MQM=60	RAD51D,RAD51L3-RFFL	missense	RAD51D:ENST00000335858:missense_variant:MODERATE:exon3/7:c.158G>A:p.Arg53Gln:PF08423,RAD51D:ENST00000345365:missense_variant:MODERATE:exon6/10:c.494G>A:p.Arg165Gln:PF08423,RAD51D:ENST00000360276:missense_variant:MODERATE:exon5/9:c.359G>A:p.Arg120Gln:,RAD51D:ENST00000394589:missense_variant:MODERATE:exon7/11:c.494G>A:p.Arg165Gln:PF08423,RAD51D:ENST00000460118:missense_variant:MODERATE:exon5/9:c.137G>A:p.Arg46Gln:PF08423,RAD51D:ENST00000590016:missense_variant:MODERATE:exon6/10:c.554G>A:p.Arg185Gln:PF13481,RAD51L3-RFFL:ENST00000593039:missense_variant:MODERATE:exon2/7:c.17G>A:p.Arg6Gln:		rs4796033	0.0950	0.1566		0.0289,0.2961,0.0450,0.1420,0.1630	0.1427,0.0368	1.3250	T,T,T,T,T,T,T	B,B,B,B,B,B,B	0.04,0.89	1.31	0.13	602954 [RAD51D (provisional) Breast-ovarian cancer,familial,susceptibility to,4,614291];	142159 [benign/likely benign DISEASE=Hereditary cancer-predisposing syndrome,Breast-ovarian cancer, familial 4,not specified,Breast and Ovarian Cancer Susceptibility];	CM172631 [CLASS=DM? MUT=ALT PHEN="Breast cancer" GENE=RAD51D];		n/a (AF>5%)	n/a (AF>5%)	1	[1] ahstaea1 08.05.2018: AF 15% in gnomAD und ExAC			RAD51D (inh=AD pLI=0.00), RAD51L3-RFFL (inh=n/a pLI=n/a)
chr17	33445549	33445549	G	A	het		QUAL=1637;DP=132;AF=0.55;MQM=60	RAD51D,RAD51L3-RFFL	intron,synonymous,5'UTR	RAD51D:ENST00000335858:intron_variant:MODIFIER:exon2/6:c.144+581C>T::,RAD51D:ENST00000345365:synonymous_variant:LOW:exon3/10:c.234C>T:p.Ser78=:PF08423,RAD51D:ENST00000357906:synonymous_variant:LOW:exon3/4:c.234C>T:p.Ser78=:,RAD51D:ENST00000360276:synonymous_variant:LOW:exon3/9:c.234C>T:p.Ser78=:,RAD51D:ENST00000394589:synonymous_variant:LOW:exon4/11:c.234C>T:p.Ser78=:PF08423,RAD51D:ENST00000460118:5_prime_UTR_variant:MODIFIER:exon3/9:c.-42C>T::,RAD51D:ENST00000590016:intron_variant:MODIFIER:exon2/9:c.144+581C>T::,RAD51L3-RFFL:ENST00000593039:intron_variant:MODIFIER:exon1/6:c.3+2761C>T::		rs9901455	0.1875	0.1624		0.3058,0.1049,0.2303,0.0824,0.0858	0.0820,0.3080	1.6530			0.64,0.92	2.12		602954 [RAD51D (provisional) Breast-ovarian cancer,familial,susceptibility to,4,614291];	183785 [benign/likely benign DISEASE=Hereditary cancer-predisposing syndrome,Breast-ovarian cancer, familial 4,not specified,Breast and Ovarian Cancer Susceptibility];			n/a (AF>5%)	n/a (AF>5%)					RAD51D (inh=AD pLI=0.00), RAD51L3-RFFL (inh=n/a pLI=n/a)
chr17	41223094	41223094	T	C	het		QUAL=4395;DP=434;AF=0.47;MQM=60	BRCA1	missense,intron	BRCA1:ENST00000309486:missense_variant:MODERATE:exon14/22:c.3949A>G:p.Ser1317Gly:,BRCA1:ENST00000346315:intron_variant:MODIFIER:exon12/18:c.4358-7126A>G::,BRCA1:ENST00000351666:missense_variant:MODERATE:exon11/19:c.1288A>G:p.Ser430Gly:,BRCA1:ENST00000352993:missense_variant:MODERATE:exon14/22:c.1411A>G:p.Ser471Gly:,BRCA1:ENST00000354071:intron_variant:MODIFIER:exon12/17:c.4358-7704A>G::,BRCA1:ENST00000357654:missense_variant:MODERATE:exon15/23:c.4837A>G:p.Ser1613Gly:,BRCA1:ENST00000468300:missense_variant:MODERATE:exon15/22:c.1525A>G:p.Ser509Gly:,BRCA1:ENST00000471181:missense_variant:MODERATE:exon16/24:c.4900A>G:p.Ser1634Gly:,BRCA1:ENST00000491747:missense_variant:MODERATE:exon15/23:c.1525A>G:p.Ser509Gly:,BRCA1:ENST00000493795:missense_variant:MODERATE:exon14/22:c.4696A>G:p.Ser1566Gly:,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.5-7126A>G::,BRCA1:ENST00000591534:missense_variant:MODERATE:exon3/11:c.310A>G:p.Ser104Gly:,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-98-20887A>G::		rs1799966	0.3558	0.3546		0.2389,0.3157,0.3785,0.3257,0.5049	0.3266,0.2426	-0.1120	T, ,T,T, ,T,T,T,T,T, ,T, 	B, ,B,B, ,B,B,B,B,B, ,B, 	0.03,0.18	0.57	0.25	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	41827 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 1,not specified,not provided];	CM1210129 [CLASS=R MUT=ALT PHEN="Breast cancer" GENE=BRCA1];	COSM3755560	n/a (AF>5%)	n/a (AF>5%)					BRCA1 (inh=AD pLI=0.00)
chr17	41234470	41234470	A	G	het		QUAL=343;DP=34;AF=0.50;MQM=60	BRCA1	synonymous,intron	BRCA1:ENST00000309486:synonymous_variant:LOW:exon11/22:c.3420T>C:p.Ser1140=:,BRCA1:ENST00000346315:synonymous_variant:LOW:exon12/19:c.4308T>C:p.Ser1436=:,BRCA1:ENST00000351666:synonymous_variant:LOW:exon8/19:c.759T>C:p.Ser253=:,BRCA1:ENST00000352993:synonymous_variant:LOW:exon11/22:c.882T>C:p.Ser294=:,BRCA1:ENST00000354071:synonymous_variant:LOW:exon12/18:c.4308T>C:p.Ser1436=:,BRCA1:ENST00000357654:synonymous_variant:LOW:exon12/23:c.4308T>C:p.Ser1436=:,BRCA1:ENST00000468300:synonymous_variant:LOW:exon12/22:c.999T>C:p.Ser333=:,BRCA1:ENST00000471181:synonymous_variant:LOW:exon12/24:c.4308T>C:p.Ser1436=:,BRCA1:ENST00000491747:synonymous_variant:LOW:exon12/23:c.999T>C:p.Ser333=:,BRCA1:ENST00000493795:synonymous_variant:LOW:exon11/22:c.4167T>C:p.Ser1389=:,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.5-18502T>C::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-43-7932T>C::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-98-32263T>C::		rs1060915	0.3363	0.3493		0.1792,0.3104,0.3771,0.3253,0.5046	0.3260,0.1888	-0.1190			0.04,0.21	0.42		113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	125703 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 1,not specified,not provided];	CM1719086 [CLASS=DM? MUT=ALT PHEN="Breast cancer" GENE=BRCA1];	COSM4416375	n/a (AF>5%)	n/a (AF>5%)	1	[1] ahstaea1 10.08.2018: AF			BRCA1 (inh=AD pLI=0.00)
chr17	41244000	41244000	T	C	het		QUAL=4694;DP=350;AF=0.49;MQM=60	BRCA1	missense,intron	BRCA1:ENST00000309486:missense_variant:MODERATE:exon9/22:c.2660A>G:p.Lys887Arg:,BRCA1:ENST00000346315:missense_variant:MODERATE:exon10/19:c.3548A>G:p.Lys1183Arg:,BRCA1:ENST00000351666:intron_variant:MODIFIER:exon6/18:c.548-951A>G::,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon9/21:c.671-951A>G::,BRCA1:ENST00000354071:missense_variant:MODERATE:exon10/18:c.3548A>G:p.Lys1183Arg:,BRCA1:ENST00000357654:missense_variant:MODERATE:exon10/23:c.3548A>G:p.Lys1183Arg:,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon10/21:c.788-951A>G::,BRCA1:ENST00000471181:missense_variant:MODERATE:exon10/24:c.3548A>G:p.Lys1183Arg:,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon10/22:c.788-951A>G::,BRCA1:ENST00000493795:missense_variant:MODERATE:exon9/22:c.3407A>G:p.Lys1136Arg:,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.5-28032A>G::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-43-17462A>G::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+33288A>G::		rs16942	0.3526	0.3534		0.2350,0.3150,0.3778,0.3240,0.5047	0.3244,0.2383	-0.3660	T,T, , ,T,T, ,T, ,T, , , 	B,B, , ,B,B, ,B, ,B, , , 	0.02,0.17	-0.36	0.07	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	41818 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 1,not specified,not provided];	CM058359 [CLASS=DP MUT=ALT PHEN="Breast cancer protection against association with" GENE=BRCA1];	COSM148277	n/a (AF>5%)	n/a (AF>5%)					BRCA1 (inh=AD pLI=0.00)
chr17	41244435	41244435	T	C	het		QUAL=10833;DP=980;AF=0.49;MQM=60	BRCA1	missense,intron	BRCA1:ENST00000309486:missense_variant:MODERATE:exon9/22:c.2225A>G:p.Glu742Gly:,BRCA1:ENST00000346315:missense_variant:MODERATE:exon10/19:c.3113A>G:p.Glu1038Gly:,BRCA1:ENST00000351666:intron_variant:MODIFIER:exon6/18:c.548-1386A>G::,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon9/21:c.671-1386A>G::,BRCA1:ENST00000354071:missense_variant:MODERATE:exon10/18:c.3113A>G:p.Glu1038Gly:,BRCA1:ENST00000357654:missense_variant:MODERATE:exon10/23:c.3113A>G:p.Glu1038Gly:,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon10/21:c.788-1386A>G::,BRCA1:ENST00000471181:missense_variant:MODERATE:exon10/24:c.3113A>G:p.Glu1038Gly:,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon10/22:c.788-1386A>G::,BRCA1:ENST00000493795:missense_variant:MODERATE:exon9/22:c.2972A>G:p.Glu991Gly:,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.5-28467A>G::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-43-17897A>G::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+32853A>G::		rs16941	0.3357	0.3490		0.1789,0.3100,0.3773,0.3250,0.5044	0.3255,0.1884	-0.4810	T,T, , ,T,T, ,T, ,T, , , 	P,B, , ,B,P, ,B, ,P, , , 	0.05,0.19	1.36	0.23	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	41815 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 1,not specified,not provided];	CM032861 [CLASS=DP MUT=ALT PHEN="Endometriosis association with" GENE=BRCA1];	COSM3755563	n/a (AF>5%)	n/a (AF>5%)					BRCA1 (inh=AD pLI=0.00)
chr17	41244936	41244936	G	A	het		QUAL=2131;DP=132;AF=0.58;MQM=60	BRCA1	missense,intron	BRCA1:ENST00000309486:missense_variant:MODERATE:exon9/22:c.1724C>T:p.Pro575Leu:PF04873,BRCA1:ENST00000346315:missense_variant:MODERATE:exon10/19:c.2612C>T:p.Pro871Leu:PF04873,BRCA1:ENST00000351666:intron_variant:MODIFIER:exon6/18:c.548-1887C>T::,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon9/21:c.671-1887C>T::,BRCA1:ENST00000354071:missense_variant:MODERATE:exon10/18:c.2612C>T:p.Pro871Leu:PF04873,BRCA1:ENST00000357654:missense_variant:MODERATE:exon10/23:c.2612C>T:p.Pro871Leu:PF04873,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon10/21:c.787+1825C>T::,BRCA1:ENST00000471181:missense_variant:MODERATE:exon10/24:c.2612C>T:p.Pro871Leu:PF04873,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon10/22:c.787+1825C>T::,BRCA1:ENST00000493795:missense_variant:MODERATE:exon9/22:c.2471C>T:p.Pro824Leu:PF04873,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.5-28968C>T::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-43-18398C>T::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+32352C>T::		rs799917		0.4855		0.8255,0.3468,0.3773,0.3335,0.5324	0.3359,0.8000	4.2470	T,T, , ,T,T, ,T, ,T, , , 	B,B, , ,B,B, ,B, ,B, , , 	0.02,0.89	1.87	0.14	113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	41812 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 1,not specified,not provided];	CM096315 [CLASS=DFP MUT=ALT PHEN="Cervical cancer decreased risk association with" GENE=BRCA1];	COSM148278	n/a (AF>5%)	n/a (AF>5%)					BRCA1 (inh=AD pLI=0.00)
chr17	41245237	41245237	A	G	het		QUAL=1538;DP=127;AF=0.46;MQM=60	BRCA1	synonymous,intron	BRCA1:ENST00000309486:synonymous_variant:LOW:exon9/22:c.1423T>C:p.Leu475=:PF04873,BRCA1:ENST00000346315:synonymous_variant:LOW:exon10/19:c.2311T>C:p.Leu771=:PF04873,BRCA1:ENST00000351666:intron_variant:MODIFIER:exon6/18:c.548-2188T>C::,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon9/21:c.671-2188T>C::,BRCA1:ENST00000354071:synonymous_variant:LOW:exon10/18:c.2311T>C:p.Leu771=:PF04873,BRCA1:ENST00000357654:synonymous_variant:LOW:exon10/23:c.2311T>C:p.Leu771=:PF04873,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon10/21:c.787+1524T>C::,BRCA1:ENST00000471181:synonymous_variant:LOW:exon10/24:c.2311T>C:p.Leu771=:PF04873,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon10/22:c.787+1524T>C::,BRCA1:ENST00000493795:synonymous_variant:LOW:exon9/22:c.2170T>C:p.Leu724=:PF04873,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.5-29269T>C::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-43-18699T>C::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+32051T>C::		rs16940	0.3353	0.3482		0.1787,0.3097,0.3774,0.3235,0.5042	0.3237,0.1877	-0.4510			0.06,0.19	0.65		113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	125554 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 1,not specified,not provided];	CM1719261 [CLASS=DM? MUT=ALT PHEN="Breast cancer" GENE=BRCA1];	COSM3755566	n/a (AF>5%)	n/a (AF>5%)	1	[1] ahstaea1 10.08.2018: AF			BRCA1 (inh=AD pLI=0.00)
chr17	41245466	41245466	G	A	het		QUAL=460;DP=62;AF=0.44;MQM=60	BRCA1	synonymous,intron	BRCA1:ENST00000309486:synonymous_variant:LOW:exon9/22:c.1194C>T:p.Ser398=:PF04873,BRCA1:ENST00000346315:synonymous_variant:LOW:exon10/19:c.2082C>T:p.Ser694=:PF04873,BRCA1:ENST00000351666:intron_variant:MODIFIER:exon6/18:c.548-2417C>T::,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon9/21:c.670+2397C>T::,BRCA1:ENST00000354071:synonymous_variant:LOW:exon10/18:c.2082C>T:p.Ser694=:PF04873,BRCA1:ENST00000357654:synonymous_variant:LOW:exon10/23:c.2082C>T:p.Ser694=:PF04873,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon10/21:c.787+1295C>T::,BRCA1:ENST00000471181:synonymous_variant:LOW:exon10/24:c.2082C>T:p.Ser694=:PF04873,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon10/22:c.787+1295C>T::,BRCA1:ENST00000493795:synonymous_variant:LOW:exon9/22:c.1941C>T:p.Ser647=:PF04873,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.5-29498C>T::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-43-18928C>T::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+31822C>T::		rs1799949	0.3365	0.3533		0.2357,0.3151,0.3772,0.3240,0.5050	0.3244,0.2396	-0.0020			0.00,0.13	0.09		113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	125536 [benign DISEASE=Hereditary cancer-predisposing syndrome,Familial cancer of breast,Hereditary breast and ovarian cancer syndrome,Breast-ovarian cancer, familial 1,not specified,not provided];	CM1719085 [CLASS=DM? MUT=ALT PHEN="Breast cancer" GENE=BRCA1];	COSM148280	n/a (AF>5%)	n/a (AF>5%)	1	[1] ahstaea1 10.08.2018: AF			BRCA1 (inh=AD pLI=0.00)
chr17	41249364	41249364	A	-	het	off-target	QUAL=594;DP=70;AF=0.39;MQM=60	BRCA1	intron	BRCA1:ENST00000309486:intron_variant:MODIFIER:exon6/21:c.-341-58del::,BRCA1:ENST00000346315:intron_variant:MODIFIER:exon7/18:c.548-58del::,BRCA1:ENST00000351666:intron_variant:MODIFIER:exon6/18:c.547+2428del::,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon7/21:c.548-58del::,BRCA1:ENST00000354071:intron_variant:MODIFIER:exon7/17:c.548-58del::,BRCA1:ENST00000357654:intron_variant:MODIFIER:exon7/22:c.548-58del::,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon7/21:c.548-58del::,BRCA1:ENST00000471181:intron_variant:MODIFIER:exon7/23:c.548-58del::,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon7/22:c.548-58del::,BRCA1:ENST00000493795:intron_variant:MODIFIER:exon6/21:c.407-58del::,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.4+27835del::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-43-22826del::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+27924del::		rs8176144	0.3349	0.3001			0.3229,0.1912	0.9130				1.49		113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	125889 [benign DISEASE=Hereditary cancer-predisposing syndrome,Breast-ovarian cancer, familial 1,not specified];			n/a (AF>5%)	n/a (AF>5%)					BRCA1 (inh=AD pLI=0.00)
chr17	41256101	41256103	AAG	-	het	off-target	QUAL=7;DP=11;AF=0.27;MQM=60	BRCA1	intron	BRCA1:ENST00000309486:intron_variant:MODIFIER:exon5/21:c.-448+36_-448+38del::,BRCA1:ENST00000346315:intron_variant:MODIFIER:exon6/18:c.441+36_441+38del::,BRCA1:ENST00000351666:intron_variant:MODIFIER:exon5/18:c.441+36_441+38del::,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon6/21:c.441+36_441+38del::,BRCA1:ENST00000354071:intron_variant:MODIFIER:exon6/17:c.441+36_441+38del::,BRCA1:ENST00000357654:intron_variant:MODIFIER:exon6/22:c.441+36_441+38del::,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon6/21:c.441+36_441+38del::,BRCA1:ENST00000471181:intron_variant:MODIFIER:exon6/23:c.441+36_441+38del::,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon6/22:c.441+36_441+38del::,BRCA1:ENST00000493795:intron_variant:MODIFIER:exon5/21:c.300+36_300+38del::,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.4+21096_4+21098del::,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-44+21185_-44+21187del::,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+21185_-99+21187del::	(AAG)n	rs147856441	0.3948	0.0082		0.0045,0.0050,0.0043,0.0059,0.0105		0.6080				0.08		113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370/Pancreatic cancer,susceptibility to,4,614320/Fanconi anemia,complementation group S,617883];	225704 [benign DISEASE=Familial cancer of breast,Breast-ovarian cancer, familial 1,not specified];			n/a (AF>5%)	n/a (AF>5%)					BRCA1 (inh=AD pLI=0.00)
chr17	56769979	56769979	C	T	het	off-target	QUAL=11259;DP=987;AF=0.46;MQM=60	RAD51C	5'UTR	RAD51C:ENST00000337432:5_prime_UTR_variant:MODIFIER:exon1/9:c.-26C>T::,RAD51C:ENST00000583539:5_prime_UTR_variant:MODIFIER:exon1/8:c.-26C>T::		rs12946397	0.1583	0.1954		0.1371,0.1329,0.1711,0.2069,0.1384	0.1988,0.1373	-3.0920			0.06,0.35	0.61		602774 [RAD51C (provisional) Fanconi anemia,complementation group O,613390/Breast-ovarian cancer,familial,susceptibility to,3,613399];	324173 [likely benign DISEASE=Fanconi anemia,Breast and Ovarian Cancer Susceptibility];			n/a (AF>5%)	n/a (AF>5%)					RAD51C (inh=AR+AD pLI=0.00)
chr17	56798207	56798207	T	C	het	off-target	QUAL=203;DP=27;AF=0.44;MQM=60	RAD51C	intron	RAD51C:ENST00000337432:intron_variant:MODIFIER:exon6/8:c.904+34T>C::,RAD51C:ENST00000583539:intron_variant:MODIFIER:exon6/7:c.904+34T>C::		rs28363318	0.2053	0.2892		0.2686,0.1845,0.0008,0.3464,0.1932	0.3519,0.2823	0.2790			0.05,0.17	-0.07		602774 [RAD51C (provisional) Fanconi anemia,complementation group O,613390/Breast-ovarian cancer,familial,susceptibility to,3,613399];				n/a (AF>5%)	n/a (AF>5%)					RAD51C (inh=AR+AD pLI=0.00)
chr17	59760996	59760996	A	G	hom		QUAL=7621;DP=310;AF=1.00;MQM=60	BRIP1	synonymous	BRIP1:ENST00000259008:synonymous_variant:LOW:exon20/20:c.3411T>C:p.Tyr1137=:		rs4986763	0.6208	0.5973		0.6549,0.7940,0.7153,0.5865,0.4560	0.5869,0.6435	3.1090			0.83,0.98	0.50		605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480/Fanconi anemia,complementation group J,609054];	183702 [benign/likely benign DISEASE=Neoplasm of ovary,Neoplasm of the breast,Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Fanconi anemia, complementation group J,not specified];			n/a (AF>5%)	n/a (AF>5%)					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59763347	59763347	A	G	hom		QUAL=369;DP=12;AF=1.00;MQM=60	BRIP1	missense	BRIP1:ENST00000259008:missense_variant:MODERATE:exon19/20:c.2755T>C:p.Ser919Pro:,BRIP1:ENST00000577598:missense_variant:MODERATE:exon18/18:c.2755T>C:p.Ser919Pro:		rs4986764	0.6278	0.5998		0.6755,0.7993,0.7153,0.5873,0.4562	0.5890,0.6611	0.1360	T,T	B,B	0.00,0.15	-0.01	0.09	605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480/Fanconi anemia,complementation group J,609054];	133756 [benign/likely benign DISEASE=Neoplasm of ovary,Neoplasm of the breast,Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Fanconi anemia, complementation group J,not specified];			n/a (AF>5%)	n/a (AF>5%)					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59763465	59763465	T	C	hom		QUAL=3671;DP=114;AF=1.00;MQM=60	BRIP1	synonymous	BRIP1:ENST00000259008:synonymous_variant:LOW:exon19/20:c.2637A>G:p.Glu879=:,BRIP1:ENST00000577598:synonymous_variant:LOW:exon18/18:c.2637A>G:p.Glu879=:		rs4986765	0.8151	0.7178		0.9118,0.8681,0.8914,0.6633,0.6994	0.6555,0.8881	-0.0280			0.11,0.93	0.58		605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480/Fanconi anemia,complementation group J,609054];	183703 [benign/likely benign DISEASE=Neoplasm of ovary,Neoplasm of the breast,Fanconi anemia,Hereditary cancer-predisposing syndrome,Familial cancer of breast,Fanconi anemia, complementation group J,not specified];			n/a (AF>5%)	n/a (AF>5%)					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59857600	59857600	A	-	het	off-target	QUAL=14;DP=28;AF=0.21;MQM=60	BRIP1	intron	BRIP1:ENST00000259008:intron_variant:MODIFIER:exon13/19:c.1935+22del::,BRIP1:ENST00000577598:intron_variant:MODIFIER:exon12/17:c.1935+22del::		rs763913233		0.0079		0.0060,0.0117,0.0085,0.0063,0.0122	0.0313,0.0359	-0.2540				-0.06		605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480/Fanconi anemia,complementation group J,609054];				0	20					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59857809	59857809	C	G	het	off-target	QUAL=183;DP=14;AF=0.64;MQM=60	BRIP1	intron	BRIP1:ENST00000259008:intron_variant:MODIFIER:exon12/19:c.1795-47G>C::,BRIP1:ENST00000577598:intron_variant:MODIFIER:exon11/17:c.1795-47G>C::	AluJb	rs4988351		0.7917		0.8567,0.4946,0.8314,0.7504,0.7927	0.7495,0.8569	0.1450			0.02,0.22	0.46		605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480/Fanconi anemia,complementation group J,609054];	262005 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					BRIP1 (inh=AR+AD pLI=0.00)
chr18	19995753	19995753	T	C	hom		QUAL=461;DP=19;AF=1.00;MQM=60	CTAGE1	synonymous	CTAGE1:ENST00000391403:synonymous_variant:LOW:exon1/1:c.2022A>G:p.Pro674=:		rs9946145	0.6855	0.8559		0.3500,0.8778,0.8287,0.9159,0.7918	0.9089,0.3939	-0.1350			0.02,0.10	0.02						n/a (AF>5%)	n/a (AF>5%)					CTAGE1 (inh=n/a pLI=0.00)
chr18	19996011	19996011	G	A	het		QUAL=1512;DP=133;AF=0.46;MQM=60	CTAGE1	synonymous	CTAGE1:ENST00000391403:synonymous_variant:LOW:exon1/1:c.1764C>T:p.Leu588=:		rs7227477	0.4942	0.5049		0.4671,0.6068,0.6173,0.4830,0.4301	0.4606,0.4502	0.0500			0.00,0.04	-0.04						n/a (AF>5%)	n/a (AF>5%)					CTAGE1 (inh=n/a pLI=0.00)
chr18	20555219	20555219	T	C	hom	off-target	QUAL=2177;DP=70;AF=1.00;MQM=60	RBBP8	intron	RBBP8:ENST00000327155:intron_variant:MODIFIER:exon6/18:c.428+37T>C::,RBBP8:ENST00000360790:intron_variant:MODIFIER:exon6/18:c.428+37T>C::,RBBP8:ENST00000399722:intron_variant:MODIFIER:exon6/18:c.428+37T>C::,RBBP8:ENST00000399725:intron_variant:MODIFIER:exon6/17:c.428+37T>C::		rs2336916		0.9651		0.8507,0.9811,0.9171,0.9844,0.9363	0.9814,0.8634	-1.6630			0.00,0.07	0.12		604124 [RBBP8 (provisional) Pancreatic carcinoma,somatic/Seckel syndrome 2,606744/Jawad syndrome,251255];				n/a (AF>5%)	n/a (AF>5%)					RBBP8 (inh=AR pLI=0.00)
chr18	20564801	20564803	TCA	-	het	off-target	QUAL=362;DP=32;AF=0.47;MQM=60	RBBP8	intron	RBBP8:ENST00000327155:intron_variant:MODIFIER:exon7/18:c.605-41_605-39del::,RBBP8:ENST00000360790:intron_variant:MODIFIER:exon7/18:c.605-41_605-39del::,RBBP8:ENST00000399722:intron_variant:MODIFIER:exon7/18:c.605-41_605-39del::,RBBP8:ENST00000399725:intron_variant:MODIFIER:exon7/17:c.605-41_605-39del::		rs3052770	0.4517	0.5690		0.2077,0.5111,0.4632,0.6427,0.5444	0.6266,0.2254	-0.2930				-0.01		604124 [RBBP8 (provisional) Pancreatic carcinoma,somatic/Seckel syndrome 2,606744/Jawad syndrome,251255];				n/a (AF>5%)	n/a (AF>5%)					RBBP8 (inh=AR pLI=0.00)
chr18	48584855	48584855	-	TT	het	off-target	QUAL=2462;DP=234;AF=0.41;MQM=59	SMAD4	intron	SMAD4:ENST00000342988:intron_variant:MODIFIER:exon7/11:c.904+44_904+45dup::,SMAD4:ENST00000398417:intron_variant:MODIFIER:exon7/11:c.904+44_904+45dup::,SMAD4:ENST00000588745:intron_variant:MODIFIER:exon4/7:c.667+3507_667+3508dup::		rs760402978		0.3070		0.1086,0.1975,0.2286,0.1842,0.1378						0.82		600993 [SMAD4 (confirmed) Pancreatic cancer,somatic,260350/Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome,175050/Myhre syndrome,139210/Polyposis,juvenile intestinal,174900];				n/a (AF>5%)	n/a (AF>5%)					SMAD4 (inh=AD pLI=0.99)
chr18	48584855	48584855	-	T	het	off-target	QUAL=2462;DP=234;AF=0.16;MQM=60	SMAD4	intron	SMAD4:ENST00000342988:intron_variant:MODIFIER:exon7/11:c.904+45dup::,SMAD4:ENST00000398417:intron_variant:MODIFIER:exon7/11:c.904+45dup::,SMAD4:ENST00000588745:intron_variant:MODIFIER:exon4/7:c.667+3508dup::		rs760402978		0.1703		0.1618,0.1565,0.2004,0.1744,0.1540						0.83		600993 [SMAD4 (confirmed) Pancreatic cancer,somatic,260350/Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome,175050/Myhre syndrome,139210/Polyposis,juvenile intestinal,174900];	492739 [benign DISEASE=not specified];			n/a (AF>5%)	n/a (AF>5%)					SMAD4 (inh=AD pLI=0.99)
chr19	17379558	17379558	C	T	het	off-target	QUAL=1316;DP=109;AF=0.48;MQM=60	BABAM1,CTD-2278I10.6	splice_region&intron,intron,intron&NMD_transcript	BABAM1:ENST00000359435:splice_region_variant&intron_variant:LOW:exon1/8:c.-51-7C>T::,BABAM1:ENST00000447614:intron_variant:MODIFIER:exon1/8:c.-13-45C>T::,BABAM1:ENST00000595632:splice_region_variant&intron_variant:LOW:exon1/5:c.-51-7C>T::,CTD-2278I10.6:ENST00000596542:intron_variant&NMD_transcript_variant:MODIFIER:exon1/9:c.-188-45C>T::,BABAM1:ENST00000598188:intron_variant:MODIFIER:exon1/8:c.-13-45C>T::,BABAM1:ENST00000601043:intron_variant:MODIFIER:exon1/8:c.-13-45C>T::		rs10424178	0.1727	0.2340		0.3548,0.0917,0.0005,0.1922,0.1109		-0.3270			0.03,0.12	0.01						n/a (AF>5%)	n/a (AF>5%)					BABAM1 (inh=n/a pLI=0.92), CTD-2278I10.6 (inh=n/a pLI=n/a)
chr19	17382505	17382505	A	T	het	off-target	QUAL=331;DP=49;AF=0.37;MQM=60	BABAM1,CTD-2278I10.6	intron,intron&NMD_transcript	BABAM1:ENST00000359435:intron_variant:MODIFIER:exon3/8:c.344+41A>T::,BABAM1:ENST00000447614:intron_variant:MODIFIER:exon3/8:c.344+41A>T::,BABAM1:ENST00000595632:intron_variant:MODIFIER:exon3/5:c.344+41A>T::,CTD-2278I10.6:ENST00000596542:intron_variant&NMD_transcript_variant:MODIFIER:exon2/9:c.111-2208A>T::,BABAM1:ENST00000598188:intron_variant:MODIFIER:exon3/8:c.344+41A>T::,BABAM1:ENST00000601043:intron_variant:MODIFIER:exon3/8:c.344+41A>T::		rs10420922	0.4631	0.5065		0.6912,0.3266,0.3144,0.4347,0.3801	0.4337,0.6714	-0.2920			0.00,0.04	-0.21						n/a (AF>5%)	n/a (AF>5%)					BABAM1 (inh=n/a pLI=0.92), CTD-2278I10.6 (inh=n/a pLI=n/a)
chr19	17387254	17387254	G	A	het	off-target	QUAL=1375;DP=102;AF=0.52;MQM=60	BABAM1,CTD-2278I10.6	intron,intron&NMD_transcript	BABAM1:ENST00000359435:intron_variant:MODIFIER:exon6/8:c.570-50G>A::,BABAM1:ENST00000447614:intron_variant:MODIFIER:exon6/8:c.569+37G>A::,BABAM1:ENST00000595632:intron_variant:MODIFIER:exon3/5:c.345-50G>A::,CTD-2278I10.6:ENST00000596542:intron_variant&NMD_transcript_variant:MODIFIER:exon5/9:c.336-50G>A::,BABAM1:ENST00000598188:intron_variant:MODIFIER:exon6/8:c.570-50G>A::,BABAM1:ENST00000601043:intron_variant:MODIFIER:exon6/8:c.570-50G>A::		rs61634114	0.0990	0.1712		0.1458,0.0804,0.0007,0.1773,0.1163	0.1716,0.1329	0.5630			0.04,0.13	0.14						n/a (AF>5%)	n/a (AF>5%)					BABAM1 (inh=n/a pLI=0.92), CTD-2278I10.6 (inh=n/a pLI=n/a)
chr19	17389648	17389648	C	T	het		QUAL=1229;DP=109;AF=0.47;MQM=60	BABAM1,CTD-2278I10.6	splice_region&intron,intron&NMD_transcript	BABAM1:ENST00000359435:splice_region_variant&intron_variant:LOW:exon8/8:c.787-6C>T::,BABAM1:ENST00000447614:splice_region_variant&intron_variant:LOW:exon8/8:c.787-6C>T::,BABAM1:ENST00000595632:splice_region_variant&intron_variant:LOW:exon5/5:c.562-6C>T::,CTD-2278I10.6:ENST00000596542:intron_variant&NMD_transcript_variant:MODIFIER:exon7/9:c.552+1930C>T::,BABAM1:ENST00000598188:splice_region_variant&intron_variant:LOW:exon8/8:c.787-6C>T::,BABAM1:ENST00000601043:splice_region_variant&intron_variant:LOW:exon8/8:c.787-6C>T::		rs10406920	0.1118	0.1840		0.1834,0.0778,0.0006,0.1781,0.1140	0.1799,0.1750	0.7670			0.22,0.33	0.10						n/a (AF>5%)	n/a (AF>5%)					BABAM1 (inh=n/a pLI=0.92), CTD-2278I10.6 (inh=n/a pLI=n/a)
chr19	17389704	17389704	G	A	het		QUAL=6312;DP=539;AF=0.47;MQM=60	BABAM1,CTD-2278I10.6	synonymous,intron&NMD_transcript	BABAM1:ENST00000359435:synonymous_variant:LOW:exon9/9:c.837G>A:p.Lys279=:,BABAM1:ENST00000447614:synonymous_variant:LOW:exon9/9:c.837G>A:p.Lys279=:,BABAM1:ENST00000595632:synonymous_variant:LOW:exon6/6:c.612G>A:p.Lys204=:,CTD-2278I10.6:ENST00000596542:intron_variant&NMD_transcript_variant:MODIFIER:exon7/9:c.552+1986G>A::,BABAM1:ENST00000598188:synonymous_variant:LOW:exon9/9:c.837G>A:p.Lys279=:,BABAM1:ENST00000601043:synonymous_variant:LOW:exon9/9:c.837G>A:p.Lys279=:		rs8170	0.1124	0.1859		0.1922,0.0789,0.0006,0.1792,0.1143	0.1811,0.1798	2.9920			0.88,0.94	1.94				CM1010189 [CLASS=DP MUT=ALT PHEN="Ovarian cancer susceptibility to" GENE=BABAM1];		n/a (AF>5%)	n/a (AF>5%)					BABAM1 (inh=n/a pLI=0.92), CTD-2278I10.6 (inh=n/a pLI=n/a)
chr20	14167283	14167283	A	G	hom		QUAL=905;DP=31;AF=1.00;MQM=60	MACROD2	intron	MACROD2:ENST00000217246:intron_variant:MODIFIER:exon3/16:c.271+100909A>G::,MACROD2:ENST00000310348:intron_variant:MODIFIER:exon3/17:c.271+100909A>G::	L1PA16	rs6074704	0.4792	0.5388				-0.5350			0.01,0.34	0.46						n/a (AF>5%)	n/a (AF>5%)					MACROD2 (inh=n/a pLI=0.15)
chr20	48301146	48301146	G	A	hom		QUAL=39629;DP=1210;AF=1.00;MQM=60	B4GALT5	intron	B4GALT5:ENST00000371711:intron_variant:MODIFIER:exon1/8:c.116-27907C>T::		rs6512586	0.4681	0.5178		0.3756,0.4473,0.3710,0.5452,0.6509	0.5455,0.3973	-0.9860			0.00,0.05	-0.27						n/a (AF>5%)	n/a (AF>5%)					B4GALT5 (inh=n/a pLI=0.99)
